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C H A P T E R   1 
Motive and Background 
 
Part of this chapter has been published in Nutrition Reviews 
2002:60(3);80-87 by Patricia Beemster, Pascal MW Groenen and Régine 
PM Steegers-Theunissen. Involvement of inositol in reproduction. 
 
 
Spina bifida is a common congenital malformation in man and is defined as a 
disorder of the spinal cord due to a failure of closure of the caudal part of the 
neural tube. Together with anencephaly a defective closure of the cranial 
neuropore, and encephalocele, a defect of the cranial bones, these 
malformations are classified as neural tube defects. In contrast to anencephaly, 
spina bifida is compatible with life. Affected children commonly exhibit severe 
neurological disorders resulting in pareses of the legs and impaired bladder and 
intestinal function. Obviously, this poses a large burden on the child, the 
parents and their family. Spina bifida can be divided into 'spina bifida occulta' 
and 'spina bifida aperta'. Figure 1 depicts the various types of spina bifida. In 
figure 1A a schematic presentation of spina bifida occulta is given, 
characterized by intact meninges and a normal spinal cord. The vertebral arcs 
are incompletely fused leaving the spinal cord partially unprotected. The 
vertebral defect is often characterized by focal hair growth, cutaneous dimples 
or a subcutaneous lipid mass. Figure 1B depicts a meningocele that is 
characterized by protruding meninges through the skin. Usually, the spinal cord 
is intact and these children may suffer from minor sensory and motor deficits, 
or none at all. Meningocele account for a small proportion (5%) of all spina 
bifida apertas occurences, whereas meningomyelocele is the most predominant 
phenotype (90%) (Figure 1C) (1). Both meninges and spinal cord protrude 
through the skin defect. The spinal cord is malformed resulting in paralyses of 
the sclerotomes of the spinal nerves below the defect. Children born with a 
meningomyelocele often show extensive hydrocephaly causing increased 
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cranial pressure that may lead to cerebral damage. These children are mostly 
bound to a wheelchair and suffer from urinary and fecal incontinence.  
A) Spina bifida  occulta 
B) Meningocele 
C) Meningomyelocele . 
 
Figure 1. Possible variations of spina bifida ranging from mild to severe. Diagram reproduced with permission 
from 'Spina Bifida and You', published by the Association for People with Spina Bifida and Hydrocephalus, 1985. 
 
In the period between 1995 and 1998 the birth-prevalence of neural tube 
defects in live born children, including spina bifida, was estimated at 5 per 
10,000 births in the Netherlands (2). This is higher compared to the rest of 
Continental Europe in which the birth-prevalence was estimated to be between 
1 and 4 per 10,000 live births (3), while the birth prevalence on the British 
Islands is approximately 11.6  per 10,000 live births (4). In this same period the 
total prevalence of neural tube defects, including elective pregnancy 
termination, was estimated to be around 12 per 10,000 children in the 
Netherlands, whereas this was around 15 per 10,000 children in the U.K. and 
Ireland in which the birth prevalence of neural tube defects have historically 
been among the highest in the world (5). During the last three decades the 
prevalence of both spina bifida and anencephaly gradually declined (4,6), 
besides secular trends and pregnancy termination after antenatal diagnosis, this 
may be due to the periconceptional use of folic acid supplements.  
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Embryology 
In the first days of the third week ectodermal cells start to proliferate between 
the ectodermal-entodermal plates. These cells then migrate in a lateral and 
cranial direction forming the mesoderm that eventually separates the ectoderm 
and entoderm completely. Starting at the beginning of the 3rd week the 
ectoderm thickens (neural plate) and at the end of the 3rd week the neural walls 
and the neural groove become visible (Figure 2). As the cells in the neural walls 
continue to proliferate they approach each other and fuse at the future cervical 
region (Figure 2).  
 
Figure 2. Four stages of primary neurulation. Reproduced with permission. 
 
From there the closure extends in a cranial and caudal direction thereby 
creating the neural tube. By day 25 and day 27 the closure of the cranial part, 
the future brain (neuroporus anterior) and caudal part, the future spinal cord 
(neuroporus posterior) of the embryo is completed. The cells that mark the 
intermediate zone between neuro-ectoderm and surface-ectoderm are the so-
called neural crest cells that will eventually form the sensory ganglias of the 
spinal cord and brain nerve. During the time of formation of the neural tube, the 
embryo starts bending and rotating as a result of specific growth and growth 
inhibition. These processes of formation, shaping and bending of the neural 
plate and closure of the neural grooves are referred to as primary neurulation. 
From here the process of secondary neurulation takes place, which involves the 
growth and differentiation of the nervous system. It should be noted however, 
that primary and secondary neurulation are not separated but both temporarily 
and spatially overlap each other. 
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During the first week after conception the neural tube develops in an embryo 
that is nourished by the surrounding endometrium that secretes large amounts 
of glycogen. This situation is known as histotrophic nutrition. The second week 
of development is mainly characterized by further invasion of the endometrial 
stroma and the formation of three cavities, i.e. 1) amnion cavity, 2) yolk sac and 
3) chorion cavity. During the period of neural tube closure i.e., the 3rd week 
post conception, hematotrophic nutrition starts after trophoblast cells have 
formed villi that are capable of transferring nutrients to the embryo. 
 
Etiology 
Spina bifida in most cases has a multifactorial origin in which environmental 
factors, such as nutrition, and genetic components interact (7,8). Evidence 
supporting the involvement of genetic factors in the pathogenesis of spina bifida 
comes from various sources: 1) the occurrence of spina bifida within families, 
2) gender differences, 3) persisting ethnic differences after migration and 4) 
increased prevalence in the offspring of consanguine parents (7,9-11). In Table 
I genetic causes of neural tube defects including spina bifida known to date are 
presented.  
 
Table I. Selection of genetic factors associated with neural tube defects. 
Gene / Chromosome References Type¶ Ref. nr. 
PAX3 Chatkupt, 1993 
Hol, 1995 
O 
O 
(12) 
(13) 
MTHFR Van der Put, 1997 O (14) 
ZIC-1, -2, and -3 Nagai, 1997 E (15) 
Xq26-q27, translocation Hol, 2000 O (16) 
SLC39A4 Kury, 2002 
Wang, 2002 
O 
O 
(17) 
(18) 
¶) O = observational study; E = experimental study. 
 
Besides genetic factors, demographic and environmental factors play a role in 
the pathogenesis of spina bifida as well. To date, much effort has been made to 
study the effects of age, socioeconomic status, parental occupation, lifestyle, 
  
 11
e.g. smoking and alcohol consumption, dietary intake, maternal illnesses, and 
use of medication, Table II.  
 
Table II. Environmental factors associated with neural tube defects. 
Determinant References Type¶ Ref. nr. 
Maternal age Leck, 1974 
Elwood, 1980 
Frey, 2003 
NTD 
NTD 
NTD 
(19) 
(1) 
(8) 
Socioeconomic status Elwood, 1980 NTD (1) 
Smoking Evans, 1979 
Shaw, 1996 
NTD 
NTD 
(20) 
(21) 
Use of alcohol Friedman, 1982 
Castro-Gago, 1987 
NTD 
SB 
(22) 
(23) 
Anticonvulsants Lewis, 1998 
Finnell, 2003 
Pippenger, 2003 
NTD 
NTD 
NTD 
(24) 
(25) 
(26) 
Dietary intake Smithells, 1976 NTD (27) 
Maternal illnesses Elwood, 1980 NTD (1) 
¶) SB = spina bifida 
 NTD = neural tube defects including spina bifida & anencephaly 
 
Most striking is the association between maternal epilepsy and spina bifida in 
the offspring. Seizure control during pregnancy is important because epileptic 
episodes are suggested to contribute to the occurrence of fetal abnormalities or 
intra uterine death. Anticonvulsive drugs, especially valproic acid, 
carbamazepine, and phenobarbital were shown to induce neural tube defects in 
the human embryo (24-26). A proposed mechanism of the teratogenicity of 
anticonvulsive drugs is the interference with the folate metabolism causing low 
concentrations of folate and high homocysteine concentrations which are both 
risk factors for neural tube defects (28,29). A second hypothetical mechanism 
may be through oxidative tissue damage as a result of the formation of reactive 
epoxide species (30). Maternal age is a yet obscure risk factor for neural tube 
defects (8). Younger women and older women of high parity have an elevated 
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risk of spina bifida offspring (1,19). Reports on maternal smoking and risk of 
spina bifida are controversial (20,21). Although a modest association between 
maternal smoking and neural tube defects was described (20), one of the 
largest studies on maternal smoking and neural tube defects was negative (21). 
While maternal alcohol use during pregnancy may cause multiple congenital 
malformations known as Fetal Alcohol Syndrome, evidence linking maternal 
alcohol use is scarce. Friendman et al. reported an association between alcohol 
abuse and neural tube defects (22). Moreover, Castro-Gago et al. described 
four brothers with meningomyeloceles being sons of an alcoholic mother (23). 
In the early seventies papers already addressed the possible association 
between low socioeconomic status and occurrence of spina bifida (9). It was 
then suggested that this association could be explained by the use of an 
unbalanced or insufficient diet in the lower socioeconomic classes. This finding 
finally led to large trials in which the preventative effect of periconceptional 
folic acid supplementation against the development of neural tube defects has 
been shown (31-36). Folate is an important substrate in the synthesis of DNA, 
and methylation of DNA, proteins and lipids. Accordingly, folate is important in 
the remethylation of homocysteine into methionine, facilitated by the vitamin 
B12-dependent enzyme, methionine synthase. Both folate and cobalamin 
shortages result in mildly increased homocysteine concentrations and have 
been demonstrated risk factors for spina bifida (29,33,37-39). The 
transsulfuration of homocysteine into cysteine via cystathione is catalyzed by 
the vitamin B6-dependent enzyme, cystathione-β-synthase. An inadequate 
vitamin B6 status was also been shown as a risk factor for neural tube defects 
(29,33). Despite the partially prevention of spina bifida by folic acid, around 
50% is possibly not sensitive to folate. Therefore, of particular interest are the 
findings of studies in which zinc and myo-inositol may contribute to the 
reduction of spina bifida in the offspring (40-42).  
 
Myo-inositol  
Myo-inositol is an important dietary and cellular constituent, and its derivatives 
are broadly distributed in mammalian tissues and cells, higher plants, fungi, and 
some bacteria where they provide important biological functions.  
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In healthy adults, the serum concentration of myo-inositol remains within a 
range of 20-70 µmol/L (43-45). However, in new-born infants and fetuses, 
serum concentrations of myo-inositol are several times higher than in adults, 
e.g. at term, the concentration of myo-inositol was reported to be 60 µmol/L in 
the umbilical artery and 45 µmol/L in the umbilical vein (43), possibly reflecting 
fetal lung development. The myo-inositol content of breast milk is fairly high, 
suggesting that myo-inositol has a specific function in neonatal growth and 
development (45,46).  
  
Derivatives 
Myo-inositol is one of nine stereoisometric hexahydroxycyclohexanes (the 
inositols) (47,48). In mammalian tissue and cells, myo-inositol is the most 
predominant of these isomers. Its molecular structure is given in Figure 3. 
Specific inositol kinases can produce phosphorylated forms of myo-inositol. 
One, or even all six carbons can be phosphorylated, leading to a variety of 
inositol mono-, bi-, tri-, and tetra-, and hexaphosphates (myo-inositol(..)P*).  
Myo-inositol also exists in the form of various inositol phospholipids, called 
phosphoinositides. Phosphoinositides are membranebound glycerophospholipids 
built around myo-inositol. Phosphatidylinositol (PI); sn-1,2-diacyl-glycero-3-
phospho-D-1-myo-inositol (Fig. 3), is the most abundant phosphoinositide in 
mammalian cells (approximately 5-20%) (47).  
Phosphatidylinositol biosynthesis (Figure 4A) is localized in the endoplasmatic 
reticulum of eukaryotic cells, and PI transporter proteins transport it to other 
parts of the cell (47). The specialized functions of phosphoinositides are mainly 
fulfilled by phosphorylated derivatives of PI (PIPs) (47). Seven of these lipids 
have been identified so far.  
Adult humans consume approximately 1 g of myo-inositol per day in different 
metabolic forms (47). Animal products mostly contain free myo-inositol and 
inositol phospholipids, while plant sources mainly provide myo-inositol in the 
form of phytic acid (inositol hexaphosphate; myo-inositol-P6) (49). 
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          Myo-inositol    Phosphatidylinositol 
Figure 3. Structures of free myo-inositol and phosphatidylinositol. 
 
Free myo-inositol is actively transported across the intestinal wall by a 
mechanism dependent on sodium and energy, which can be inhibited by glucose 
(50,51). It is transported in human blood plasma at a concentration of 
approximately 30 µM in normal subjects (44). Circulating free myo-inositol is 
taken up by most tissues by a membrane-associated, sodium-dependent myo-
inositol cotransporter that is temperature dependent, energy dependent, and 
saturable (47,51-53). Although this carrier is distinct from the normal glucose 
transporter in cells, transport of myo-inositol is competitively inhibited by 
glucose (44,51). 
Besides the possibility of the absorption of free myo-inositol from the intestine, 
there are two other ways for cells to obtain myo-inositol. Firstly, several 
mammalian tissues (including testis, mammary gland, brain, liver, and kidney) 
are able to synthesize myo-inositol from glucose by the enzyme 1L-myo-
inositol 1-phosphate synthase (EC 5.5.1.4) (50,54). For example, it has been 
estimated that one human kidney can synthesize approximately 2 g of myo-
inositol per day (50). This enzyme can be inhibited by lithium (47). The second 
possibility for cells to obtain myo-inositol is by recycling of phosphatidyl-
inositol diphospate (PIP2; Figure 4B). The intermediates of this recycling to 
myo-inositol are several inositol (poly)phosphates. As shown in Figure 4B, 
some of the enzymes involved in the recycling of myo-inositol are also 
sensitive to lithium. This means that cells that are exposed to lithium, will 
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ultimately be depleted of myo-inositol, and thus are completely dependent on 
myo-inositol from extra-cellular sources (55). 
  
Figure 4. A) A schematic presentation of the pathway whereby myo-inositol is converted into the 
phosphoinositides (44). B) Recycling of phosphatidylinositol diphosphate (PIP2) to free myo-inositol via various 
intermediate inositol (poly)phosphates (myo-inositol(..)P*). The arrows with circles represent lithium sensitive 
enzymes: grey circle, inositol polyphosphate 1-phosphatase; white circles, inositol monophosphate phosphatase 
(55). 
 
Glycosyl-phosphatidylinositol (GPI) is a very particular derivative of myo-
inositol. The GPI structures covalently anchor several proteins to the plasma 
membrane. They are present in vertebrates, invertebrates, insects, protozoa, 
yeast and slime moulds, but not in bacteria, fungi and higher plants (54,56). 
Some 150 different GPI-anchored proteins have been identified, belonging to a 
diverse family of molecules, including enzymes, adhesion molecules, antigens, 
differentiation markers, and protozoan coat components (54,57). These proteins 
are located exclusively on the extra-cellular side of the plasma membrane 
owing to their lack of a transmembrane domain and cytoplasmatic tail (57). 
Although there is structural and functional heterogeneity of GPI-linked proteins, 
all GPI anchors have a highly conserved core structure. It is built up by 
sequential addition of individual sugars and ethanolamine phosphate to a PI 
molecule on the cytoplasmic side of the rough endoplasmatic reticulum and 
consists of ethanolamine-PO4-6Manα1-2Manα1-6Manα1-4GlcNH2α1-6-myo-
inositol-1-PO4-lipid (Figure 5) (54,56). The C-terminus of the protein directs 
addition to the GPI anchor (54). 
      Ins(1,4)P2                          Ins(1,3,4,5)P4
 Ins                Ins(3,4)P2         Ins(1,3)P2
    Ins3P                 Ins1P
     Ins(1,4,5)P3
  Ins4P                       Ins(1,3,4)P3
  
 Ins                     Ins
PIP2myo-inositol
PI
PIP
PIP2
ATP
ATP
(A) (B)
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Lipid moiety
Membrane
P
myo-inositol
Glucosamineglycan
P
MannosePEthanolamine
Protein
Ethanolamine
PLD
PLC
 
Figure 5. Structure of GPI-anchor (54,56,57). The anchor can be cleaved by phospholipase C or D (PLC and 
PLD respectively) (57). 
 
The kidneys play a major role in the regulation of plasma myo-inositol 
concentration. Besides being able to synthesize myo-inositol, they are also the 
primary site of disposal. In humans, chronic renal failure has been shown to 
cause markedly elevated myo-inositol levels which were brought to normal 
levels following renal transplantation (50). In this same study, the human kidney 
was found to dispose of 1 g per day myo-inositol, which rose to 21 g per day 
when it was exposed to hyperinositolemia. In fact, the kidney is the only organ 
containing myo-inositol oxygenase (EC 1.13.99.1), the rate limiting enzyme in 
the catabolism of myo-inositol (58). This enzyme catalyses the first step in the 
catabolism of myo-inositol, the reaction by which myo-inositol is oxidized to 
glucuronic acid. Later, it was shown in the adult rabbit that myo-inositol 
oxygenase activity was mainly found in the cortex of the kidney, while cyclase 
(=1L-myo-inositol 1-phosphate synthase) activity, which synthesizes myo-
inositol from glucose, was mainly found in the medulla of the kidney (58). The 
rat kidney has been shown to dispose of myo-inositol for a significant part by 
degrading it to respiratory CO2, while urinary excretion only played a small part 
in the disposal of myo-inositol (47). 
 
Function 
Free myo-inositol itself has been implicated in the control of cell volume and 
cell osmolality (52). Others have shown that myo-inositol is also a lipotropic 
factor. In rats, dietary myo-inositol was shown to prevent accumulation of 
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triglycerides in the liver, and in gerbils it was shown to prevent lipid 
accumulation in the intestine (59,60).  
Several water soluble inositolphosphates have been identified, e.g. at least 25 
compounds have been identified in the fungus Dictyostelium, and in mammalian 
cells (61,62). The most studied of the inositolphosphates is myo-inositol-1,4,5-
triphosphate (63-65). This second messenger is formed by cleaving of PI(4,5)P2 
when cells are stimulated by growth factors or other hormones: 
 
 
 
 
The result, modulation of the calcium ion (Ca2+) concentrations and specific 
protein phosphorylation processes via PKC, modulates a network of further 
cellular processes (65). This important signaling pathway is involved in 
fertilization, cell growth, transformation, secretions, smooth muscle cell 
contraction, sensory perception, neural signaling, and has been implicated in the 
control of cell proliferation (63,65).  
However, several other inositol phosphates also have various biological 
functions. Myo-inositol-(3,4,5,6)-tetraphosphate was shown to regulate Ca2+-
stimulated Cl- secretions. Besides being relevant to salt and fluid secretions, 
this may also regulate osmolarity, pH, and smooth muscle excitability (66). 
Myo-inositol-1,3,4,5,6-pentaphosphate and myo-inositol-hexaphosphate are 
the two most abundant myo-inositol polyphosphates in most eukaryotic cells, 
with concentrations of between 10 µM and 1 mM, but their roles remain highly 
speculative (67). The one well known cytosolic function of myo-inositol-
1,3,4,5,6-pentaphosphate is modulation of the oxygen affinity of hemoglobin in 
avian erythrocytes (68). The idea that these compounds might act as short-
term cellular signals has been dismissed since they are only slightly affected by 
extra-cellular signals. It has been suggested that myo-inositol-1,3,4,5,6-
pentaphosphate and myo-inositol-hexaphosphate merely serve as stores of 
myo-inositol and/or phosphate (69). However, their ability to bind to certain 
proteins might serve several biological functions (66,69). 
PI(4,5)P2
Diacylglycerol
Ins(1,4,5)P3
Phospholipase C
Protein kinase C (PKC)
Ca2+
  18 
Phosphatidylinositol is enriched in stearic and arachidonic acids, which may 
serve as a source of releasable arachidonic acid for eicosanoid synthesis (47). 
In addition, PI can modulate the activity of membrane-bound enzymes such as 
Na/K ATPase, and mediate trans-membrane passage of proteins (47). 
Phosphatidylinositol has also been found to affect tyrosine hydroxylase, an 
enzyme that catalyzes the rate-limiting step in the biosynthesis of 
catecholamines, dopamine and norepinephrine (47). 
Since phosphoinositides can be quickly made and degraded, they seem ideal 
regulators of the highly dynamic cytoskeleton and endomembrane. There are 
indications that PI(4,5)P2, PI(3,5)P2, and PI3P may serve such a role. Recent 
studies have revealed that PI(3,4,5)P3 functions as a second messenger of the 
insulin signaling pathway, leading to increased glucose uptake and glycogen 
synthesis (70).  
Besides anchoring of proteins, other functions of the GPI anchor have been 
proposed, but it remains obscure why some proteins are anchored by a trans-
membrane polypeptide, and others by GPI. One of the most clear additional 
roles of GPI-anchors is the fact that they are susceptible to cleavage by 
phospholipase C or D (Figure 5) (57). This would allow for rapid down-
regulation of the protein from the cell surface and/or for the generation of its 
soluble form (54). This release may be either hormonally or developmentally 
regulated. For example, several GPI-anchored proteins are susceptible to 
release from the cell-surface in response to insulin, possibly through the action 
of PLC. Also, GPI-anchors allow for denser clustering of proteins, and for more 
lateral mobility in the membrane than trans-membrane polypeptide anchors. 
The GPI-anchors can act as a targeting signal in polarized epithelial cells, 
directing the protein to the apical membrane. Furthermore, certain GPI-
anchored proteins are concentrated into detergent-insoluble lipid domains in 
the membrane where they are involved in the clathrin-independent endocytic 
process called potocytosis (54,57). Trans-membrane signaling may also occur 
through GPI-anchored proteins when they interact with protein-tyrosine 
kinases. 
Greene and Copp showed that supplementation of pregnant curly tail (ct) mice 
with an intra peritoneal injection of 400 mg/kg myo-inositol 24 h before 
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completion of neural tube closure reduces the occurrence of spina bifida with 
70% (41). In vitro, myo-inositol in a concentration of 50 µg/ml also enhanced 
neuropore closure. This could be abolished by adding 200 µg/ml lithium chloride 
to the culture medium, so the myo-inositol effect seems to be mediated by the 
phosphatidylinositol cycle. However, the lithium chloride did not worsen the 
delay of neuropore closure in ct embryos in the absence of myo-inositol, 
suggesting that the basic abnormality in ct embryos does not involve a myo-
inositol deficiency. Investigation of the downstream mechanism of myo-inositol 
lead to the conclusion that the arachidonic acid pathway is not mediating the 
effect on the neuropore, arachidonic acid even inhibited the preventive effect of 
myo-inositol. The beneficial effect of myo-inositol could, however, be 
mimicked by a protein kinase C (PKC) agonist, so myo-inositol could be 
stimulating this enzyme. Both myo-inositol and the PKC agonist caused up 
regulation of retinoic acid receptor beta expression. Possibly, myo-inositol 
supplementation stimulates PKC, which in turn enhances expression of the 
retinoic acid receptor beta, and thereby prevents NTDs in ct mouse embryos.  
As described previously, cellular uptake of myo-inositol is competitively 
inhibited by high levels of glucose that are present in the diabetic state. This 
may be an explanation for the observation that diabetic mothers have an 
increased risk for neural tube defects in their offspring (42,51,71-73).  
 
Zinc 
Zinc is an essential trace element for more than two hundred enzymes and is 
therefore important for the stabilization of the structure of proteins and nucleic 
acids, protection of erythrocytes and other tissues from super-oxide ion 
damage (super-oxide dismutase), regulating hormone activity of glucagon, 
insulin, growth and sex hormones and is indispensable in viral and immune 
phenomena (74-78). Its importance is being emphasized by experimental and 
human studies in which maternal zinc deficiency resulted in subfertility, 
prolonged labor, intrauterine growth retardation, teratogenesis, and embryonic 
or fetal death (79). With respect to teratogenesis a wide range of embryonic or 
fetal malformations have been noted under which defects of the central nervous 
system, such as spina bifida and skeletal defects. 
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In observational studies zinc concentrations in hair, serum and amniotic fluid, 
were associated with spina bifida. The data, however, are very conflicting (80) 
(81-83). 
Although zinc is ubiquitously available in a regular human diet and is found in 
red meats, poultry, oysters, eggs, legumes, nuts, milk, yogurt, whole-grain 
cereals, its bioavailability is modified by other constituents of the diet (74). For 
instance, phytic acid forms insoluble complexes with dietary zinc thereby 
inhibiting the uptake of zinc in the small intestine (84,85). Similarly, the milk 
protein casein binds zinc in the intestinal lumen making it unavailable for 
absorption (84,85). Additionally, other trace elements such as calcium, copper 
and iron are able to block zinc uptake by interference with zinc transporters. 
The genes that are involved in mammalian zinc transport have recently been 
cloned and belong to the ZnT family (86). To date, four have been cloned and at 
least in some, expression is regulated by dietary zinc intake (ZnT-1). These 
transporters have been observed in most tissues under which the enterocytes 
of the small intestine and renal tubular cells.  
Zinc in blood plasma is transported at concentrations ranging from 10 to 18 
µmol/l, whereas zinc in erythrocytes is approximately 10 times that of the 
plasma concentration. As previously mentioned zinc deficiency has been 
associated with congenital malformations in both experimental and human 
studies. Especially, patients with the rare autosomal recessive disease 
acrodermatitis enteropathica causing severe zinc deficiency, demonstrated 
significantly elevated risk of spina bifida in the offspring (87). Other reports 
also associated zinc metabolism with neural tube defects (81,88-90). Of interest 
is the report by Uriu-Hare et al. demonstrating enhanced diabetes-induced 
teratogenicity by maternal dietary zinc deficiency in streptozocin-induced 
diabetic Sprague-Dawley rats, suggesting a link between the glucose and myo-
inositol carbohydrate metabolism and zinc metabolism (91). 
 
Objectives of the thesis 
From this review it has become clear that myo-inositol and zinc play a role in 
the etiology of spina bifida. Low tissue concentrations of myo-inositol, possibly 
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mediated by high glucose concentrations, and a compromised zinc status may 
be risk factors for spina bifida. Therefore, this thesis aims to investigate:  
1. myo-inositol and zinc status and related environmental determinants as risk 
factors for spina bifida (Part I); 
2. the kinetic and course of myo-inositol and zinc in blood and amniotic fluid 
during pregnancy (Part II). 
 
Outline of the thesis 
The studies in part I are based on a nationwide case-control triad study and 
concern the role of myo-inositol, zinc and related environmental factors in the 
etiology of spina bifida. In chapter 2, a case-control study is presented to 
evaluate the concentrations of both nutrients determined in the blood of the 
mothers and children with spina bifida and controls. In chapters 3 and 4, 
polymorphisms in genes coding for proteins transporting myo-inositol and zinc 
and myo-inositol and zinc concentrations are evaluated in a case-only design of 
spina bifida mothers and children. In the case-control studies presented in 
chapters 5 and 6, possible associations between maternal and child B-vitamin 
status, and maternal nutritional intakes and spina bifida offspring are evaluated, 
and in chapter 7 lifestyle factors possibly involved in the etiology of spina bifida 
are investigated. 
In part II, studies on the kinetics and course of myo-inositol and zinc in blood 
and amniotic fluid during pregnancy are described. In chapter 8 the results of a 
kinetic study are presented in which the effects of myo-inositol loading on 
serum and urinary myo-inositol concentrations are studied. A longitudinal study 
was undertaken to describe the normal course of myo-inositol and zinc 
concentrations in serum and red blood cells during normal pregnancy in chapter 
9. In chapter 10, amniotic fluid concentrations of these nutrients are studied to 
provide early information of myo-inositol and zinc status. The 1H-NMR 
technique is employed to identify alterations in the composition of the amniotic 
fluid of pregnancies affected by spina bifida and controls (chapter 11). In 
chapter 12 the results of this thesis are discussed. 
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PART I 
 
Myo-inositol, Zinc and Environmental Factors 
 
 
 
 
 
 
 
 
Chapter 2: Maternal myo-inositol, glucose and zinc status is associated 
 with the risk of offspring with spina bifida. 
Chapter 3: Spina bifida and genetic factors related to myo-inositol,  
 glucose and zinc. 
Chapter 4: Genetic variants in ZIC1, ZIC2 and ZIC3 are no major  
 risk factors for neural tube defects in humans. 
Chapter 5: Low maternal dietary intakes of iron, magnesium and niacin  
 are associated with spina bifida in the offspring. 
Chapter 6: Marginal maternal vitamin B12 status is associated with an  
 increased risk of spina bifida offspring. 
Chapter 7: Periconceptional health and lifestyle factors in parents  
 of spina bifida offspring. 
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C H A P T E R   2 
 
Maternal myo-inositol, glucose and zinc status is associated 
with the risk of offspring with spina bifida 
 
Pascal MW Groenen, Petronella GM Peer, Ron A Wevers,  
Dorine W Swinkels, Barbara Franke, Edwin CM Mariman,  
Régine PM Steegers-Theunissen 
 
American Journal Obstetrics and Gynecology 2003;189:1713-1719. 
 
  
OBJECTIVE: To investigate the maternal and children's myo-inositol, glucose and zinc 
status in association with spina bifida risk.  
STUDY DESIGN: Sixty-three mothers and 70 children with spina bifida and 102 control 
mothers and 85 children were investigated. The maternal and child's serum myo-
inositol, serum glucose and red blood cell zinc concentrations were measured when the 
child was between 1 and 3 years of age. These data were compared between cases and 
controls. The association with spina bifida was expressed by the ratio of geometric 
means and by odds ratios and 95% confidence interval (OR (95% CI)) for a cutoff value 
at the extreme 10th percentile of the control group.  
RESULTS: The geometric mean of the maternal myo-inositol concentration tended to 
be 5% (95% CI, -1%-11%) lower in cases. Interestingly, the OR for the extreme low 
maternal myo-inositol concentration was 2.6 (1.1-6.0). The glucose and zinc 
concentrations were significantly higher, 7% (95% CI, 4%-10%), and significantly lower, 
5% (95% CI, 0%-9%), in case-mothers compared with control-mothers. The ORs (95% 
CI) for maternal high glucose and low zinc concentrations were 4.6 (2.0-10.5) and 2.9 
(1.2-7.0), respectively. The geometric mean of the myo-inositol concentration tended 
to be 7% (95% CI, 0%-14%) lower in spina bifida children and the glucose and zinc 
concentrations were comparable.  
CONCLUSION: Maternal myo-inositol, glucose and zinc status are associated with the 
risk of spina bifida offspring. Furthermore, the myo-inositol status of the child seems to 
contribute to this risk as well.  
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Introduction 
 
Maternal nutrition is an important environmental factor in the etiology of neural 
tube defects (1). Folic acid supplementation is widely used to prevent spina 
bifida and anencephaly, which both are categorized as neural tube defects (2,3). 
Not all neural tube defects respond to periconceptional folic acid 
supplementation (4). Studies in mice provide evidence that neural tube defects 
associated with homozygosity for mutations in PAX3, Cart1 and crooked tail 
genes can be prevented by folic acid (5-7). This is in contrast to the folate-
resistant curly tail mouse with a genetic predisposition for neural tube defects 
(8).  
Experimental data suggests that myo-inositol (MI) and D-chiro-inositol 
supplementation reduce the birth-prevalence rate of spina bifida in the curly tail 
mouse model for neural tube defects (9,10). Moreover, dietary inositol seems to 
reduce the frequency of neural tube defects in Streptozotocin-induced diabetic 
Sprague-Dawley rats (10-12). Human studies on this issue are scarce. One 
recent case-report describes the beneficial effect of periconceptional treatment 
of inositol in combination with folic acid in an apparent folate-resistant spina 
bifida family (13). 
Myo-inositol is the predominant stereoisomer of hexahydroxycyclohexane in 
mammalian tissue that plays a key role in the intracellular inositol-1,4,5-
triphosphate signaling pathway (14-15).  After receptor activation by a wide 
variety of hormones and growth factors, membrane-bound phosphatidylinositol-
4,5-biphosphate is cleaved into inositol-1,4,5-triphosphate and diacylglycerol. 
Inositol-1,4,5-triphosphate triggers calcium release from the endoplasmic 
reticulum, resulting in cellular reactions such as activation of the protein kinase 
C enzyme and DNA transcription. In healthy adults the serum concentration of 
MI is approximately 30 µmol/L and reflects the dietary inositol intake, e.g. 
vegetables and liver, endogenous synthesis from glucose, cellular metabolism 
and clearance (14,16,17). The adult diet contains approximately one gram of MI 
per day that is taken up by sodium- and energy-dependent cotransporters that 
are located in the cells of the intestine and in most other tissues (15,18). Other 
sources for MI are inositol-1,4,5-triphosphate recycling and the de novo 
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biosynthesis from glucose by myo-inositol-1-phosphate synthase (EC 5.5.1.4.) 
(19). Myo-inositol clearance is accomplished by myo-inositol oxygenase (EC 
1.13.99.1) into D-glucuronate and is followed by renal excretion (20).  
Cellular uptake of MI is competitively inhibited in diabetes mellitus because of 
hyperglycemia. Diabetic mothers have an increased risk for neural tube defects 
in their offspring. The teratogenicity of hyperglycemia could therefore be 
explained by a secondary cellular MI depletion, as suggested by studies in both 
man and rats (12,18,21-24). 
A derangement of maternal zinc status, leading to enzymatic and hormonal 
disturbances and cellular dysfunctions, is implicated in the etiology of neural 
tube defects as well (25-29). The link between the teratogenicity of zinc 
deficiency, MI shortage, and hyperglycemia can be partially due to the diabetic 
state (30). This is in line with the finding that diabetic patients suffer from zinc 
deficiency. 
The aims of this study were to determine the concentrations of MI, glucose and 
zinc in the blood of mothers and their children with spina bifida and in control 
subjects and their children and to estimate the risk for spina bifida induced by a 
low MI and a low zinc status and elevated glucose concentrations.  
 
 
Subjects and Methods 
 
Patients and controls 
We designed a case-control study, i.e. case-mothers and their children and 
control-mothers and their children. Between August 1999 and December 2001, 
76 mothers and their children with spina bifida were recruited in collaboration 
with the Dutch Spina Bifida Teams of the University Medical Centers in 
Nijmegen, Utrecht, Groningen, Rotterdam, Leiden, Amsterdam and the regional 
hospitals in Tilburg and Zwolle. Dutch Caucasian children, between one and 
three years of age, with a nonsyndromic meningo(myelo)cele diagnosed by a 
geneticist and neuropediatrician at birth, further indicated as spina bifida, were 
eligible to participate. For the control subjects to resemble the population of 
cases, they were recruited from midwiferies, nurseries and acquaintances of the 
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case-mothers in Nijmegen and surroundings in The Netherlands as previously 
described by Van Rooij et al. (31). One hundred and eleven children in the same 
age range without a major congenital malformation, and their mothers were 
recruited. Exclusion criteria were (i) pregnancy at the moment of blood 
sampling, (ii) consanguinity, (iii) a familiar relationship between the spina bifida 
and control subjects and (iv) maternal diabetes mellitus. 
Mothers of a child with spina bifida were invited to participate by the Spina 
Bifida Team. After the investigator provided the mother information about the 
study, informed consent was obtained. Appointments were made at the 
Department of Pediatrics of the University Medical Center in Nijmegen for 
blood sampling and verification by the investigator of the questionnaires (filled 
out at home) for information about current lifestyle, demographic factors and 
pregnancy. 
Among the spina bifida group, 13 mothers (9 pregnancies and 4 withdrawals) 
and, in the control group, 9 mothers (8 pregnancies and 1 withdrawal) were 
excluded. In 26 control and 6 spina bifida children blood sampling could not be 
performed. The younger age of the control children more frequently lead to 
failure of blood sampling. Thus, 63 mothers and 70 children with spina bifida 
and 102 control mothers and 85 children were included in the study. The study 
protocol was approved by the Institutional Review Board of the University 
Medical Center Nijmegen in the Netherlands. 
 
Blood sampling 
Mothers and their children visited the outpatient clinic of the University Medical 
Center Nijmegen in the Netherlands. Mothers fasted from 10 p.m. the day 
before the blood sampling and were asked to refrain from adding sugar to their 
children's breakfast. Two milliliters of maternal venous blood and 1 mL venous 
blood of the child was drawn into a Vacutainer blood-collecting tube (Becton 
Dickinson, Rutherford, NJ) that contained potassium oxalate and sodium fluoride 
for the MI measurement. In addition, 4 mL and 0.75 mL of venous blood from 
the mother and the child respectively, were drawn into a Vacutainer that 
contained EDTA for the measurement of zinc. 
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Measurement of MI and glucose 
Myo-inositol and glucose concentrations were determined by trimethylsilylation 
and gas chromatography according to a modification of the procedure by Jansen 
et al. (32), which has been described elsewhere (33). The detection limit of MI 
and glucose was ± 0.5 µmol/L. The intra-assay coefficient of variation for MI 
and glucose was 10.4% and 4.3%, respectively. 
 
Measurement of zinc 
Red blood cell zinc concentrations were determined by flame atomic absorption 
spectrophotometry (Perkin Elmer 4100; Norwalk, Connecticut, USA). To 1 mL 
of venous blood, 9 mL of a physiological salt solution was added; the sample 
was centrifuged for 10 minutes at 400x g at 4°C. The supernatant was removed; 
the cell pellet resuspended into 10 mL of a physiological salt solution and 
centrifuged for 10 minutes at 400x g at 4°C. After removal of the supernatant, 
the red blood cells were lysed by adding 2 mL of MilliQ (Millipore; Billerica, 
USA). The lysed red blood cell samples were stored at – 20°C until assayed. 
The intra- and inter-assay coefficient of variation for zinc were 3.4% and 3.5%, 
respectively (level 12 µmol/L). 
 
Statistical analysis 
Because of the data were skewed positively, they were summarized with the 
geometric mean that can be interpreted as the median and P5-P95 interval. The 
differences in concentrations of blood parameters between the spina bifida and 
control group were assessed with a Students t test after logarithmic 
transformation of the concentrations. Back transformation of the 95% 
confidence intervals (95% CI) for the difference in means after logarithmic 
transformation yields a 95% CI for the ratio of geometric means of the original 
data. To control for the higher age of spina bifida children an analysis of 
covariance was employed. The 95% CIs were computed for the ratio of 
geometric means. 
Maternal serum concentrations of MI, glucose and red blood cell zinc were 
dichotomized at the extreme 10th percentile value of the control mothers. An 
elevated risk for a spina bifida child in the extreme groups can be inferred from 
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the odds ratios (OR) with 95% CI. The simultaneous effect of these extreme 
concentrations was established in a logistic regression model. Also, the possible 
confounding effect of patient characteristics was adjusted for in a multivariate 
logistic regression model. Pearson correlation coefficients were calculated after 
logarithmic transformation of the blood concentrations.  
Probability values of < .05 were considered statistically significant. All 
statistical analyses were performed with the SAS software (version 8; SAS 
Institute Inc, Cary, NC). 
 
 
Results 
 
Characteristics of the case and control group are summarized in Table I. 
Mothers were comparable with regard to age and oral contraceptive use at the 
moment of blood sampling. Current alcohol use was clearly higher in control 
mothers than in cases. The educational level was apparently lower in case 
mothers. Children with spina bifida were older at the moment of blood sampling 
than controls. 
The geometric mean of the maternal serum MI concentrations tended to be 5% 
(95%CI, -1%-11%) lower in cases (Table II). Serum glucose and red blood cell 
zinc concentrations were significantly higher, 7% (95%CI, 4%-10%), and 
significantly lower, 5% 95%CI, 0%-9%) in mothers of a child with spina bifida 
compared with controls (Table II). Because of the heterogeneous etiology of 
spina bifida and for internal validity, cutoff values were determined by taking 
the extreme 10th percentile value of the control group as an abnormal low 
maternal MI (≤13.2 µmol/L), low zinc (≤190 µmol/L) and high glucose 
concentration (≥4.5 mmol/L). The OR (95% CI) for maternal MI was 2.6 (1.1-
6.0), for glucose was 4.6 (2.0-10.5), and for zinc was 2.9 (1.2-7.0) respectively 
(Table III). 
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Table I. Characteristics at blood sampling of the two groups of mothers  
and their children expressed as medians (5th – 95th percentile) or frequency (%). 
 
 Spina bifida group Control group P 
Mothers N=63 N=102  
 Age (years) 32.0 (25.4 – 39.1) 33.2 (27.5 – 39.2) 0.27 
 Oral contraceptive use (yes) 49.2% 42.2% 0.41 
 Smoking (yes) 23.8% 15.7% 0.18 
 Alcohol use (yes) 52.4% 74.5% <0.05
 Educational level (high) 31.8% 66.7% <0.01
    
Children N=70 N=85  
           Age (years) 1.7 (0.8 – 3.8) 1.1 (0.8 – 2.5) <0.01
           Gender (boy) 34.3% 47.1% 0.23 
 
The geometric mean of the serum MI concentrations tended to be 7% (95%CI, 
0%-14%) lower in spina bifida children (Table II). The glucose and zinc 
concentrations in children were not statistically significantly different. Little is 
known about the influence of age on biochemical parameters, particularly in 
young children. Because of the difference of child age between both groups, we 
adjusted the associations for child's age at the time of blood sampling.  The 
adjusted associations between the blood concentrations and spina bifida were 
not statistically significant (Table II). In children, the extreme 10th values and 
ORs (95% CI) for abnormal low MI was ≤19.1 µmol/L, for low zinc was ≤118 
µmol/L and for high glucose concentration was ≥4.3 mmol/L. The ORs (95% CI) 
were for child MI 2.7 (1.0-7.2), glucose 1.8 (0.6-10.5) and zinc 1.4 (0.4-4.5) 
respectively, Table IV. The adjusted associations between the child blood 
concentrations and spina bifida were not statistically significant (Table IV). 
To identify a subgroup of women who might be especially at risk for a marginal 
MI and zinc status, and hyperglycemia, we selected out of the spina bifida 
mothers who had used folic acid or a multivitamin supplement including folic 
acid during the periconceptional period of the index-pregnancy. The rationale 
was that, for women who used folic acid and still gave birth to a child with spina 
bifida, the spina bifida could not be due to folate deficiency but to other factors, 
e.g. marginal MI and zinc status and hyperglycemia. This group (n = 33 
mothers) was compared with the control mothers (n = 60 mothers), who 
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periconceptionally used a similar supplement. It revealed that low MI, high 
glucose or low zinc concentrations were more frequent in the case-mothers 
who used supplements periconceptionally (OR, 2.8 [0.9-9.0], 4.3 [1.5-12.3] 
and 4.5 [1.3-15.3], respectively).  
 
Table II. Concentrations of blood parameters in mothers and their children,  
expressed as geometric means (5th – 95th percentile) and ratio of geometric means (95% 
confidence intervals). 
Parameter  
(Spina bifida/Controls) 
Spina bifida group Control group RatioCrude 
(95% CI) 
P RatioAge Adjusted 
(95% CI) 
P 
Mothers N=63 N=102     
Myo-inositol (µmol/L) 
(N=63/101) 
15.5 (11.3 – 22.0) 
 
16.3 (12.3 - 22.3)  
 
0.95 
(0.89 – 1.01) 
0.08   
Glucose (mmol/L) 
(N=63/101) 
4.4 (3.7 – 5.3) 4.1 (3.7 – 4.7) 1.07 
(1.04 – 1.10) 
<0.01   
Zinc (µmol/L) 
(N=56/96) 
209 (143 – 274)  219 (169 – 262)  0.95 
(0.91 – 1.00) 
0.04   
       
Children N=70 N=85     
Myo-inositol (µmol/L) 
(N=68/73) 
23.8 (15.2 – 38.1)  
 
25.7 (17.5 – 35.0)  
 
0.93 
(0.86 – 1.00) 
0.06 1.03 
(0.96 – 1.11) 
0.40 
Glucose (mmol/L) 
(N=68/73) 
3.9 (3.2 – 4.8)  
 
3.8 (3.1 – 4.5)  
 
1.03 
(0.99 – 1.07) 
0.18 1.01 
(0.97 – 1.07) 
0.55 
Zinc (µmol/L) 
(N=51/74) 
153 (97 – 209)  
 
145 (114 – 206)  
 
1.05 
(0.98 – 1.14) 
0.18 0.98 
(0.89 – 1.07) 
0.65 
 
Ratiocrude: crude ratio of geometric means; RatioAge Adjusted: Adjusted ratio of geometric means 
95% CI: 95% Confidence Interval; P: P-value of Students T-test after logarithmic 
transformation of the data  
 
Table III. The spina bifida risk of myo-inositol, glucose and zinc concentrations in mothers.  
 Mothers   
 
Spina bifida 
group 
Control 
group 
Univariate 
Odds Ratio 
(95% CI) 
Multivariate 
Odds Ratio 
(95% CI) 
Myo-inositol, serum (µmol/L)a     
 10.0 – 13.2 15 11 2.6 (1.1 – 6.0) 2.7 (1.0 – 7.5) 
 13.2 – 40.0 48 90 1.00 (reference) 1.00 (reference) 
     
Glucose, serum (mmol/L)b     
 3.3 – 4.5 42 91 1.00 (reference) 1.00 (reference) 
 4.5 – 6.3 21 10 4.6 (2.0 – 10.5) 3.8 (1.5 – 9.9) 
     
Zinc, red blood cell (µmol/L)a     
 105 – 190 14 10 2.9 (1.2 – 7.0) 5.3 (1.7 – 16.0) 
 190 – 281 42 86 1.00 (reference) 1.00 (reference) 
Odds Ratios and 95% confidence intervals; a10%; b90% cutoff values of the control group  
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Current supplement use was more frequent in case-mothers compared to 
control mothers, 28.6% and 12.8%, respectively. Therefore, in the control 
mothers, an evaluation was performed about whether the use of folic acid, zinc 
or multivitamin supplements influenced the concentrations of MI, glucose, and 
zinc. No significant differences in the biochemical parameters could be 
observed (data not shown). In addition, adjustment for current use of 
multivitamins, educational level, body mass index, smoking, and the use of 
alcohol and oral contraceptives gave similar OR estimates for the association 
between marginal MI and zinc status, and hyperglycemia and spina bifida 
offspring (Table III). 
 
Table IV. The association of the myo-inositol, glucose and zinc concentrations with spina bifida 
in children.  
 Children   
 Spina bifida 
Group 
Control 
Group 
Univariate 
Odds Ratio 
(95% CI) 
Age Adjusted 
Odds Ratio 
(95% CI) 
Myo-inositol (µmol/L)a     
 13.0 – 19.1 14 7 2.7 (1.0 – 7.2) 0.9 (0.3 – 3.1) 
 19.1 – 51.9 45 60 1.00 (reference) 1.00 (reference) 
 Age    2.9 (1.6 – 5.3) 
     
Glucose (mmol/L)b     
 3.1 – 4.3  50 61 1.00 (reference) 1.00 (reference) 
 4.3 – 6.0 9 6 1.8 (0.6 – 5.5) 1.1 (0.3 – 3.9) 
 Age    2.9 (1.7 – 4.9) 
     
Zinc (µmol/L)a     
 71 – 118 6 7 1.4 (0.4 – 4.5) 2.8 (0.7 – 11.4) 
 118 – 283 37 60 1.00 (reference) 1.00 (reference) 
 Age    11.9 (4.0 – 35.7) 
Odds Ratios and 95% confidence intervals; a10%; b90% cutoff values of the control group  
 
Correlation analysis revealed significant associations between the maternal and 
child MI concentrations, rPearson=0.24 (p<0.01) and an inverse correlation 
between maternal glucose and zinc concentrations, rPearson=-0.27 (p<0.05), in 
the case group. 
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Discussion 
 
This study demonstrates for the first time in humans that a low maternal serum 
MI concentration is associated with a 2.6-fold increased risk of offspring with 
spina bifida. The same determinant in mothers who used a periconceptional folic 
acid containing supplement, known to reduce folate-dependent spina bifida risk, 
revealed a similar increased (2.8-fold) risk estimate. Data from experimental 
animal studies support this finding (10-13). In mothers of spina bifida children 
the geometric mean MI concentration was 5% lower compared to controls. 
These findings are in line with the multifactorial etiology of spina bifida, which 
suggests that only a subset of these mothers carries this risk factor. Whether 
the low MI concentration reflects a derangement in MI metabolism because of 
functional polymorphisms in MI pathways and/or decreased dietary MI intake 
needs further investigation.  
Of interest is the 7% lower MI concentration in children with spina bifida 
compared to control children. Together with the lower MI concentrations in 
their mothers and the significant association between those levels, this may 
suggest the involvement of functionally related genetic aberrations in MI 
metabolism. On the other hand, the MI concentrations in the children of both 
groups were comparable after adjustment for age at the moment of blood 
sampling. The age difference in our study population is due to a subset of spina 
bifida children between 2.5 and 3.8 years of age. It is unknown whether the MI 
concentrations decrease during these years of life. The lower MI concentrations 
in children could be a physiological response to the maturation of the organ 
systems that are involved in MI metabolization and/or the changing dietary 
pattern in childhood.  
The finding of the lower serum MI concentrations in spina bifida children is in 
line with our recent results from another study. We demonstrated in a case-
control study that inositol levels, determined by proton magnetic resonance 
spectroscopy in vivo in brain tissue of fetus with spina bifida and hydrocephalus 
were significantly lower compared to controls (34). Whether a derangement in 
tissue-specific MI metabolism is a cause of spina bifida needs further 
elucidation. 
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In diabetic pregnancies, hyperglycemia is associated with an increased risk for 
spina bifida. It was surprising therefore to establish that mildly elevated 
maternal serum glucose concentrations of ≥ 4.5 mmol/L, in the absence of 
diabetes in our study group, also increased the risk for spina bifida 4.3-fold in 
periconceptionally supplemented mothers to 4.6-fold in the total group. High 
glucose concentrations interfere with the cellular uptake of MI, as has been 
demonstrated in rats and in diabetic patients (12,35). The lower MI 
concentrations in mothers of spina bifida children might partially be explained 
by the mildly elevated glucose concentrations. However, maternal serum MI and 
serum glucose concentrations were not correlated (rPearson = -0.03). It is 
possible that these minor correlations cannot be detected in serum, because 
these processes take place at the cellular level. Another explanation is that the 
study size may not be large enough to detect minor correlations. 
Myo-inositol and glucose can be independent risk factors for spina bifida as 
well. A logistic regression model in which both MI and glucose were 
incorporated gave similar risk estimates as obtained when MI and glucose were 
considered separately.  
Hyperinsulinism is a strong risk factor for neural tube defects and may be the 
driving force for the observed risk in obese women (22). This is in line with the 
finding that in our study the median body mass index in mothers of spina bifida 
offspring was slightly higher than in control mothers, i.e. 25.4 versus 23.0. Fine 
et al. reported that elevated maternal glucose concentrations can cause changes 
in Pax-3 expression, a gene associated with neural tube defects in mice (36). A 
similar effect may be present in man. Whether the mildly elevated glucose 
concentrations are due to hyperinsulinism or a high carbohydrate intake needs 
further investigation. 
A maternal zinc concentration of < 190 µmol/L was associated with an almost 
3-fold increased risk for spina bifida offspring in the whole group of mothers 
and a 4.5-fold increase in risk in periconceptionally supplemented mothers. 
However, the geometric mean red blood cell zinc concentration was only 5% 
lower in the spina bifida group compared with the controls. This is suggestive 
of a deranged zinc metabolism or transfer in only a subset of the mothers in our 
study and supports reports of others (25,28,29). Zinc deficiency was a risk 
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factor in the Turkish population but seems not the explanation for our findings, 
as no zinc deficiency was present in our study population. Of interest is that 9 
of the 20 case mothers with a high glucose concentration also had a low zinc 
concentration, whereas none of the 10 control mothers showed this 
combination.  
Zinc determinations have been subject to discussion about accuracy, because 
measurements in different tissues represent different zinc parameters, i.e. 
toenail zinc concentrations represent the zinc status over several weeks to 
months, whereas serum concentrations represent the situation at the time of 
measurement (37). We determined the zinc concentration in red blood cells, a 
stable parameter that can be used as proxy for tissue zinc status. The goal of 
our study was to obtain valid information about the preconceptional nutritional 
status of the index pregnancy. The moment of blood sampling was chosen at 15 
months after delivery, because nutritional habits, in general, are not changing 
outside pregnancy and are only influenced by episodes of illnesses, dieting and 
increased needs due to breastfeeding and pregnancy. From this background our 
assumption is that the nutritional pattern prior to conception is comparable to 
that of 15 months after the index pregnancy. This has been supported by 
Devine et al. who studied the continuity and change in women's weight 
orientations and lifestyle practices though pregnancy and the post partum 
period (38). Our assumption is further supported by a study by Leck et al. who 
reported correlation coefficients of more than one half between the 
concentrations of carotenoids in serum and folate in red blood cells determined 
at 8 to 10 weeks of pregnancy and one year later (39).  
Social class is associated with the occurrence of neural tube defects and 
nutrition is correlated with social class (40,41). We found fewer highly educated 
women in the case group than in the control group; however, the educational 
level was not associated with the MI, glucose and zinc blood concentrations. An 
additional multivariate logistic regression analysis with social class as a 
covariable confirmed that social class did not confound the association between 
the blood concentrations and risk for spina bifida offspring. Together with the 
findings of mildly elevated glucose and lower zinc concentrations in the case 
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mothers may point to an increased carbohydrate and decreased intake of zinc 
sources such as meats.  
We had missing values of MI, glucose and zinc concentrations. These were 
random missings in children due to either problems in the determination of 
hematocrite as a result of the small volume of the blood sample taken or to the 
parents' refusal to the blood withdrawal from their child.  
In summary, this study provides substantial evidence that periconceptional 
maternal MI, glucose and zinc status are associated with the occurrence of 
spina bifida in man. Whether derangements in the metabolism or transfer of 
these nutrients in the mother or child, and/or an unbalanced diet is involved 
needs further investigation. Moreover, the findings of this study support the 
possibility of using MI as an adjuvant therapy to a folic acid supplement to 
prevent spina bifida in man. 
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OBJECTIVE: Myo-inositol, glucose and zinc and related genetic factors are suggested 
to be implicated in the etiology of spina bifida. We investigated the biochemical 
concentrations of these nutrients and polymorphisms in the myo-inositol transporter  
KST1, myo-inositol synthase ISYNA1, and zinc transporter SLC39A4 in association with 
spina bifida risk.  
STUDY DESIGN: Seventy-six spina bifida triads only were ascertained. In mothers, 
fathers and spina bifida children polymorphisms determined were KST1 (445C>T), 
ISYNA1 (1029A>G) and SLC39A4 (1069C>T). Serum myo-inositol and glucose, and red 
blood cell zinc concentrations were determined in mothers and spina bifida children. 
Transmission disequilibrium tests (TDT) were applied to determine associations 
between the polymorphisms and spina bifida. Associations between biochemistry and 
genotypes were studied by one-way analysis of variance (ANOVA). Interactions were 
analyzed by conditional logistic regression. 
RESULTS: No association between KST1, ISYNA1 and SLC39A4 and spina bifida was 
shown, χ2KST1=0.016, p=0.90; χ2ISYNA1=1.52, p=0.22, χ2SLC39A4=0.016, p=0.90; degrees of 
freedom [df] = 1. Maternal glucose concentrations were comparable for the KST1 
genotypes. Significantly lower myo-inositol concentrations were observed in mothers 
with KST1 wildtype (CC), mean (SD) 14.2 (2.6) µmol/L compared to KST1 TT-
genotype, 17.0 (3.4) µmol/L, p<0.05. No significant associations were observed between 
ISYNA1 and myo-inositol and glucose, and between SLC39A4 and zinc. A significant 
interaction was demonstrated between a maternal glucose <4.5 mmol/L and ISYNA1 
1029A>G polymorphism on spina bifida risk. 
CONCLUSION: The combination of maternale glucose <4.5 mmol/L and ISYNA1 
1029A>G polymorphism  protects against spina bifida offspring. Moreover, maternal 
KST1 445C>T polymorphism contributes to the serum myo-inositol concentration.  
Larger studies should confirm these findings.  
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Introduction 
 
Neural tube defects (NTDs) are congenital malformations arising from 
incomplete closure of the neural tube during the first weeks of embryogenesis. 
The most common types of NTDs in humans are spina bifida and anencephaly, 
with a birth prevalence of 0.7 per 1,000 and 0.4 per 1,000 live births, 
respectively, in the Netherlands. About 70-80% of all human spina bifida cases 
are considered to be caused by a combination of genetic, lifestyle and 
environmental factors (1). Nutrition, in particular the B-vitamin folate, is an 
important lifestyle factor involved in the pathogenesis of spina bifida. 
Periconceptional folic acid supplementation reduces the occurrence and 
recurrence risk of spina bifida in human (2,3). Other nutrients associated with 
spina bifida are the glucose derivative myo-inositol (MI) (4-6) and the trace 
element zinc (7-10). Obesity (11-14) and alcohol consumption (15) are both 
lifestyle determinants affecting carbohydrate metabolism and as such NTD risk. 
The six-carbon sugar alcohol derivative MI is the most predominant 
stereoisomer of inositol in living cells. Greene and Copp showed a reduction of 
spina bifida offspring in the genetically predisposed for spina bifida curly tail 
(ct) mouse, after MI supplementation (4). The same protective effect was 
observed in diabetic Sprague-Dawley rats having an increased risk of NTD 
offspring (15). This finding is of particular interest because diabetic mothers 
have an increased risk of spina bifida offspring (16). Moreover, type II diabetes 
is often observed in obese women who also have a higher risk of spina bifida 
offspring that could be related to hyperinsulinism (13). Our observation in man 
that low maternal MI and mildly elevated glucose concentrations are risk factors 
for spina bifida offspring is herewith in line (6). 
Although in ct mice MI increases the flux through the inositol-lipid cycle 
stimulating protein kinase C activity, the underlying molecular mechanism for 
the association between low MI and spina bifida risk is unknown. Myo-inositol 
supplementation may overcome a diminished uptake in the mother and/or 
transfer to the embryo. Several studies have shown that MI is taken up by 
H+/Na+- and energy dependent cotransporters located in the membranes of 
several adult murine tissues, including kidney, spleen, lung, liver, placenta and 
  
 49
brain, as well as in embryonic tissues (17,18). In humans the three genes known 
to transport MI are HMIT, a H+/MI cotransporter, and SMIT1 and KST1/SMIT2, 
the latter two being Na+/MI cotransporters, Figure 1, (19-12).  
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Figure 1. Zinc and myo-inositol uptake in humans. Schematic representation of myo-inositol (MI) 
and zinc (Zn2+) uptake, transport, synthesis and function of candidate genes, KST1, ISYNA1 and
SLC39A4. ‘?’ represents an unknown MI-transporter in the small intestine.  
 
Apart from possible defects in the transport of MI, the synthesis of this nutrient 
can also be affected in MI related spina bifida. In the adult mouse, most tissues 
are able to synthesize myo-inositol-1-phosphate from D-glucose-6-phosphate 
by 1L-myo-inositol-1-phosphate synthase (ISYNA1; EC 5.5.1.4) (22). As the 
analysis of the EST database at the NCBI (http://www.ncbi.nlm.nih.gov/dbEST/) 
shows, ISYNA1 is expressed in embryos and extra-embryonic tissue. Genetic 
defects in this enzyme may result in low maternal and/or low embryonic 
intracellular MI concentrations and might ultimately disrupt signal transduction, 
cellular function and differentiation leading to spina bifida.  
The trace element zinc has also been associated with spina bifida and 
anencephaly. A study in rats was the first to show an increased incidence of 
NTDs and other congenital malformations due to zinc deficiency (7). The 
association between zinc deficiency and NTDs has been shown in humans as 
well (8-10). A severe zinc deficiency together with an increased spina bifida 
risk is also observed in women suffering from Acrodermatitis Enteropathica, 
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which is a rare autosomal recessively inherited disease. These patients show 
defective intestinal absorption of zinc, which can be overcome by zinc 
supplementation (23,24). Recently, the SLC39A4 gene has been described as a 
cause in Acrodermatitis Enteropathica patients (23,24). It encodes a zinc 
transporter that is involved in zinc uptake from the intestinal lumen that  is 
expressed in the visceral mesoderm that surrounds the developing embryo and 
is regulated by zinc (25). SLC39A4 therefore seems a good candidate gene for 
spina bifida, especially in cases where low zinc concentrations are observed. 
In this study we investigated polymorphisms in three candidate genes, KST1 
(445C>T), ISYNA1 (1029A>G) and SLC39A4 (1069C>T) for their involvement in 
the etiology of human spina bifida by using the Transmission Disequilibrium 
Test. We also studied these genetic data in combination with MI, glucose and 
zinc concentrations in blood of spina bifida patients and their mothers, 
periconceptional body mass index (BMI) and alcohol intake.  
 
 
Subjects and Methods 
 
Subjects 
From the case-control triad study on spina bifida as previously described by us 
(6), we selected 76 parents and their children with nonsyndromic 
meningo(myelo)cele further referred to as spina bifida. Briefly, eligible for this 
study were children with spina bifida between one and three years of age and 
both their parents of Dutch Caucasian origin. Exclusion criteria were pregnancy 
or breastfeeding at the moment of blood sampling, consanguinity, maternal 
diabetes mellitus, and blood transfusion within three months prior to blood 
sampling. The study protocol was approved by the Institutional Review Board of 
the University Medical Center Nijmegen, The Netherlands. 
 
Blood sampling and DNA isolation 
Parents and their children visited the outpatient clinic of the University Medical 
Center Nijmegen. Mothers fasted from 10 p.m. the day prior to blood sampling 
and were asked to refrain from adding sugar to their children's breakfast. 
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Mothers filled out at home a questionnaire regarding periconceptional use of 
alcohol defined as any alcohol use during the period 3 months prior to 
conception until 3 months after conception. During the hospital visit these 
questionnaires were checked and body weight and length were measured to 
calculate the body mass index (kg/m2). Two mL of maternal venous blood and 1 
mL venous blood of the child was drawn into a potassium oxalate and sodium 
fluoride containing vacutainer tube for MI and glucose measurements. In 
addition, 4 mL and 0.75 mL of venous blood from the mother and the child 
respectively, were drawn into an EDTA containing vacutainer tube for the 
measurement of zinc. Ten mL of venous blood from both parents was drawn 
into EDTA containing vacutainers for DNA isolation. Children's DNA was 
isolated from the blood left over from the MI measurement. If the latter was not 
possible, DNA was isolated from buccal swabs. Genomic DNA was extracted 
from whole blood according to standard procedures (26) or from buccal swabs 
according to the protocol by Richards and coworkers (27). 
 
Measurement of MI and glucose 
Myo-inositol and glucose concentrations were determined by trimethylsilylation 
and gas chromatography according to a modification of the procedure by Jansen 
et al. (28,29). The detection limit of both MI and glucose were 0.5 µmol/L. The 
intra-assay coefficient of variation (CV) for MI and glucose was 10.4% and 
4.3%, respectively.  
 
Measurement of zinc 
Red blood cell zinc concentrations were determined by flame atomic absorption 
spectrophotometry (AAS) (Perkin Elmer 4100; Norwalk, Connecticut, USA). To 
1 mL of venous blood 9 mL of a physiological salt solution was added and the 
sample was centrifuged for 10 minutes at 400x g at 4°C. The supernatant was 
removed and the cell pellet resuspended in 10 mL of physiological salt solution 
after which centrifugation was repeated. After removal of the supernatant, the 
red blood cells were lysed by adding 2 mL of MilliQ. The lysed red blood cell 
samples were stored at -20°C until assayed. The intra- and inter-assay CV for 
zinc were 3.4% and 3.5% respectively, at a concentration of 12 µmol/L zinc. 
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KST1, ISYNA1 and SLC39A4  
For the KST1 gene we studied the common genetic variant, 445C>T present in 
exon 7 of the gene in transmembrane domain 5 of the encoded protein where it 
changes an amino acid, V182A. Protein structure prediction programs (TMPred: 
http://www.ch.embnet.org/software/TMPRED_form.html; Predictprotein: 
http://www1.embl-heidelberg.de/Services/sander/predictprotein/) did not reveal 
any changes of secondary structure for this variant. However, the amino acid 
valine at position 182 is conserved between species (e.g. in mouse and rabbit). 
Therefore, this amino acid position might be important for protein function. The 
ISYNA1 gene contains a common SNP in the coding region that was identified 
by Haga et al. (30). This genetic variant, 1029G>A, does not result in an amino 
acid change (L343L) in the encoded protein and is therefore not considered to 
be a functional polymorphism itself. In our study it served as a marker SNP for 
unknown functional variants in linkage disequilibrium. A common SNP, 
1069C>T, located in exon 7 was analyzed for the SLC39A4 gene (30). This 
genetic variant results in an amino acid change, A357T. Protein structure 
prediction programs revealed that the variant disrupts an α-helix structure in 
the protein. Therefore this polymorphism might have a functional impact on the 
gene product.  
 
PCR amplification 
PCR amplification of KST1 and SLC39A4 fragments was performed in a 50 µL 
reaction volume containing 100 ng genomic DNA, 250 ng of each primer (Table 
I), 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 0.01% (w/v) gelatin, 
0.1% Triton X-100 (w/v), 0.35 mM dNTPs and 2 U Taq DNA polymerase 
(Invitrogen, Breda, The Netherlands). Amplification of ISYNA1 fragments was 
performed in a 50 µL reaction volume containing 100 ng genomic DNA, 250 ng 
of each primer (Table I), 60 mM Tris-HCl (pH 8.5), 15 mM (NH4)2SO4, 1.5 mM 
MgCl2, 10% DMSO (v/v), 0.35 mM dNTPs and 2 U Taq DNA polymerase 
(Invitrogen). Samples were denatured at 92°C for 5 minutes and then subjected 
to 35 (38 for SLC39A4) cycles of amplification (92°C for 1 minute, annealing 
temperature (Table I) for 1 minute and 72°C for 1 minute), followed by a final 
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extension step of 72°C for 3 minutes. Amplifications were performed in a PTC-
200 thermal cycler (MJ-Research Inc. via Biozym, Landgraaf, The Netherlands). 
  
Table I: PCR amplification conditions. Sequences were obtained from GenBank (Accession no. 
NM_052944, AF220530 and NM_130849). Mismatch positions are underlined for primer ISYN 
for. 
Primer name Primer sequence 5’-3’ PCR product (bp) Annealing temperature (°C) 
KST1 for  CCTCCTTTCTTCACAGGTAG 139 53 
KST1 rev CCTTTGTTCAGTCTTACCAGC   
ISYN for GACGGGACACCGCTGATCGTTTA 
GGCAACAACGATGGGGAGCAGCT 
109 56 
ISYN rev ACCATGTCGTCCACCACGTTGC   
SLC39A4 for GCTTTCACAGCCGCCTCAC 209 51 
SLC39A4 rev GGCACACCTTGGGCGTCAG   
  
 
RFLP analysis 
PCR products were purified before digestion with restriction enzymes. 
MultiScreen PCR MANU03050 plates (Millipore, Amsterdam, The Netherlands) 
were used for purification of the PCR fragments from KST1 and SLC39A4. 
ISYNA1 amplification products were purified using the Montage SEQ96 
Sequencing Reaction Cleanup Kit (Millipore) because of the small size of the 
fragment.  
Seventy-six nuclear triads were genotyped for frequent genetic variants, 
described in literature or databases, in each of the coding regions of the genes, 
KST1, ISYNA1 and SLC39A4. The genetic variants were 445C>T (V182A) in 
KST1 (21), 1029A>G (L343L) in ISYNA1 (dbSNP ID: rs2303697; 
http://www.ncbi.nlm.nih.gov/SNP/) and 1069C>T (A357T) in SLC39A4 (dbSNP 
ID: rs2272662) (30). The C>T change at position 445 of KST1 abolishes an AluI 
restriction site. Digestion of the KST1 PCR product with AluI resulted in a 
fragment of 56 bp and a fragment of 83 bp for the homozygous 445C genotype. 
A PvuII restriction site was generated by PCR using a forward primer with 
mismatches (Table I) for the analysis of the frequent genetic variant 1029G>A 
in ISYNA1. Digestion of the ISYNA1 PCR product with PvuII resulted in a 
fragment of 47 bp and a fragment of 62 bp for the homozygous 1029G 
genotype. The C>T change at position 1069 of SLC39A4 abolishes a BstEII 
restriction site. Digestion of the SLC39A4 PCR product with this enzyme 
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resulted in two fragments of 91 and 118 nucleotides, respectively, for the 
homozygous 1069C genotype.  
Restriction reactions were performed overnight in a 15 µL volume, containing 
10 µl of the purified PCR product, 5 U of restriction enzyme and the appropriate 
restriction buffer. KST1 was digested at 37ºC with AluI (Invitrogen, Breda, The 
Netherlands), ISYNA1 at 37ºC with PvuII (Invitrogen) and SLC39A4 at 60ºC 
with BstEII (New England Biolabs, Frankfurt am Main, Germany). Detection of 
fragments was performed by electrophoresis on a 4% agarose gel. 
 
Statistical analysis 
The Transmission Disequillibrium Test (TDT) was performed to test for 
associations between transmission of alleles of the candidate genetic variants 
and spina bifida in the offspring. 
Means (SD) were calculated for MI, glucose and zinc blood concentrations and 
one-way analysis of variance (ANOVA) was applied to determine the 
contribution of the specific genotypes on the blood concentrations of MI, 
glucose and zinc. We employed a conditional logistic regression model to test 
for and calculate the magnitude of the interactions between the transmission of 
specific alleles and observable covariates, i.e. dichotomized blood 
concentrations of MI, glucose and zinc, BMI (≤ 25 kg/m2 vs. > 25 kg/m2) and 
periconceptional use of alcohol (yes vs. no). The cut-off values were 13.2 
µmol/L for MI, 4.5 mmol/L for glucose and 190 µmol/L for zinc as described 
previously (6). 'Risk' alleles were coded 1 and control alleles were code 0. 
Conditional Odds Ratios (OR) were calculated for the magnitude of the 
interaction effect. The Likelihood ratio test was performed to evaluate the 
significance of the interactions of the transmission of specific alleles and 
observable covariates. This procedure has been described by Beaty et al. (31). 
P-values less than 0.05 were considered statistically significant. All statistical 
analyses were performed using the SAS System for Windows version 8 (SAS 
institute Inc, Cary, NC).  
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Results 
 
In this study we used frequent genetic variants in the coding regions of each of 
the genes, KST1, ISYNA1 and SLC39A4 to determine their contribution and that 
of related biochemical determinants and BMI and alcohol use as effect-
modifiers on spina bifida risk. 
The genotype frequencies in spina bifida children for each of the variants were 
consistent with Hardy Weinberg equilibrium. Genotyping resulted in 61, 64 and 
62 informative transmissions in KST1, ISYNA1 and SLC39A4, respectively 
(Table II). The TDT tests showed no statistical significances (Table II; χ2KST1= 
0.016, p=0.90; χ2 ISYNA1= 1.52, p=0.22, χ2SLC39A4=0.016, p=0.90; degrees of 
freedom [df] = 1). 
 
Table II. Transmission disequilibrium testing of genetic variants in KST1, ISYNA1,  
SLC39A4 in complete spina bifida triads. 
 
 KST1 (445C>T) ISYNA1 (1029A>G)  SLC39A4 (1069C>T) 
  Non transmitted  Non transmitted   Non transmitted 
  T C  A G   T C 
T 44 30 A 47 38  T 22 30 
Transmitted 
C 29 19 G 28 15  C 31 41 
 
χ2KST1=0.016, P=0.90; χ2ISYNA1=1.52, P=0.22; χ2SLC39A4=0.016, P=0.90  
 
Genotypes of the patients for the genetic variants of KST1 and ISYNA1 were 
evaluated together with the mean MI and glucose concentrations in serum of 
spina bifida patients and their mothers. The same was carried out for the 
SLC39A4 genotypes and zinc concentrations in red blood cells of patients and 
mothers (Table III). Although one-way ANOVA demonstrated equal mean MI 
concentrations in both mothers and children, mothers with the CC genotype in 
KST1 had significantly lower MI concentrations than mothers with the TT 
genotype (Table III; [CCmothers]MI: 14.2 µmol/L, [TTmothers] MI: 17.0 µmol/L, 
p<0.05). The glucose concentrations did not vary significantly between the 
KST1 genotypes. One-way ANOVA revealed no association between the 
genetic variants in ISYNA1 or SLC39A4 and MI or glucose profiles in serum of 
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spina bifida patients and their mothers and mean zinc concentration in red blood 
cells from patients and mothers, respectively (Table III).  
Using conditional logistic regression modeling, we observed a significant 
interaction between low maternal glucose concentration, the transmission of the 
1029G allele in the ISYNA1 gene and spina bifida risk (Table IV; ORGlucose≥4.5 
mmol/L=1.27 and ORGlucose<4.5 mmol/L=0.35, χ2interaction= 4.361, P<0.05, [df]=1). No 
significant interactions were observed for the genes KST1 and SLC39A4, and 
the MI, glucose and zinc concentrations in blood, Table IV. In addition, allelic 
transmission in the genes KST1, ISYNA1 and SLC39A4, maternal BMI and 
periconceptional alcohol intake did not reveal significant interactions with spina 
bifida risk, Table IV. 
 
Table III. Interactions between KST1, ISYNA1 and SLC39A4 variants and mean (SD) concentrations of serum myo-inositol and glucose and red 
blood cell zinc in spina bifida children and their mothers. 
  Mother  Overall P-value†  Spina Bifida Child  Overall P-
value† 
KST1 genotype CC CT TT  CC CT TT  
MI¶ (µmol/L) 14.2 (2.6)* 
n=10 
15.6 (3.2) 
n=29 
17.0 (3.4) 
n=20 
0.07 25.5 (8.2) 
n=12 
23.1 (3.9) 
n=27 
24.5 (6.9) 
n=26 
0.48 
Glucose (mmol/L) 
4431 (423) 
n=10 
4385 (523) 
n=29 
4356 (638) 
n=20 
0.94 3679 (405) 
n=12 
3925 (408) 
n=27 
3859 (506) 
n=26 
0.30 
         
ISYNA1 genotype AA AG GG  AA AG GG  
MI (µmol/L) 14.9 (3.0) 
n=29 
16.5 (3.1) 
n=21 
16.3 (3.4) 
n=9 
0.18 24.0 (7.3) 
n=29 
24.5 (4.8) 
n=31 
24.4 (7.1) 
n=7 
0.95 
Glucose (mmol/L) 
4372 (538) 
n=29 
4319 (574) 
n=21 
4499 (520) 
n=9 
0.71 3918 (552) 
n=29 
3949 (532) 
n=31 
3611 (387) 
n=7 
0.31 
         
SLC39A4 genotype CC CT TT  CC CT TT  
Zinc (µmol/L) 216 (37.0) 
n=14 
211 (30.2) 
n=30 
214 (29.2) 
n=8 
0.88 160 (21.0) 
n=16 
161 (43.3) 
n=24 
148 (54.2) 
n=10 
0.68 
¶ MI: Myo-inositol; † Overall P-value of one-way ANOVA; * P<0.05  CC-genotype compared to TT-genotype  
 
Discussion 
 
Most evidence of the role of nutritional factors in the etiology of spina bifida 
comes from the B-vitamin folate. Less is known about other causes of spina 
bifida in humans. Recently, we showed that a low maternal MI concentration is a 
risk factor for human spina bifida (6). Therefore, in the current study the 
455C>T polymorphism in the MI transporter gene KST1 was studied in the 
same study groups of mothers and their children with spina bifida. Mothers with 
the KST1 445CC genotype had significantly lower MI serum levels. However, it 
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revealed from the TDT and conditional logistic regression analysis that this 
gene is not expected to be an important risk factor for spina bifida. The KST1 
gene has also been studied in association with other neurological disorders, like 
infantile convulsions, choreoathetosis, and benign familial infantile convulsions 
(21), and did not seem to play a major role either. Because KST1 is one of 
three MI transporters in humans, we also tried to identify and study genetic 
variants in SMIT1. Several genetic variants are described in the NCBI database 
(dbEST), including rs1782995, rs2105485, rs2409513, rs2409514, rs2105486, 
rs2409515, rs2105487 and rs2409516 that were located in intron 1 of the gene. 
However, these variants were not detected by sequence analysis in 10 
unrelated patients with spina bifida of our panel. In murine, Berry et al. showed 
that SMIT1 is the major MI transporter in the transfer from the mother to 
embryo from embryonic day 10.5 onwards (32). The knockout mice showed 
disturbances in rhythmic respiratory neuronal activity, however no spina bifida 
was observed in the offspring. It may well be that other MI transporters such as 
HMIT is involved in spina bifida, or that MI transport simply is not critical in the 
MI-supply of the embryo. Besides species differences, this may be an important 
explanation for our negative findings, since the embryo is able to synthesize MI 
from glucose.  
Therefore, we also investigated whether synthesis of MI induced by ISYNA1 
played a role in spina bifida. Transmission disequilibrium testing revealed no 
association between the 1029A>G allele and spina bifida. However, modeling of 
combined allelic transmission data and maternal glucose serum concentrations 
demonstrated a lower risk of spina bifida offspring in mothers with the 1029G-
allele and having borderline glucose concentrations. This may suggest that the 
1029G-allele is involved in pathways involved in neural tube development that 
can be modulated by glucose status. Experimental studies should be performed 
to prove the relevance of this finding. 
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Table IV. Conditional logistic regression analyses testing for interaction between the 
transmission of KST1, ISYNA1 and SLC39A4 alleles and the covariates myo-inositol, glucose 
and zinc concentrations, body mass index, and periconceptional use of alcohol 
Model Description Odds 
Ratio 
Likelihood ratio 
Statistic 
P 
KST1     
I. All trios (N=55) 1.12 0.170 0.68 
II. Inositol > 13.2 µmol/L 1.24 
 Inositol ≤ 13.2 µmol/L 0.88 0.319 Model II vs. I, P>0.05 
III. Glucose ≥ 4.5 mmol/L 1.33 
 Glucose < 4.5 mmol/L 1.00 
0.260 Model III vs. I, P>0.05 
IV. Alcohol Yes 1.87 
 Alcohol No 0.90 
1.487 Model IV vs. I, P>0.05 
V. BMI > 25 kg/m2 1.37 
 BMI ≤ 25 kg/m2 0.83 0.809 Model V vs. I, P>0.05 
     
ISYNA1     
I. All trios (N=55) 0.56 3.966 0.05 
II. Inositol > 13.2 µmol/L 0.49 
 Inositol ≤ 13.2 µmol/L 0.83 0.566 Model II vs. I, P>0.05 
III. Glucose ≥ 4.5 mmol/L 1.27 
 Glucose < 4.5 mmol/L 0.35 
4.361 Model III vs. I, P<0.05 
IV. Alcohol Yes 1.00 
 Alcohol No 0.43 
1.797 Model IV vs. I, P>0.05 
V. BMI > 25 kg/m2 0.71 
 BMI ≤ 25 kg/m2 0.39 0.995 Model V vs. I, P>0.05 
     
SLC39A4     
I. All trios (N=48) 1.14 0.200 0.66 
II. Zinc > 190 µmol/L 1.13 
 Zinc ≤ 190 µmol/L 1.18 0.004 Model II vs. I, P>0.05 
III. Alcohol Yes 0.85 
 Alcohol No 1.28 
0.372 Model III vs. I, P>0.05 
IV. BMI > 25 kg/m2 1.07 
 BMI ≤ 25 kg/m2 1.26 0.067 Model IV vs. I, P>0.05 
KST1 (445C>T): Allele C is coded as 0 and T is coded as 1; ISYNA1 (1029A>G): Allele A is 
coded as 0 and G is coded as 1; SLC39A4 (1096C>T): Allele C is coded as 0 and T is coded as 
1  
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We and others showed before that a low zinc concentration is a risk factor for 
spina bifida (6,9,10). Therefore, we studied the association between the zinc 
transporter SLC39A4 gene and spina bifida. No association was observed 
between the 1069C>T variant of the SLC39A4 and spina bifida, nor was this 
variant associated with altered zinc concentrations in mothers or their affected 
children. Apparently the SLC39A4 variant or those in linkage disequilibrium 
appear no major risk factors for spina bifida. These results leave the possibility 
open that other variants in SLC39A4, or other means of zinc transfer to 
embryos are involved in zinc related spina bifida. Genes that are implicated in 
zinc transfer are the family members of SLC39A4, ZIP1-3, and genes from the 
ZnT family. Their precise roles in maternal and embryonic zinc transfer with 
regard to formation of the neural tube remains to be investigated.  
The absence of interactions between BMI, alcohol consumption and the 
biochemical and genetic determinants can be interpreted as that these factors 
work independently, the groups were to small to show interactions or no 
interactions exist. 
The strengths of this study are the homogeneity of the well-defined and 
clinically diagnosed spina bifida patients, and the availability of biochemical and 
genetic information of the mother and her spina bifida child. Moreover, the 
case-triad only design enabled us to analyze by TDT in the best manner the 
associations between the genetic variants and spina bifida. On the other hand in 
this study associations have been tested without proper adjusting the type I 
error chance threshold. As a result, the overall type I error will be larger than 
0.05, and thus increases the number of false positive results. Therefore, the 
allelic impact on the biochemical blood parameters have to be interpreted with 
caution, and the association between KST1 CC genotype and maternal MI in 
particular. Nevertheless, this and the finding that the borderline maternal 
glucose concentration together with 1029A>G polymorphism in ISYNA1 may 
contribute to the prevention of spina bifida, is very interesting and has to be 
confirmed in larger studies. Moreover, confirmation of our findings in a control 
population is worthwhile to pursue. 
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OBJECTIVE: Neural tube defects (NTD) are congenital malformations arising from 
incomplete neural tube closure during early embryogenesis. Most NTD in humans show 
complex inheritance patterns, with both genetic and environmental factors involved in 
the etiology of this malformation. More than 120 mouse models for human NTD exist. 
NTD have been observed in mice deficient for the Zic family genes, Zic1, Zic2 and Zic3.  
STUDY DESIGN: We performed mutation analysis in the human orthologs of these 
genes using DNA material from a large panel of NTD patients.  
RESULTS: In ZIC2 we identified a deletion of one codon that encodes an alanine residue 
located in the amino terminal alanine stretch of the protein. The deletion was present in 
one patient, but not in 364 controls. That may suggest a role - albeit small - of this 
variant in the etiology of NTD in humans. Transmission disequilibrium testing of a 
frequent polymorphism in the ZIC2 gene (1059C>T, H353H) in parent-spina bifida 
aperta child triads showed no association with NTD. One silent polymorphism 
(858G>A,V286V) of unknown significance was identified in ZIC3. Neither mutations nor 
polymorphisms were found in the coding region or flanking sequences of ZIC1.  
CONCLUSION: Our data indicate that ZIC1, ZIC2 and ZIC3 are no major risk factors for 
NTD in humans.  
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Introduction 
 
Neural tube defects (NTD) are congenital malformations which arise from 
incomplete closure of the neural tube during early embryogenesis. The most 
common types of NTD in humans are spina bifida and anencephaly, with a birth 
prevalence of 1 per 1,700 and 1 per 1,500 births in the Netherlands, 
respectively.  
About 70-80 % of all NTD in humans show complex or multifactorial inheritance 
patterns, indicating that both genetic and environmental factors play a role in 
the etiology of these malformations (1). Periconceptional supplementation with 
the nutrient folic acid is known to reduce the occurence and recurrence of 
human NTD (2,3). Another environmental factor involved in the etiology of 
human NTD is zinc. Zinc is essential for proper functioning of many proteins in 
the cell, including enzymes and transcription factors. Dietary zinc deficiency in 
rats changes the activity of enzymes in different tissues (4). A relationship 
between zinc and NTD has been demonstrated in animal studies (5) and has 
been shown in humans as well (6-11). Several zinc-dependent transcription 
factors are established risk factors for murine NTD, like the Zic gene family 
members Zic1 (12), Zic2 (13) and Zic3 (14-16). The Zic gene family members in 
vertebrates, Zic1, Zic2, Zic3, Zic4 and Zic5, are the orthologs of the Drosophila 
pair-rule segmentation gene odd-paired, which is involved in parasegmental 
subdivision and visceral mesoderm development (17,18). Zic genes are 
expressed in the dorsal neural tube and its derivatives, especially in the 
cerebellum (17). Their involvement in neural development has been investigated 
in humans, mice and frogs (12,13,19-21).  
Zic1-deficient mice show cerebellar abnormalities and multiple malformations in 
the axial skeleton, including spina bifida occulta (12).  
Zic2 knockdown mice exhibit a whole spectrum of NTD including spina bifida 
occulta, spina bifida aperta, exencephaly and anencephaly (13). Furthermore, 
these mice show holoprosencephaly. The latter also occurs in human patients 
with mutations in ZIC2 (19), sometimes in combination with neural tube defects, 
which links ZIC2 to human NTD. Furthermore, holoprosencephaly in 
combination with exencephaly forms part of the phenotypic spectrum of 
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the13q32 deletion syndrome. In patients with this syndrome a region of 
approximately 1 Mb encompassing ZIC2 is deleted on the long arm of 
chromosome 13 (22). Recently, suggestive evidence for a role of ZIC2 in human 
NTD was provided by transmission disequilibrium testing of a genetic variant of 
ZIC2 in hispanic NTD-patients (23). 
The Zic3 gene is involved in murine NTD as well. Zic3-deficient mice show 
exencephaly as well as tail defects and situs abnormalities (16). The Zic3 gene 
is fully enclosed in a X-linked deletion in the spontaneous mouse mutant Bent 
tail. Spina bifida and exencephaly occur in these mice together with tail defects 
and situs abnormalities (14,15,24). As for the human situation, mutations in the 
X-linked gene ZIC3 and a deletion of 0.6-1 Mb in size encompassing the ZIC3 
gene have been reported in patients with situs abnormalities, in one case 
combined with a lumbosacral neural tube defect (25). Furthermore, Goerss et al. 
reported a US family with a spina bifida aperta and a Xq26-q27 duplication that 
fully contains the ZIC3 gene (26). These data might provide a link between ZIC3 
and human NTD.  
Combined phenotypic and genotypic data of mouse models for Zic1, Zic2 and 
Zic3 deficiency, and limited clinical and genetic patient data make the zinc-
dependent genes, ZIC1, ZIC2 and ZIC3 good candidates for human NTD. We 
therefore performed mutation analysis in these genes in a large panel of NTD 
patients. 
 
 
Subjects and Methods 
 
Patients and DNA isolation 
With approval of the local ethics committee patients with non-syndromic NTD 
have been collected from the Dutch population. 38 familial cases (selected 
according to criteria described by Mariman et al. (27) and 79 isolated NTD 
cases (27) were used for mutation analysis (group I). The types of NTD in the 
familial group were spina bifida aperta (37) and encephalocele (1). The isolated 
group consisted of patients with spina bifida aperta (75), anencephaly (2) and 
encephalocele (2). Additional isolated spina bifida aperta patients came from a 
second collection (group II; Groenen et al. (28) ). 50 of those patients were 
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added to the panel for ZIC1 mutation screening. Spina bifida aperta patients of 
group I with their parents, and 97 spina bifida aperta patients from group II with 
their parents were included in the TDT of a genetic variant in ZIC2. The control 
group used to test the relevance of the deletion in ZIC2 consisted of 364 
unaffected and unrelated subjects randomly recruited from the Dutch 
population. For mutation screening in the X-linked ZIC3 gene, members of an 
Icelandic family with possible X-linked NTD (29) and a patient from an 
American family with X-linked NTD (30) were added to the panel of patients 
from group I. Genomic DNA was extracted from whole blood according to 
standard procedures (31) or from buccal brushes according to a protocol by 
Richards and coworkers (32).  
 
SSCP and SSLP analysis 
PCR amplification of ZIC1 fragments was performed in 25 µl reaction volume 
containing 50 ng genomic DNA, 125 ng of each primer, 10 mM Tris-HCl pH 9.0, 
50 mM KCl, 1.5 mM MgCl2, 0.01 % (w/v) gelatin, 0.35 mM dNTPs and 0.5 U Taq 
DNA polymerase (Invitrogen, Breda, The Netherlands). Optionally 10 % DMSO 
(v/v) was included in the reaction. Primer sequences, annealing temperatures 
and specifics of the PCR protocol are provided in Table I. PCR amplification of 
ZIC2 and ZIC3 fragments was performed in 25 µl reaction volume containing 50 
ng genomic DNA, 62.5 ng of each primer, 10 mM Tris-HCl pH 9.0, 50 mM KCl, 
1.5 mM MgCl2, 0.01 % (w/v) gelatin, 0.4 mM dATP, 0.4 mM dTTP, 0.4 mM 
dGTP, 0.1 mM dCTP, 0.17 µl [α32P] dCTP (ICN Biomedicals, Zoetermeer, The 
Netherlands) and 0.5 U Taq DNA polymerase (Invitrogen). Optionally 10 % 
DMSO (v/v) was added to the reaction. For specific conditions of the PCR 
reactions see Table I. Amplification-conditions were similar for all 3 genes: 
samples were denatured at 92°C for 5 minutes and then subjected to 35 cycles 
of amplification (92°C for 1 minute, annealing temperature for 1 minute and 
72°C for 1 minute), followed by a final extension step of 72°C for 3 minutes. 
Amplifications were performed in a PTC-100 thermal cycler (ZIC2 and ZIC3) or 
in a PTC-200 thermal cycler (ZIC1) (MJ-Research Inc. via Biozym, Landgraaf, 
The Netherlands). 
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Table I. Primers and conditions for amplification of the coding region and flanking 
sequences of the human genes, ZIC1, ZIC2 and ZIC3. The genomic sequences of ZIC1, 
ZIC2 and ZIC3 were retrieved from Genbank (Accession no. NT_005775, NT_009952 and 
NT_011719).  
 
Primer name Primer sequence Region of the gene PCR product 
(bp)
Annealing 
temperature (°C)
DMSO 10% 
(v/v)
ZIC1(1)for 5´-GGCTCGCCCCGAGCAGC-3´ Exon 1 196 62 +
ZIC1(1)rev 5´-GCCGAAGCCAGCTCGTGC-3´
ZIC1(2)for 5´-GCGCCTTCAAGCTCAACCC-3´ Exon 1 199 62 +
ZIC1(2)rev 5´-CGCCGCGTCGCCAAAACC-3´
ZIC1(3)for 5´-GCGGGACTTTCTGTTCCGC-3´ Exon 1 192 61 +
ZIC1(3)rev 5´-CCCGTTGACCACGTTAGGC-3´
ZIC1(4)for 5´-GCTTCACGAGCAGGCTGC-3´ Exon 1 183 61 -
ZIC1(4)rev 5´-CGCCGGCGCCGTGATGC-3´
ZIC1(5)for 5´-GCAGCTGCACGGCTACGG-3´ Exon 1 204 60 -
ZIC1(5)rev 5´-GTGCTCCACGGTGACGTGC-3´
ZIC1(6)for 5´-GGCCAACCCCAAAAAGTCG-3´ Exon 1 205 55 -
ZIC1(6)rev 5´-GGGAAGGGGCAGGGAAAGG-3´
ZIC1(7)for 5´-CCACATCCGCGTGCACACG-3´ Exon 1/Intron1 137 55 -
ZIC1(7)rev 5´-GGTAGGGGTCCTACAGCTG-3´
ZIC1(8)for 5´-CCCCTCTCATTCTACTTTGGC-3´ Intron1/Exon 2/Intron2 212 55 +
ZIC1(8)rev 5´-GGCGACGAGAGTGCGGCG-3´
ZIC1(9)for 5´-CGCACTGGCTCTTTATGTCC-3´ Intron2/Exon 3 282 55 -
ZIC1(9)rev 5´-CTCTTAAATAGGGTTTTGTTCG-3´
ZIC2(1)for 5´-CGCTGGCCATGCTCCTGG-3´ Exon 1 184 62 +
ZIC2(1)rev 5´-GGCGGAGTCAACGAAGCCG-3´
ZIC2(2)for 5´-GCGGCGGCGCAGAACGGC-3´ Exon 1 198 52 +
ZIC2(2)rev 5´-GTAGGAGCCAACGTGCGC-3´
ZIC2(3)for 5´-GCGGCCGCAGCGCTCGG-3´ Exon 1 200 55 +
ZIC2(3)rev 5´-GAAGAGGAGGTGGCCCTGC-3´
ZIC2(4)for 5´-CTGCACCACGCGCACTCG-3´ Exon 1 201 50 +
ZIC2(4)rev 5´-GGTTGTGGAGTTGCGCCGC-3´
ZIC2(5)for 5´-CGCGGACCGACCCCTAC-3´ Exon 1 203 58 -
ZIC2(5)rev 5´-GGGATTGCTCAGTTGCTCGG-3´
ZIC2(6)for 5´-CAGGAGCTAATCTGCAAGTGG-3´ Exon 1 225 60 -
ZIC2(6)rev 5´-CTGTGTGCACGCGGATGTG-3´
ZIC2(7)for 5´-GAGGGCAAGCCCTTCAAGG-3´ Exon 1 168 54 +
ZIC2(7)rev 5´-CCTGTCCCAGCCCGCGG-3´
ZIC2(7)pyro1 5´-biotin-GAGGGCAAGCCCTTCAAGG-3´ Exon 1/Intron1 168 54 +
ZIC2(7)pyro2 5´-TCCGAGAACCTCAAGA-3´
ZIC2(8)for 5´-GCGCCGATGTTTGCCGTCC-3´ Intron1/Exon 2/Intron2 243 63 +
ZIC2(8)rev 5´-CCTCCTCCCGGCCGCCG-3´
ZIC2(9)for 5´-GGGGAACATTTCTGGGGGTG-3´ Intron 2/ Exon 3 174 56 -
ZIC2(9)rev 5´-GGGCGTGGACGACTCATAGC-3´
ZIC3(5'UTR)for 5'-GAGTAACGAGCCTGCCTAC-3' 5'UTR 520 55 -
ZIC3(5'UTR)rev 5'-CCGTCCAGGAGCATCGTCA-3'
ZIC3(1)for 5´-CGGTACCCTCTCTCACCTCG-3´ Exon 1 157 55 -
ZIC3(1)rev 5´-CATGCCTGCCGGCTCACGGTT-3´
ZIC3(2)for 5´-GCTGAATCCCTTCGGGGACT-3´ Exon 1 203 59 +
ZIC3(2)rev 5´-TAGCTGGGCACCCTGGCTGG-3´
ZIC3(3)for 5´-CCACCATCACCATCATCACCC-3´ Exon 1 191 55 -
ZIC3(3)rev 5-´GATGCCAGCTGGAGCAATGC-3´
ZIC3(4)for 5´-ACGGGCTCTTCGGCGGCTC-3´ Exon 1 251 63 -
ZIC3(4)rev 5´-GCTGTAGTTAGGAAACTGAGCG-3´
ZIC3(5)for 5´-CCATACCGCCCAGTGGCCA-3´ Exon 1 189 55 -
ZIC3(5)rev 5´-GCTGAGCCTCGTCGATCC-3´
ZIC3(6)for 5´-CAAGCAGGAGCTGTCGTGC-3´ Exon 1 212 55 -
ZIC3(6)rev 5´-GGTTGACCAGTTTGTACTTCG-3´
ZIC3(7)for 5´-CTGCTACTGGGAGGAGTGC-3´ Exon 1/Intron1 218 55 -
ZIC3(7)rev 5´-GGGTATCGCCAGTGGAACC-3´
ZIC3(8)for 5´-GGCGCTGAACCGTATTTTACC-3´ Intron1/Exon 2/Intron2 249 55 -
ZIC3(8)rev 5´-GTGTTTACCAAACCGCCGATCC-3´
ZIC3(9)for 5´-AATTTTAATATTCAATTTAATTAATAATATAATACA-3´ Intron2/Exon 3 256 54 +
ZIC3(9)rev 5´-TTGGTCCAATTCTATAAATTAACAG-3´
ZIC3(3'UTR)for1 5'-TGAGGACAAACACAAACCCTG-3' 3'UTR 807 55 -
ZIC3(3'UTR)rev1 5'-CAAAACAAGAGAAAGGAGTCAG-3'
ZIC3(3'UTR)for2 5'-GTGACGTTTAGTATACAGTTGC-3' 3'UTR 837 55 -
ZIC3(3'UTR)rev2 5'-ACAAATCAGCCTTTGCCTTCC-3'  
For SSCP analysis PCR products were mixed with 1 volume formamide dye 
buffer (95 % (w/v) formamide, 0.05 % (w/v) bromophenol blue, 0.05 % (w/v) 
xylenecyanol and 20 mM EDTA), denatured at 94°C for 5 minutes and placed on 
ice. 3.5 µl of each sample was loaded on a 5 % non-denaturing polyacrylamide 
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gel with and without 10 % glycerol. Electrophoresis was performed at 4°C, at 40 
W for 3-6 hours. Earlier studies have shown that using this procedure 
approximately 80 % of all point mutations will be detected in our hands. 
However, large deletions that are only present on one allele will be missed, 
since the analysis is not a quantitative one. 
In the case of fragment ZIC2(1) containing a 3 bp deletion in one patient PCR 
was also performed for 364 control samples. Obtained products were analysed 
by simple sequence length polymorphism (SSLP) analysis on a 6.6 % denaturing 
polyacrylamide gel. ZIC1 bands from SSLP and SSCP analyses were visualized 
by a standard silver staining procedure (33). Gels with separated ZIC2 and ZIC3 
bands were dried and exposed to Kodak X-omat S film overnight.  
 
Sequence analysis 
PCR fragments producing aberrant SSCP banding patterns were analyzed on an 
ABI PRISM 3700 automated sequencer using the DyeDeoxyterminator cycle 
sequencing kit according to the protocol of the manufacturer (Applied 
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Sequences were 
determined using the forward and reverse amplification primers for SSCP 
analysis (Table I). Positions of identified polymorphisms in ZIC1, ZIC2, and ZIC3 
were numbered starting with 1 at the first nucleotide of the ATG translation 
start codon. 
 
Pyrosequence analysis 
PCR amplification of templates used for pyrosequencing was performed in 50 µl 
reaction volume containing 100 ng genomic DNA, 10 pmol of primer 
ZIC2(7)pyro1, 20 pmol of primer ZIC2(7)for (Table I), 10 mM Tris-HCl pH 9.0, 
50 mM KCl, 1.5 mM MgCl2, 0.01% (w/v) gelatin, 0.35 mM dNTPs, 10 % DMSO 
(v/v)  and 1 U Taq DNA polymerase (Invitrogen, Breda, The Netherlands). 
Samples were denatured at 92°C for 5 minutes and then subjected to 40 cycles 
of amplification (92°C for 1 minute, 54°C for 1 minute and 72°C for 1 minute), 
followed by a final extension step of 72°C for 3 minutes. Amplifications were 
performed in a PTC-200 thermal cycler (MJ-Research Inc. via Biozym). 
Pyrosequencing (34) was performed on a PSQTM96 System with ZIC2(7)pyro2 
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primer (Table I) according to the protocol of the manufacturer (Pyrosequencing 
AB, Uppsala, Sweden). 
 
Statistical analysis 
Association between variant alleles of ZIC2 and susceptibility to spina bifida 
aperta was tested using Mc Nemar's transmission disequilibrium testing (TDT) 
(35). In order to include missing parental genotypes in TDT-testing a loglinear 
method described by Weinberg (36) was also used (data not shown). 
 
 
Results 
 
SSCP analysis was performed on the coding region and flanking sequences of 
ZIC2 to screen for possible polymorphisms and mutations in 117 NTD patients. 
307 bp of the 3' end of the coding region were left out of the analysis because 
the high GC-content of this sequence caused problems with the PCR 
amplification. The analysis resulted in the identification of two sequence 
variations in ZIC2. The first one was a single nucleotide polymorphism (SNP), a 
C→T transition located at position 1059 (H353H) of the coding region of the 
gene (exon 1). The allelic frequency of the 1059C>T polymorphism was 14 % 
(Table II). Two groups of parent-affected child triads (only cases with spina 
bifida aperta were included) were genotyped for the SNP by pyrosequence 
analysis (Table IIA). The genotype frequencies found in group I, II and in the 
combined group were consistent with the Hardy Weinberg equilibrium. 
Genotyping resulted in a total of 67 informative transmissions (Table IIB). The 
genotyping data for the complete triads were analyzed by TDT for an 
association between the transmission of alleles and susceptibility to NTD. The 
analysis showed that carrying the 1059C allele does not confer an increased 
risk for NTD in our pedigrees, as the results showed no statistical significance 
(group I: χ 2= 1, p=1; group II: χ 2= 4, p=0.05, groups I + II: χ 2=1.8, p=0.18; 
degree of freedom [df] = 1).  
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Table II.  (A) Genotype distribution of parent-affected child triads (mother, father, child) 
for the 1059C>T polymorphism in the ZIC2 gene for two groups of spina bifida aperta 
patients (group I and II). Percentages are given for the combined groups (% I + II). 
Mother, father, child denote the number of copies of the 1059C allele carried by the 
mother, the father, and the spina bifida aperta child, respectively. (B) Contingency table 
of transmitted/nontransmitted allele distributions as observed for the complete triads of 
the combined group (I + II). 
 
A 
mother,father,child I (n=99) II (n=97) % (I + II)
0,2,1 3 0 1.5
1,1,0 1 2 1.5
1,1,1 1 3 2.0
1,1,2 2 0 1.0
1,2,1 7 7 7.1
1,2,2 4 2 3.1
2,0,1 1 0 0.5
2,1,1 8 7 7.7
2,1,2 9 5 7.1
2,2,2 52 44 49
Subtotal of complete triads 88 70
?,1,? 1 0 0.5
1,?,1 0 2 1.0
1,?,? 0 1 0.5
1,?,2 0 1 0.5
1,2,? 0 2 1.0
1,?,? 1 0 0.5
?,?,2 0 5 2.6
?,2,2 1 2 1.5
?,2,? 2 5 3.6
?,1,2 0 2 1.0
?,?,0 0 1 0.5
2,1,? 0 1 0.5
2,?,? 6 4 5.1
2,?,1 0 1 0.5
Subtotal of incomplete triads 11 27  
“ ?”  represents missing data due to failed genotyping or unavailability of family 
members. Abbreviations: I=group I, II=group II. 
 
B 
T C Total
T 4 28 32
C 39 242 281
Total 43 270 313
Transmitted allele
I + II
Nontransmitted allele
 
 
The results obtained by TDT were confirmed by a log-linear modeling 
approach described by Weinberg et al. in which incomplete triads could be 
included in the analysis (36), as well (data not shown).  
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The second sequence variation identified in ZIC2 was a deletion of one codon 
(94-96delGCG) in exon 1 that resulted in the deletion of an alanine in the 
amino-terminal stretch of 9 alanine residues in ZIC2. The so-called A8 variant 
was detected in one male isolated spina bifida aperta patient. The deletion was 
confirmed by SSLP analysis and by sequence analysis. The patient was found to 
be heterozygous for the A8 variant. Both the unaffected parents and 
grandparents of the patient were subsequently tested for the carriership of the 
A8 variant by SSLP analysis (Figure 1). This showed that the mother and the 
grandmother of the patient were heterozygous for the A8 variant, whereas all 
other family members carried only the A9 variant. To test the possible 
relevance of the A8 variant in the etiology of NTD a group of 364 non-related 
controls were analyzed. None of these individuals carried the A8 variant.  
 
Figure 1. SSLP analysis of part of exon 1 of ZIC2. Pedigree in which the A8 variation of 
the ZIC2 gene is segregating. Arrows mark the observed shifted bands. 
 
To test the presence of other NTD risk factors in the patient with the A8 
variant or his mother they were also genotyped for the 677C>T polymorphism 
in the MTHFR gene (37), and for a haplotype in the promoter region of the 
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PDGFRα gene (38). The patient proved to be heterozygous at position 677 of 
MTHFR, his mother was homozygous for the 677C allele. For PDGFRα the 
patient was found to be homozygous for the H2α haplotype. 
ZIC3 was also screened for the presence of mutations or polymorphisms of the 
coding region and its flanking sequences by SSCP analysis in 120 NTD patients. 
A G→A transition at position 858 of the coding region (exon 1) that did not 
result in an amino acid change (V286V) was detected in one spina bifida aperta 
patient (Figure 2). Except for the 858G>A polymorphism no other genetic 
variation in the coding region of ZIC3 was detected in the patients. In the 
search of polymorphisms that could be used for association studies the 5'-and 
3' untranslated regions of ZIC3 were analysed by direct sequence analysis in 20 
arbitrary isolated spina bifida patients. No polymorphisms were detected in 
these sequences, either.  
The third ZIC gene family member that we analyzed by SSCP analysis was 
ZIC1. Neither polymorphisms nor mutations were detected in the coding region 
and its flanking sequences in 167 NTD patients.  
 
Figure 2. Allelic band patterns obtained through SSCP analysis of part of exon 1 of ZIC3.  
The first three lanes show the common SSCP pattern of controls (C), lane 4 shows the 
altered pattern of a spina bifida aperta patient (P). Arrows mark the shifted bands. 
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Discussion 
 
In the absence of large multigeneration pedigrees direct candidate gene 
analysis is the most suitable approach to identify risk factors for human NTD. In 
this paper we performed genetic variation analysis in 3 candidate genes that are 
risk factors for murine NTD. ZIC1 turned out to have perfectly identical coding 
regions and flanking sequences in all our patients. In ZIC3 we identified one 
silent variant in one single patient, indicating the conserved nature of the ZIC3 
gene. This is consistent with data of Carrel et al. who did not detect any 
mutations or polymorphisms in coding and flanking sequences of human ZIC3 in 
three X-linked NTD families (39).  
Recently supporting evidence for an association of ZIC2 gene with human NTD 
has been published by Brown et al. (23) In a case control study approach a 
polyhistidine tract variant (10H allele) was found to be associated with isolated 
and non-syndromic human NTD. This association was confirmed by TDT, 
although with very few transmissions to analyse. The 10H allele was 
predominantly present in patients with a Hispanic genetic background. We did 
not observe this polymorphism in our Dutch patients. However, we identified a 
different novel frequent polymorphism in the coding region of ZIC2 (1059C>T, 
H353H). By TDT analysis we could not confirm the association between ZIC2 
and human NTD. However, rare genetic variations like the A8 variant identified 
in one of our male spina bifida patients might still play a role in the etiology of 
this malformation. This deletion leading to a reduction of alanine residues from 
9 to 8 in the most proximal alanine stretch of the ZIC2 protein was also 
observed in the unaffected mother and grandmother of the proband, but not in 
364 controls. Datamining showed that the length of the alanine stretch is 
conserved between humans and mouse. The ZIC2 protein contains 3 tracts 
consisting of 5 or more consecutive alanine residues. Polyalanine tracts have 
been proposed to repress transcription directly (40), but might also act as 
flexible spacer elements between functional domains (41). Expansions of 
polyalanine tracts are already known to cause human disease (42-45) probably 
due to aggregation of the expanded protein (46). This also holds true for the 
ZIC2 protein itself: a 10 residue expansion of the 15 residue polyalanine tract 
has been observed in several unrelated HPE patients with a profound 
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developmental delay and microcephaly (47). However, whether the deletion of 
residues from the alanine stretches and in particular the newly identified A8 
variant of ZIC2 has an effect on the function of the protein remains to be 
elucidated by functional studies.  
Up to now many mouse model-based NTD candidate genes have been screened 
for their involvement in human NTD (48). Mostly only subtle changes, like 
infrequent missense mutations or silent polymorphisms, have been found in the 
coding regions of these genes. According to a threshold model of Mueller et al. 
combinations of negative influences caused by functional allelic variants might 
be needed to exceed a threshold which allows defects to occur in processes 
like the neural tube formation (49). We therefore screened the patient 
displaying the A8 variant of ZIC2 (and his mother where appropriate) for the 
presence of additional NTD risk factors, namely the 677C>T polymorphism in 
MTHFR and the H1/H2 haplotype in the PDGFRα promoter. Homozygosity and 
(to a lesser extend) heterozygosity for the 677C>T polymorphism in MTHFR is 
known to be associated with decreased enzyme activity and elevated plasma 
homocysteine levels (37,50,51). This increases the risk for NTD, especially if 
both mother and child possess the variant allele. Our patient proved 
heterozygous for the 677T allele, his mother was homozygous for the wildtype 
allele. This suggests that the NTD risk of the patient might be (further) 
increased somewhat by posession of an MTHFR variant. The patient was found 
to be homozygous for the H2α haplotype in the promoter region of the PDGFRα 
gene, which is thought to be a neutral factor in the etiology of NTD (38).  
Although it has been known for a long time that both genetic and environmental 
factors are involved in the etiology of human NTD, the task of identifying the 
specific risk factors involved has been very hard. Especially the genetic causes 
of this malformation are not well understood, yet. This is probably due to the 
fact that combinations of unfavorable genetic variants are more important than 
isolated mutations. Unraveling combinations of risk factors for NTD has been 
slowed down by the fact that until now all the genetic factors for human NTD 
have been identified with laborious methods like SSCP-analysis and sequencing. 
Better and faster techniques like mass spectrometry and SNP microarrays are 
now becoming available (52). Apart from that, a better characterization of the 
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neural tube defects of patients included in the studies, i.e. subdivision of NTD in 
encephalocele, anencephaly, spina bifida occulta, meningocele and myelo-
meningocele, could be of great importance for the homogeneity of the patient 
sample in association studies. Lastly, since there is a lot of evidence showing 
the large impact of environmental factors in the etiology of the anomaly, life 
style factors like diet, drug use, illness, biochemical characteristics and 
personal environment of the mothers of patients in the periconceptional period 
should be taken into account in association studies, as well. In conclusion, there 
might be a long way to go until we fully understand the role of genetic variation 
in the etiology of NTD. 
 
 
Added note 
 
During the review process of this paper additional polymorphisms in the ZIC 
genes were published in the online SNP database dbSNP 
(URL:http://www.ncbi.nlm.nih.gov/SNP). In ZIC1 one simple base pair deletion 
has been identified in intron 1 (+178delTG; rs3832180) in a sample of 24 
unrelated Japanese individuals, and two SNPs were found in the genomic region 
of the gene (rs3058068; rs1394042). None of them has been confirmed yet. In 
ZIC2 several polymorphisms have now been described: the 1059C>T SNP in 
exon 1 is listed as rs1831992. An additional SNP has been identified in exon 3, 
a silent 1263C>T variant (G421G; rs1133911) we did not observe in our 
patients. In intron 1 and the 3' UTR SNPs have been identified as well: 
rs1334586 is present in intron 1 and has been observed with a frequency of  45 
% for the minor allele in a sample of 21 Japanese individuals. The SNP in the 3' 
UTR, a 456A>G variant (rs13542) has a frequency of  17 % in a sample of 94 
unrelated CEPH individuals (Caucasian genetic background). In ZIC3 one SNP 
has been identified in the 3' UTR (*648T>A; rs1053654). This SNP was not 
present in a sample of 20 of our patients analysed by sequence analysis. 
Using this information it would be possible to perform haplotype analysis at 
least for ZIC1 and ZIC2 and in this way extract more information about possible 
associations of the genes with disease. 
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OBJECTIVE: Evidence about the preventive effects of nutrients other than folate on the 
occurrence of spina bifida, is scarce. Therefore, the aim of this work was to investigate 
the role of maternal nutritional intake and spina bifida offspring.  
STUDY DESIGN: In 106 case-mothers and 181 control-mothers nutrient intake was 
obtained by a food frequency questionnaire about 24 months after conception of the 
index-pregnancy. Energy adjusted mean nutrient intakes were compared and odds 
ratios (OR) and 95% confidence intervals (CI) were calculated.  
RESULTS: Although mean nutrient intakes were comparable to the Dutch food 
consumption survey data, fat, cholesterol, iron and folate intake were below the Dutch 
Recommended Daily Allowances (1998). Case-mothers showed a significantly lower 
intake of plant proteins (7%), polysaccharides (4%), fibers (7%), iron (6%), magnesium 
(6%) and niacin (4%) compared to control-mothers. Mono- and disaccharides were 
significantly higher (6%) in the case-mothers than in control-mothers. The adjusted OR 
(95% CI) in the lowest quartiles were for plant proteins 5.4 (2.3 – 12.4), fibres 3.1 (1.5 
– 6.8), iron 3.5 (1.4 – 8.3), magnesium 1.9 (0.9 – 4.1) and niacin 2.5 (1.2 - 5.2). Mono- 
and disaccharide and polysaccharide intakes in the highest quartile revealed ORs (95% 
CI) of 2.9 (1.4 – 6.3) and 0.5 (0.3 – 1.0), respectively.  
CONCLUSION: The nutritional intake of Dutch women seems to be compromised in food 
groups containing iron and folate. Low preconceptional intakes of plant proteins, iron, 
magnesium and niacin are associated with a 2- to 5-fold increased spina bifida risk.  
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Introduction 
 
In the seventies and eighties of the twentieth century, spina bifida and 
anencephaly were reported to be more frequent in the lower social classes 
(1,2). Nutritional intake is associated with social class and poor nutrition was 
suggested to be an important risk factor for these central nervous system 
malformations (3). Smithells et al. reported lower concentrations of red blood 
cell folate, white blood cell vitamin C, riboflavin saturation index and serum 
vitamin A in blood samples of non-pregnant women in the lower social classes 
compared to women in the upper classes (4). Of interest was the finding that 
mothers of neural tube defect offspring showed lower red cell folate and white 
blood cell vitamin C concentrations in the first trimester of pregnancy compared 
to control-mothers. Since, several groups have reported lower B-vitamin 
concentrations, in particular of folate, in mothers of infants with neural tube 
defects (5,6).  
B-vitamins are taken from dietary sources such as green leafy vegetables, 
beans, liver and dairy products. Thiamin is involved in the carbohydrate 
metabolism and is essential for the decarboxylation of α-keto acids (7). Studies 
in rats showed that thiamin deficiency results in thinning of the intestinal 
microvillus membrane, aberration of intestinal function and polyneuropathy (8). 
Riboflavin as flavin adenine dinucleotide (FAD) is an intermediate in cellular 
respiration and acts as a cofactor for methylenetetrahydrofolate reductase 
(MTHFR) in which a polymorphism was shown to be a risk factor for spina 
bifida (9,10). Niacin and the active coenzymes NAD and NADPH are involved in 
energy requiring and generating cellular reactions, and in the regulation of the 
lipid status, i.e., cholesterol, apolipoprotein B, triglycerides and lipoproteins. It 
was shown in diabetic patients that niacin supplementation is effective for the 
treatment of dyslipidemia, which is frequently observed in these patients (11). 
Pregnant mice with a cholesterol shortage exhibited severe growth retardation 
and defective closure of the neural tube in their offspring (12). Pyridoxine is 
involved in racemizations, amino acid side chain modifications and 
transamination reactions. It is a cofactor of cystathionine-β-synthase that 
converts homocysteine into cystathionine. Folate functions as a one-carbon 
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carrier and as such is involved in purine and pyrimidine synthesis and 
methionine metabolism. Smithells et al. were the first to suggest that maternal 
folate deficiency is associated with the occurrence of neural tube defects in the 
offspring (13). We demonstrated that maternal hyperhomocysteinemia, as a 
functional marker of folate status, is a risk factor for spina bifida offspring (14). 
As hyperhomocysteinemia can be treated by folic acid supplementation, these 
findings are in line with the results of intervention studies showing that 
periconceptional vitamin supplementation reduces the occurrence and 
recurrence risk of spina bifida offspring (6,15,16). Cobalamin is involved in the 
conversion of methylmalonic acid into succinic acid and folate metabolism 
acting as a cofactor for methionine synthase. A maternal cobalamin shortage 
resulting in a mild hyperhomocysteinemia has also been associated with spina 
bifida (14,17). 
Minerals have also been implicated in the pathogenesis of neural tube defects. 
Lower maternal serum and hair concentrations of zinc have been associated 
with neural tube defects (18-20). Moreover, zinc affects folate status as a 
cofactor for methionine synthase and γ -glutamyl hydrolase. Calcium is a 
second messenger in the inositol-tri-phosphate-signaling pathway responsible 
for gene transcription, muscle contraction and differentiation of cells. A reduced 
availability of cellular calcium induces abnormalities in neural tissues in 
experimental studies (21). Intracellular magnesium is a cofactor for ATP-
requiring enzymes, such as hexokinase, which phosphorylates glucose. Of 
interest is that Shaw et al. demonstrated that maternal periconceptional intake 
of magnesium decreased the risk of offspring with neural tube defects (22). 
The aim of the current study was to investigate the independent effects of 
preconceptional maternal intake of various macronutrients, vitamins and 
minerals on the risk of spina bifida in the offspring. 
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Subjects and Methods 
 
Study Design and Data collection 
Between August 1999 and December 2001, we performed a previous described 
case-control study in which 132 mothers of a child with spina bifida were 
enrolled in collaboration with the Dutch Spina Bifida Teams of the University 
Medical Centers in Nijmegen, Utrecht, Groningen, Rotterdam, Leiden, 
Amsterdam and the local hospitals in Tilburg and Zwolle (23). Dutch Caucasian 
mothers and their children, between one and three years of age, with a 
nonsyndromic meningo(myelo)cele were eligible to participate.  
Meningo(myelo)cele, further indicated as spina bifida, was diagnosed by a 
neuropediatrician at birth. Control mothers (n=236) were recruited from 
acquaintances and from nurseries in Nijmegen and surroundings as described in 
more detail by Groenen et al. (23) and Van Rooij et al. (24). 
In general, the individual nutritional pattern is rather constant (25) and is 
influenced only by episodes of temporary dieting, illnesses, nausea and 
increased needs due to growth such as in (26,27). Under the assumption that 
the nutritional pattern after pregnancy is a proxy for the preconceptional 
nutritional pattern, mothers filled out a validated food frequency questionnaire 
(FFQ) covering the intake 3 months before the study moment. Some questions 
refered to the intakes of the proceeding year (28,29). The frequency in which 
mothers used the food groups could be indicated per day, per week, month, 
year or never. They were also asked about the preparation methods, additions 
and portion sizes. All FFQs were individually checked for completeness and 
consistency at the hospital or by phone by the researcher. Consequently, the 
average daily nutrient intake was estimated by multiplying the frequency of 
consumption of food items by the portion size and nutrient content per gram 
based on the 1998 electronic version of the Dutch food-composition table 
except for folate and cobalamin that were based on the 2001 electronic version 
(30,31). Additionally, mothers provided information on environment and lifestyle 
factors such as the use of folic acid supplements and smoking, in the 
periconceptional period that was defined as the period 3 months prior until 3 
months after conception. 
  85
Eighteen of the 132 case-mothers and 38 out of 236 control-mothers, 
respectively, were excluded due to excessive vomiting and/or a change in 
nutritional intake in the periconceptional period compared to the study moment. 
Four case-mothers and 4 controls were excluded for analysis, because 
information on periconceptional excessive vomiting and/or change in nutritional 
pattern was lacking. Finally, the FFQ of 4 case and 13 control-mothers was not 
completed properly resulting in 106 case and 181 control questionnaires 
entering the analyses. 
The study protocol was approved by the Institutional Review Board of the 
University Medical Center Nijmegen in the Netherlands. 
 
Statistical analysis 
We used the nutrient residual (energy-adjusted) method to adjust for total 
energy intake as described by Willet et al. (32). Briefly, the crude nutrient 
intakes of the individuals were log-transformed and regressed on their total 
energy intake. This regression equation was used to calculate the expected 
mean nutrient log-intake for the mean total energy intake of the study 
population. The energy-adjusted log-intake of each individual was calculated 
by adding the expected mean nutrient log-intake of the study population to the 
individual residual that was derived from the regression analysis. Differences in 
energy-adjusted log-nutrient intakes between the groups were evaluated using 
Students t test. The energy-adjusted nutrient log-intakes were back-
transformed to present energy-adjusted summary measures on the original 
scale. 
The association between maternal nutrient intake and spina bifida offspring was 
stratified by the use of periconceptional folic acid containing supplements, 
because of the modification of the risk of spina bifida (15).  
The energy-adjusted nutrient intakes were divided into quartiles based on the 
control-mothers. The risk of spina bifida was estimated by using odds ratios 
(OR) with 95% confidence intervals (CI) by comparing each quartile of a nutrient 
intake with the highest one in a logistic model. Multiple logistic regression 
analysis was performed to adjust for potential confounding factors, i.e. 
periconceptional smoking, alcohol consumption and periconceptional use of folic 
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acid containing supplements. From the analysis revealed that control mothers 
appeared to be higher educated than case-mothers. Education is considered a 
proxy for social class and thereby nutritional habits (3). Adjustment for 
education would lead to an overcorrection of the data and may eliminate 
relevant differences in the nutritional pattern.  
In order to construct a composite variable for macronutrients (total protein, 
total fat and total carbohydrates), minerals (calcium, phosphorus, iron, 
magnesium and iron) and vitamins (thiamin, riboflavin, niacin, pyridoxine, folate 
and cobalamin), we summarized the Z-scores of the underlying variables. The 
individual Z-scores were calculated by subtracting the mean intake of the 
individual intake and divide it by the standard deviation. A high Z-score thus 
indicates that an individual has a relatively high intake of all the nutrients in a 
given nutrient group compared to their peers. Additionally, ratios between 
proteins from plant and animal sources, between saturated and non-saturated 
fats and between mono- and disaccharides and polysaccharides were calculated 
because they may be indicative for differences in nutritional patterns.  
All statistical analyses were performed using the SAS System for Windows 
version 8 (SAS institute Inc, Cary, NC). P-values of less than 5% were 
considered significant. 
 
 
Results 
 
Mothers of a child with spina bifida were slightly younger and had a lower 
education than controls (Table I).  Spina bifida children were more likely to be 
females. In both groups mothers did not report any previous pregnancy 
complicated by spina bifida and had a comparable parity, control-mothers mean 
1.61 and case-mothers mean 1.66 children (P = 0.9, Wilcoxon's rank test), 
respectively.  
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Table I. Characteristics of the study populations1  
 Mothers of spina 
bifida offspring 
 
Mothers of control 
offspring 
 
Maternal age, y 32.0 (25.2 –37.9) 33.1 (27.5 – 38.9)b 
Gender child, boy 40.4 52.6a 
Pregnancy planned, yes 85.5 90.7 
Education, high 38.2 57.2a 
Periconceptional vitamin supplement use, yes 31.8 42.8c 
Periconceptional smoking, yes 24.6 22.2 
Periconceptional alcohol use, yes 37.3 45.9 
1 Values are expressed as medians (5th – 95th percentile) or frequency (%), n=106 for mothers 
with spina bifida children and n=181 for mothers with control children. Means with common 
superscripts differ: a, P ?  0.01, b, 0.01 < P ?  0.05, and c, P = 0.06.  
 
The energy-adjusted geometric mean intakes were compared with both the 
Dutch National Food Consumption Survey (FCS) 1998 and the Dutch 
Recommended Daily Allowances (RDA) for women in reproductive ages (20-55 
years) (Table II). Except for the lower intakes of cholesterol, iron and folate, 
mean nutrient intakes were comparable to or above the FCS and RDA. Nutrient 
intakes in case-mothers tended to be slightly lower compared with control 
intakes, albeit in general not statistically significant. In case-mothers a 
significantly lower intake was demonstrated for plant proteins, polysaccharides, 
fibers, iron, magnesium and niacin, while a higher intake was observed for 
mono- and disaccharides (Table II). The comparison of the consumption of 22 
food groups for case and control-mothers with the FCS (1998) data for women 
in reproductive ages (20-55 years) revealed a higher consumption of nuts, 
seeds and snacks but a lower consumption of bread in case-mothers compared 
to control-mothers.  
Adjustment for education did not substantially affect the associations between 
nutrient intake and spina bifida risk. 
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Table II. Intakes of macronutrients, minerals and vitamins of mothers of a child with spina bifida 
and controls1. 
  
FCS2 
 
RDA3 
Mothers of spina 
bifida offspring 
Mothers of control 
offspring 
Macronutrients     
Total Protein, g/d 76  79.7 (63.5 –99.5) 81.2 (64.6 –99.0) 
 Animal Protein NA6  49.0 (29.8 –70.7) 48.4 (32.0 –68.7) 
 Plant Protein NA  29.4 (23.6 –37.2) 31.7 (23.6 –41.3)a 
Fat, g/d 85  85.9 (71.6 –99.2) 86.6 (71.7 –105.5) 
 Saturated Fat 33  35.3 (27.9 –43.9) 35.9 (29.0 –44.8) 
 Mono Unsaturated Fat 30  33.4 (26.1 –40.7) 33.2 (25.0 –41.7) 
 Poly Unsaturated Fat 15  16.0 (11.1 –22.9) 16.3 (10.8 –23.3) 
Cholesterol, mg/d 200  201.7 (129.5 –305.5) 204.6 (144.6 –288.5) 
Carbohydrates, g/d 228  259.5 (215.5 –304.8) 256.6 (216.9 –299.8) 
 Mono-/disaccharides 108  131.8 (89.5 –178.9) 123.9 (80.8 –169.7)a 
 Polysaccharides 119  124.0 (95.8 –162.2) 129.5 (100.3 –162.1)a 
Fibres, g/d 20  22.9 (17.6 –29.5) 24.6 (18.1 –32.1)a 
     
Minerals     
Calcium, mg/d 963 700-9004 1095 (610.1 –1679) 1118 (676.9 –1751) 
Phosphorus, mg/d 1387 700-1400 1548 (1164 –1965) 1588 (1221 –2025) 
Iron, mg/d 10.7 15.0 11.7 (9.21 –14.0) 12.5 (9.73 –15.6)a 
Magnesium, mg/d 302 250-300 346.4 (265.7 –1225) 367.3 (278.5 –1399)a 
Zinc, mg/d 9.0 9.0 10.3 (7.84 –13.3) 10.6 (8.08 –14.0) 
     
Vitamins     
Vitamin A5, µg/d 803 800 827.4 (517.0 –1436) 903.3 (529.2 –1668) 
Thiamin, mg/d 1.22 1.04 1.09 (0.79 –1.35) 1.12 (0.86 –1.42) 
Riboflavin, mg/d 1.45 1.34 1.63 (0.98 –2.44) 1.66 (1.10 –2.42) 
Niacin, mg/d NA 13.04 16.5 (13.0 –21.4) 17.2 (12.7 –22.3)b 
Pyridoxine, mg/d 1.49 1.14 1.68 (1.31 –2.08) 1.69 (1.34 –2.03) 
Folate, µg/d NA 200-3004 191.1 (144.0 –247.1) 198.3 (150.8 –253.5) 
Cobalamin, µg/d NA 2.54 4.18 (2.34 –6.85) 4.31 (2.58 –7.32) 
Vitamin C, mg/d 81 70 110.2 (62.8 –197.6) 108.8 (65.5 –216.2) 
Vitamin E5, α-TE-eq/d 11.6 9.5 13.2 (9.46 –19.9) 13.0 (8.91 –19.0) 
 
 
1 Values are expressed as energy adjusted (geometric) mean intakes with 5th –  95th percentile interval, n=106 
for mothers of spina bifida children and n=181 for mothers of control children.  
Means with common superscripts differ: a, P ≤  0.01 and b, 0.01 < P ≤  0.05. 
2 FCS: Dutch National Food Consumption Survey 1998 (30) 
3 RDA: Dutch Recommended Daily Allowances 1998 (38) 
4 The revised RDAs are as follows: calcium 1000 mg/d, thiamin 1.1 mg/d, riboflavin 1.5 mg/d, niacin 17 mg/d, 
pyridoxine 1.5 mg/d, folate 300 mg/d, cobalamin 1.5 µg/d. 
5 Vitamin A is expressed as retinol-equivalents and vitamin E is expressed as α-tocopherol-equivalents. 
6 NA: not available 
 
Because periconceptional supplementation with folic acid is associated with 
spina bifida risk and the observation of a significant difference in 
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periconceptional supplement use in case and control-mothers (Table I), we 
adjusted the associations between nutrient intake and spina bifida risk for the 
use of these supplements use. The association between nutrient intakes and 
spina bifida offspring was not significantly modified by periconceptional use of 
folic acid supplements. However, it is still possible that the use of 
periconceptional vitamins confounds the association between nutrient intakes 
and spina bifida. Individuals taking vitamins may be more aware of their 
nutrition habits and the importance of a healthy diet. We therefore present in 
Table III ORs for spina bifida risk adjusted for periconceptional vitamin intake, 
smoking and alcohol use. Dose-response associations between nutrient intake 
quartiles and risk of spina bifida offspring were observed for all seven food 
groups. Using the highest quartile as a reference, increased risks of spina bifida 
offspring were observed for the lowest quartiles, OR (95% CI): for plant 
proteins 5.4 (2.3 – 12.4), fibres 3.1 (1.5 – 6.8), iron 3.5 (1.4 – 8.3), magnesium 
1.9 (0.9 – 4.1) and niacin 2.5 (1.2 – 5.2). For mono- and disaccharides and 
polysaccharides we used the lowest quartile as a reference revealing ORs (95% 
CI) of 2.9 (1.4 – 6.3) and 0.5 (0.3 – 1.0), respectively.  
Combining the nutrient intakes by Z-scores revealed that case-mothers 
demonstrated a significantly lower intake of minerals compared to control-
mothers (Table IV). The intakes of all vitamins combined, in particular that of B 
vitamins, were lower in the case-mothers, albeit not statistically significant.  
The protein ratio demonstrated a significantly increased intake of proteins from 
animal over plant sources in case-mothers (Table IV). In addition, case-
mothers have a slightly higher ratio of mono- and disaccharides over 
polysaccharides compared to controls.  
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Table III. Maternal nutrient intakes and risk of spina bifida offspring1. 
Nutrient intake  FCS3 Spina Bifida 
 
Control 
 
 
ORCrude 
 
ORAdjusted (95% CI)2 
Plant protein, g/d NA4 n n   
 20.5-28.8   50 46 5.4 5.4 (2.3 – 12.4) 
 28.8-31.9   28 45 3.1 3.0 (1.3 – 7.3) 
 31.9-35.6   19 45 2.1 2.2 (0.9 – 5.4) 
 35.6-48.1   9 45 1.0 1.0 (Reference) 
Mono-/disaccharides, g/d      
 69.2-106.9   13 46 1.0 1.0 (Reference) 
 106.9-126.2  108 24 45 1.9 1.9 (0.9 – 4.2) 
 126.2-143.0   31 45 2.4 2.4 (1.1 – 5.3) 
 143.0-218.7   38 45 3.0 2.9 (1.4 – 6.3) 
Polysaccharides, g/d      
  78.8-117.6   41 46 1.0 1.0 (Reference) 
 117.6-130.5  119 24 45 0.6 0.6 (0.3 – 1.1) 
 130.5-142.8   21 45 0.5 0.5 (0.3 – 1.1) 
 142.8-184.1  20 45 0.5 0.5 (0.3 – 1.0) 
Fibres, g/d      
 13.0-22.0  20 44 46 3.3 3.1 (1.5 – 6.8) 
 22.0-24.8   29 45 3.2 2.1 (1.0 – 4.7) 
 24.8-28.3   20 45 1.5 1.5 (0.7 – 3.5) 
 28.3-37.0   13 45 1.0 1.0 (Reference) 
Iron, mg/d      
   7.6-11.2  10.7 35 46 3.8 3.5 (1.4 – 8.3) 
 11.2-12.6   44 45 4.5 4.6 (2.0 – 10.7) 
 12.6-13.7   18 45 2.0 2.0 (0.8 – 4.8) 
 13.7-24.8   9 45 1.0 1.0 (Reference) 
Magnesium, mg/d      
 186.7-330.3  302 33 46 2.2 1.9 (0.9 – 4.1) 
 330.3-377.6   45 45 3.0 2.8 (1.4 – 5.9) 
 377.6-407.4   13 45 0.9 0.9 (0.4 – 2.0) 
 407.4-532.0  15 45 1.0 1.0 (Reference) 
Niacin, mg/d NA     
   8.4-15.7   42 46 2.7 2.5 (1.2 – 5.2) 
 15.7-17.5   25 45 1.7 1.6 (0.8 – 3.5) 
 17.5-19.5   24 45 1.6 1.5 (0.7 – 3.3) 
 19.5-26.6   15 45 1.0 1.0 (Reference) 
1 Odds ratios and 95% confidence intervals per quartile of intake, n=106 for mothers with spina 
bifida children and n=181 for mothers with control children. 
2 Odds ratios and 95% confidence intervals adjusted for periconceptional use of tobacco and 
alcohol and folic acid containing supplements. 
3 FCS: Dutch National Food Consumption Survey 1998 (30) 
4 NA: No FCS value available 
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Table IV. Combined measures of nutrient intake1. 
  Spina Bifida 
 
Control 
 
Summed Z-Scores    
 Macronutrients  -0.06 ± 1.08 0.04 ± 1.05 
 Minerals  -0.79 ± 4.00 0.46 ± 4.04a 
 Vitamins  -0.62 ± 5.39 0.36 ± 5.49 
 Vitamins, B-complex only  -0.54 ± 4.26 0.32 ± 4.41 
 Vitamins, A, C and E (Anti-oxidants)  -0.08 ± 2.01 0.05 ± 1.75 
    
Ratio    
 Animal/plant protein  1.15 ± 0.10 1.13 ± 0.10a 
 Saturated/unsaturated fat  0.57 ± 0.03 0.57 ± 0.03 
 Mono- and disaccharides/polysaccharides  1.01 ± 0.07 0.99 ± 0.06 
1 Z-scores are presented as mean ± SE. Means with common superscripts differ: a, P ≤ 0.05.  
 
 
Discussion 
 
This study demonstrates for the first time that the dietary intake of iron, 
magnesium, niacin, fibres, plant proteins and polysaccharides was significantly 
lower in mothers of spina bifida offspring compared to control-mothers. The 
lowest intakes were associated with a two to five-fold increased risk for spina 
bifida offspring, independent of periconceptional folic acid use. By contrast, 
high dietary intake of mono- and disaccharides threefold increased spina bifida 
risk, while the intake of polysaccharides was associated with a reduction in 
spina bifida risk. Together with our recent finding that mildly increased glucose 
concentrations are associated with increased spina bifida risk (23), this 
supports the importance of an optimal carbohydrate status during embryo-
genesis (34-36). While the differences between the nutrient intakes between 
case-mothers and controls were small, they are substantiated by the dose-
response relations. The relevance of these findings is not clear, however points 
to the multifactorial etiology of spina bifida in which maternal nutrition plays an 
important role. Of interest is that these data emphasize the importance of the 
maternal balance of macro- and micronutrient intakes and spina bifida risk. 
Strikingly, a lack of most of the nutrients derived from the plant domain, e.g. 
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plant proteins, fibers, niacin and polysaccharides) was associated with an 
increased spina bifida risk. Although it is not possible to indicate precisely 
which products are responsible for these associations, our data suggest that the 
associations may partly be explained by the differences in intakes of bread and 
nuts, seeds and snacks. In the Netherlands, bread consumption is an important 
source for B vitamins, including folate despite the absence of folate fortification 
in the Netherlands. 
The overall dietary intakes of the mothers in both groups were comparable to 
the FCS of 1998 for women in reproductive ages (20-55 years) (28). However, 
the mean intakes of fibres, all minerals and vitamin C exceeded the data of the 
FCS of 1998 by 15% or more indicating that our FFQ may not have estimated 
these minerals with enough precision. Therefore, comparing the results to the 
RDA value may not be appropriate. Nevertheless, internal comparisons are still 
valid. The intakes of fats, cholesterol, iron and folate were lower than the RDA 
values that are institutional values that aim to pursue an optimal nutrient status 
in a given population. Mean nutrient intakes that are roughly equal to the RDA 
indicate an adequate nutritional status. By contrast, higher mean nutrient 
intakes represent excessive intakes possibly leading to adverse outcomes such 
as the association between fat intake and risk of cardiovascular disease. Lower 
mean nutrient intakes represent inadequate intakes and point to a subgroup at 
risk of nutritional deficiencies. The geometric means of folate and iron intakes 
were below the RDA which means that more than 50% of our study population is 
at risk of folate and iron deficiency. Although this may not yet lead to clinical 
symptoms, the risk of spina bifida offspring may increase when the nutritional 
needs increase. It is important to realize that the values estimated by our FFQ 
are not absolute values and therefore they  have to be carefully compared and 
interpreted to the RDA-values. During the last three years the Dutch RDA's 
have been revised and several guidelines are changed. Since our study 
population was ascertained prior to the revising of some RDA values, we used 
the old guidelines. For completeness, we have added the new RDAs as a 
footnote to Table II. 
Maternal niacin intake of less than or equal to 15.7 mg per day was associated 
with a 2.5-fold (95% CI: 1.2 – 5.2) increased risk of spina bifida offspring. It is 
  93
noteworthy that the increased risk is observed at a niacin intake slightly above 
the RDA. This may indicate that the RDA for niacin intake in women of 
reproductive age is not sufficient, being 17 mg per day during pregnancy. The 
relative shortage in niacin intake in mothers of spina bifida offspring may 
partially be explained by the lower bread consumption. Closer investigation of 
the intakes of the other B vitamins suggests that the overall intake of B 
vitamins is lower in case-mothers compared to controls. Although the 
underlying mechanism of niacin on neural tube closure is not clear, the effect of 
niacin shortage on cholesterol-lipoprotein metabolism may be of interest in this 
regard (33). In experimental studies, pregnant knockout mice lacking a specific 
enzyme involved in the pathway of the biosynthesis of cholesterol exhibited 
severe growth retardation and defective closure of the neural tube in the 
offspring (34). In man, inborn errors of cholesterol metabolism have been 
associated with abnormal development of the brain such as a 7-
dehydrocholesterol reductase deficiency (35). Therefore, polymorphisms in 
related genes may contribute to the development of spina bifida.  
A deficient iron intake of less than 12.6 mg/d was associated with a 3.5- to 
4.6-fold increased spina bifida risk. While non-pregnant women may not suffer 
from clinical symptoms due to deficient iron intake, it may well become a 
problem during pregnancy in which the needs are significantly enhanced. This is 
supported by the frequently observed microcytic anemia in the second and third 
trimester of pregnancy. Iron deficiency present in the first trimester may 
therefore play a role in the pathogenesis of spina bifida although literature 
relating dietary iron intake and spina bifida is scarce. 
Maternal magnesium intake of less than 378 mg per day  was associated with a 
two- to threefold higher risk of spina bifida offspring. Although the RDA for 
magnesium seems appropriate for non-pregnant women, a higher magnesium 
intake during pregnancy may  prevent spina bifida. Shaw et al. showed a 0.7 
lower risk of neural tube defects in mothers with a magnesium intake of over 
258 mg per day (22). In the present study an odds ratio of 0.9 was observed in 
mothers with an intake of more than 407.4 mg of magnesium per day. The 
difference between the 25% cutoff values of control mothers in our study and 
that of Shaw et al. is striking: < 330 mg and < 258 mg of magnesium, 
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respectively (22). Differences in nutritional habits and lifestyles between the 
investigated countries and populations may explain these findings.  
Although these data are informative, the following issues have to be addressed. 
Firstly, FFQs give an average intake over a long time period and aberrations in 
individual  nutritional patterns will therefore not severely influence the results. 
Our assumption was that the  nutritional pattern is rather constant and is 
influenced by episodes of illnesses, dieting, and increased needs due to 
pregnancy and breastfeeding. This has been confirmed by two studies in which 
nutrition, the continuity and change in women's weight orientations and lifestyle 
practices through pregnancy and the post partum period were studied (26,27). If 
in our study nutritional changes have occurred, this would have affected the 
nutritional 'biochemical' parameters. In a longitudinal pregnancy study we 
measured serum myo-inositol and glucose and red blood cell zinc 
concentrations at various time points before, during and after pregnancy. The 
comparison of the preconceptional values with those determined around 24 
months after the index-pregnancy, as a part of the present study were not 
significantly different (23). In another longitudinal pregnancy study we 
determined folate concentrations in serum and red cells preconceptionally and 
in the study described by Van Rooij et al. months after the index-pregnancy 
(24,36). It revealed that the folate values were comparable at both time points 
again supporting our hypothesis. In addition, Riboli et al. demonstrated 
reasonable correlations between FFQ data determined at baseline and two to 
four years later in a subgroup of women enrolled in the NYU Women's Health 
Study (25).  
The intake of many nutrients are correlated (37). Simultaneous adjustment of 
the intake of one nutrient for all others may lead to difficulties in the 
interpretation due to multi-collinearity. To overcome this problem we 
calculated summary measures for macronutrients, minerals and vitamins by 
summing up Z-scores. These Z-scores revealed that case-mothers had lower 
mineral and vitamin intakes compared to controls. In addition, we investigated 
the association of nutritional intake and spina bifida risk by comparison of ratios 
between nutrients to reveal differences in food patterns. The ratios pointed to a 
higher intake of animal proteins and mono- and disaccharides in case-mothers 
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compared to controls, which may reflect an imbalance of macro- and 
micronutrients intakes.  
As previously mentioned characterizing the nutritional pattern and quality 
thereof may be difficult. Based on the relationship between folate and spina 
bifida risk and the current results, we explored the use of the dietary intakes of 
folate and/or iron as measures of the quality of diet. We calculated coefficients 
of correlation for the association between the intakes of folate and/or iron and 
the summed Z-scores for vitamins and minerals. A substantial part of the 
variation in vitamin intake and to a lesser extend the variation in mineral intake, 
could be explained by the variation in folate intake (r2 = 0.65 and r2 = 0.35, 
respectively). R-squares for iron intake and vitamin and mineral intake were 
less pronounced (r2 = 0.43 and r2 = 0.17, respectively). Using both folate and 
iron intakes only marginally increased the r2 for vitamins 0.70 and for minerals 
0.28. These coefficients of correlation indicate that the dietary intake of folate 
may be considered as an indicator for vitamin intake in future research. This 
finding may prove of great value and may save lots of resources in future work 
in terms of cost/efficiency. 
In summary, mothers of a spina bifida child demonstrated lower intakes of iron, 
magnesium, and niacin compared to controls. Overall intakes however, were 
comparable to the Dutch FCS and RDA except for the intakes of iron and folate. 
These findings strengthen the advice for a balanced diet, rich in vegetables and 
fruits. In addition this study shows the importance of periconceptional use of 
folic acid supplements since the average Dutch diet does not provide adequate 
amounts of this nutrient. 
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OBJECTIVE: To investigate B vitamins and homocysteine as risk factor for spina bifida 
offspring.  
STUDY DESIGN: Blood samples of 45 mothers and their spina bifida children and 83 
control mothers and their children were obtained to determine serum and red blood cell 
folate (RCF), serum vitamin B12, whole blood vitamin B6 and total plasma homocysteine.  
RESULTS: In case-mothers the vitamin B12 concentration was 21% lower (95% CI: 8% - 
33%) compared to controls. Unlike folate, vitamin B6 and homocysteine, a vitamin B12 
concentration ≤185 pmol/L was associated with a 3.5-fold (95% CI: 1.3 – 8.9) increased 
spina bifida risk. In children, no differences in folate, vitamin B6, B12 and homocysteine 
concentrations were observed after adjustment for child's age.  
CONCLUSION: A marginal maternal vitamin B12 status is associated with an increased 
risk of spina bifida offspring.  
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Introduction 
 
Among the most common congenital malformations are the neural tube defects 
(NTD) of which spina bifida and anencephaly predominate in man. Maternal 
supplementation with folic acid during the periconceptional period has been 
shown to reduce both the occurrence and recurrence risk of these 
malformations in the offspring (1-3). Although folate metabolites are important 
substrates for the transfer of one-carbon moieties, DNA synthesis, repair and 
methylation, the exact mechanisms by which folic acid supplementation 
prevents NTD is not understood. Experimental and epidemiological data suggest 
that a part of the protective effect by folic acid is based on a decrease of the 
homocysteine plasma level (4). Steegers-Theunissen et al. demonstrated that 
an elevated homocysteine concentration could be regarded as a sensitive 
functional marker of the folate vitamin status, in particular (5). Therefore, a 
mild hyperhomocysteinemia can be regarded as a primary or secondary risk 
factor in a subset of mothers who gave birth to spina bifida offspring. 
Rosenquist et al. supported this finding in an experimental study using avian 
embryos that were treated with high concentrations of homocysteine showing 
an induction of congenital defects of the heart and neural tube (6). Moreover, 
they observed that folic acid supplementation was only effective in preventing 
NTD when it resulted in a reduction of homocysteine concentrations.  
In addition, vitamin B12 and B6 have been associated with NTD (4,5,7-9). 
Intracellular vitamin B12 acts as a cofactor in the remethylation of homocysteine 
into methionine by methionine synthase, i.e. vitamin B12 deficiency may cause 
severe hyperhomocysteinemia (10). Vitamin B12 deficiency can result in a 
functional folate deficiency, while normal to increased folate concentrations are 
present in blood, commonly known as the methyl-folate trap (11). Low 
intracellular vitamin B12 concentrations can be due to a deranged absorption, 
transport or cellular uptake. Recently, Afman et al. reported that genetic 
variations in transcobalamin II result in low vitamin B12 and increased 
homocysteine concentrations and may therefore be associated with NTD 
offspring (12).  
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Vitamin B6, as pyridoxal-5'-phosphate (PLP), is involved in the transsulfuration 
of homocysteine into cysteine by the cystathionine-β-synthase enzyme. A PLP 
deficiency leading to hyperhomocysteinemia was demonstrated as a risk factor 
for NTD (4,5). Folate, vitamin B12 and PLP can reduce elevated homocysteine 
levels and may as such contribute to the prevention of NTD. 
In the present study, we investigated the maternal and childs' B-vitamin status 
in association with spina bifida risk.   
 
 
Subjects and Methods 
 
Patients and controls 
We performed a case-control study between August 1999 and December 2001 
as previously described (13). Seventy-six mothers and their children with spina 
bifida were recruited in collaboration with the Dutch Spina Bifida Teams of the 
University Medical Centers in Nijmegen, Utrecht, Groningen, Rotterdam, Leiden, 
Amsterdam and regional hospitals in Tilburg and Zwolle. Dutch Caucasian 
children, between one and three years of age, and diagnosed by a 
neuropediatrician at birth with a nonsyndromic meningo(myelo)cele, e.g. spina 
bifida, were eligible. Control children (n=111) had no major congenital 
malformations and were in the same age range as cases. Both control mothers 
and children were recruited by infant welfare centers, nurseries and 
acquaintances of the case-mothers in Nijmegen and surroundings in the 
Netherlands as previously described (13-15). Exclusion criteria for cases and 
controls were (i) pregnancy at time of blood sampling, (ii) consanguinity, (iii) 
familiar relationship between spina bifida and control families, (iv) maternal use 
of folic acid antagonists and (v) maternal use of vitamin B containing 
supplements three months before the moment of blood sampling.  
After written informed consent, blood samples were taken at the Department of 
Pediatrics of the University Medical Center in Nijmegen. At the same time the 
investigator verified the self-administered questionnaires on lifestyle, 
demographic factors, vitamin supplementation and pregnancy. 
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Thirty-one spina bifida mothers and 28 control mothers were excluded because 
of the use of vitamin B containing supplementation (18 and 13 respectively), 
pregnancy (9 and 8 respectively) or withdrawal for blood sampling (4 and 7 
respectively). In 5 spina bifida children and 29 control children blood sampling 
could not be performed because informed consent was not obtained (4 and 21 
respectively) or blood sampling was unsuccessful (1 and 8 respectively). Thus, 
45 mothers and 71 children with spina bifida and 83 control mothers and 82 
children were included in the study. The study protocol was approved by the 
Institutional Review Board of the University Medical Center Nijmegen in the 
Netherlands. 
 
Blood sampling and laboratory analysis 
Although mothers fasted the day prior to blood sampling, this was for ethical 
reasons not requested for the children. Venous blood of both mother and child 
was drawn into anti-coagulant-free vacutainer tubes for folate and vitamin B12 
measurements according to Molloy and Scott and Kuemmerle et al (16,17). The 
intra- and interassay coefficients of variation (CV) for folate and vitamin B12 
were 6.1% and 10.2%, and 5.7% and 6.3%, respectively.  
For PLP determination maternal and infant venous blood was drawn into lithium 
heparin vacutainer tubes and analyzed according to Schrijver et al (18). The 
intra- and interassay CVs of 1.4% and 7.3%, respectively. Lastly, venous blood 
of the mother and child was drawn into EDTA containing vacutainer tubes for 
measurement of total homocysteine. The tubes were immediately placed on ice 
and processed within 2 hours after blood sampling and analyzed according to 
Te Poele-Pothoff et al (19). Both intra- and interassay CVs were <6.5%. The 
remaining EDTA blood was used to determine the hematocrite. 
 
Statistical analysis 
Because of the positively skewed data, geometric means were calculated that 
can be interpreted as the median and 5th – 95th percentile range. The 
differences in concentrations of blood parameters between the spina bifida and 
control group were assessed with Students t test after logarithmic 
transformation of the concentrations. Back transformation of the 95% 
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confidence intervals (95% CI) for the difference in means after logarithmic 
transformation yields a 95% CI for the ratio of geometric means of the original 
data. To control for the higher age of spina bifida children analysis of 
covariance was employed. 95% Confidence intervals were computed for the 
ratio of geometric means. 
Maternal concentrations of serum folate, red cell folate (RCF), serum vitamin 
B12, whole blood PLP and plasma total homocysteine were dichotomized with a 
cut-off point at 10% or 90% of the value in control mothers. Odds ratios (OR) 
with 95% confidence intervals (95% CI) were calculated to estimate spina bifida 
risk. The simultaneous effect of these extreme concentrations was established 
in a logistic regression model. Also, the possible confounding effect of patient 
characteristics was adjusted for in a multivariate logistic regression model. 
Correct use of periconceptional vitamin B containing supplements was defined 
as the use of a B-vitamin supplement from four weeks prior until 6 weeks after 
conception. 
Pearson correlation coefficients were calculated after logarithmic 
transformation of the blood concentrations of mother-child pairs in the case and 
control group. All statistical analyses were performed using the SAS System for 
Windows Version 8. 
 
 
Results 
 
The characteristics of the spina bifida and control group are summarized in 
Table I. The geometric mean of the vitamin B12 serum concentration was 21% 
(95% CI: 8 - 33%) lower in mothers with spina bifida offspring compared to 
control mothers (Table II). There were no significant differences in geometric 
mean concentrations of maternal serum folate, RCF, PLP and total 
homocysteine between both groups. The OR for a vitamin B12 of less than 185 
pmol/L was 3.5 (95% CI: 1.3 - 8.9), while the ORs for serum folate, RCF, PLP 
and total homocysteine were close to unity (Table III). Because B vitamin 
concentrations affect homocysteine concentrations, we calculated multivariate 
logistic models including 2 or 3 vitamins with or without interaction terms 
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between the vitamins. These OR estimates did not differ from the univariate OR 
estimates (data not shown). Adjustment for oral contraceptive use, educational 
level, smoking and alcohol use did not affect the ORs (data not shown). 
 
 
Table I. Characteristics of mothers and children with spina bifida and control mothers and  
children expressed as medians (5th – 95th percentile) or frequency (%). 
 Spina Bifida group Control group 
Mothers N=45 N=83 
 Age at blood sampling (years) 32.3 (25.3 –38.4) 33.3 (28.1 –40.0) 
 Body mass index at blood sampling  (kg/m2) 25.4 (19.9 –37.3) 22.8 (19.1 –30.0)* 
 Educational level (high) 26.7 68.7** 
 Current smoking (yes) 26.7 18.1 
 Current use of alcohol (yes) 55.6 73.5** 
 Current use of oral contraceptives (yes) 51.1 45.8 
 Periconceptional use of folate (yes) 31.1 42.2 
   
Children N=71 N=82 
 Child age (years) 1.70 (0.80 –3.80) 1.10 (0.80 –1.50)* 
 Gender (boy) 33.8 46.3 
*) Wilcoxons' rank test between the groups, P ≤ 0.05; **) Chi-square test, P ≤ 0.05  
 
 
The geometric mean concentrations of serum folate and RCF in children with 
spina bifida were 32% (95% CI: 16% - 45%) and 24% (95% CI: 11 - 35%) lower 
compared to controls, respectively (Table II). These differences disappeared 
after adjustment for children's age at the time of blood sampling. The geometric 
mean concentrations of children's vitamin B12, PLP and total homocysteine did 
not reach statistical significance. 
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Table II. Blood concentrations of folate, vitamin B12, pyridoxal-5'-phosphate and total 
homocysteine in mothers and their children. 
 Spina bifida 
Group 
Control 
Group 
  
 Geometric mean (5th – 95th percentile) Ratio SB/CT of geometric means 
Mothers N=45 N=83    
 Serum folate (nmol/L), N=43/82 12.6 (4.2 – 27.0) 13.3 (7.0 – 30.4) 0.95 (0.77 – 1.16)   
 RCF¶ (nmol/L), N=40/83 615 (146 – 1472) 637 (352 – 1388) 0.97 (0.80 – 1.16)   
 Serum vitamin B12 (pmol/L), N=44/83 223 (119 – 413) 283 (155 – 550) 0.79 (0.67 – 0.92) *  
 Whole blood PLP† (nmol/L), N=44/83 56.6 (39.0 – 81.0) 58.3 (37.0 – 89.0) 0.97 (0.89 – 1.06)   
 Plasma tHcy‡ (µmol/L), N=45/83 12.9 (8.2 – 18.5) 11.8 (8.1 – 16.8) 1.10 (0.98 – 1.23)   
      
Children  N=71 N=82  Age Adjusted 
 Serum folate (nmol/L), N=68/73 27.9 (7.9 – 87.9) 41.3 (13.8 – 92.2) 0.68 (0.55 – 0.84) * 0.91 (0.72-1.15) 
 RCF* (nmol/L), N=68/73 1054 (419 – 2171) 1394 (834 – 2515) 0.76 (0.65 – 0.89) * 0.98 (0.82-1.16) 
 Serum vitamin B12, (pmol/L), N=69/80 488 (260 – 1110) 498 (271 – 846) 0.99 (0.87 – 1.12)  0.98 (0.84–1.14) 
 Whole blood PLP† (nmol/L), N=69/76 94.6 (59.0 – 190) 103 (57.0 – 170) 0.93 (0.83 – 1.03)  1.04 (0.92–1.17) 
 Plasma tHcy‡ (µmol/L), N=68/76 7.0 (5.4 – 10.7) 6.8 (5.3 – 8.9) 1.03 (0.97 – 1.09)  0.99 (0.92-1.05) 
¶ RCF: Red blood cell folate; † PLP: Pyridoxal-5'-Phosphate; ‡ tHcy: Total homocysteine; *) 
Student's t test, P ≤ 0.05  
 
Table III. Folate, vitamin B12, pyridoxal-5'-phosphate and total homocysteine  
concentrations in mothers and risk of spina bifida offspring. 
 Mothers  
 Spina Bifida Control Odds Ratio 
(95% Confidence Interval) 
Folate (nmol/L), seruma 
 2.4 - 7.5 
 7.5 - 179 
 
7 
36 
 
9 
73 
 
1.6 (0.5 – 4.6) 
1.00 (reference) 
RCF¶ (nmol/L)a 
 139 - 394 
 394 – 1900 
 
6 
34 
 
9 
74 
 
1.7 (0.5 – 4.4) 
1.00 (reference) 
Vitamin B12 (pmol/L), seruma 
   48 - 185 
 185 – 851 
 
13 
31 
 
9 
74 
 
3.5 (1.3 – 8.9)* 
1.00 (reference) 
PLP† (nmol/L), whole blooda 
 35 – 44 
 44 – 120 
 
6 
38 
 
9 
74 
 
1.3 (0.4 – 3.9) 
1.00 (reference) 
tHcy‡ (µmol/L), plasmab 
 6.9 - 16 
 16  - 85.8 
 
40 
5 
 
76 
7 
 
1.00 (reference) 
1.4 (0.5 – 4.6) 
a10%; b90% cut-off values of the control group; ¶ RCF: Red blood cell folate;  
† PLP: Pyridoxal-5'-Phosphate; ‡ tHcy: Total homocysteine; *) P≤0.05  
 
Periconceptional use of a vitamin supplement was a potential effect-modifier 
for the association between vitamin concentrations and spina bifida risk (Table 
IV). Only for vitamin B12 serum concentrations this effect-modification was 
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demonstrated. The case-control ratio for mothers not using supplements was 
significantly lower than for mother who did use supplements. 
Table V shows the correlations of the blood concentrations in mothers and in 
children and between mothers and children. All correlations appeared to be low. 
Within-group Pearson correlation coefficients between maternal and child red 
cell folate revealed a correlation of 0.68, P<0.01 for cases and of 0.34, P<0.01 
for controls, respectively. Additionally, between case-mothers and case-
children a correlation coefficient of 0.47, P<0.01 was observed between the 
serum vitamin B12 concentrations. 
 
Table IV. Geometric mean (5th – 95th percentile) concentrations of B vitamins and  
total homocysteine in mothers of spina bifida offspring (cases) and control mothers  
stratified by periconceptional use of vitamin supplements. 
 Periconceptional vitamin supplement use 
          Yes           No  
  
Case (N=14) 
 
Control (N=35) 
 
Case (N=31) 
 
Control (N=48) 
 Geometric means 
(5th – 95th percentile) 
 
Ratio of 
geometric 
means 
Geometric means 
(5th – 95th percentile) 
 
Ratio of 
geometric 
means 
Folate, serum 11.8 
(2.4-31.0) 
12.7 
7.0-25.8) 
0.93 13.0 
(4.5-26.3) 
13.8 
(6.6-30.5) 
0.95 
RCF¶ 552 
(139-1498) 
658 
(343-1419) 
0.84 647 
(345-1427) 
622 
(358-1246) 
1.04 
Vitamin B12, serum 255 
(66.0-741) 
278 
(110-640) 
0.92 210 
(131-392) 
288 
(155-550) 
0.73* 
PLP†, whole blood 55.6 
(41.0-81.0) 
57.3 
(36.0-100) 
0.97 57.1 
(39.0-81.0) 
59.1 
(37.0-89.0) 
0.97 
tHcy‡ , plasma 14.3 
(9.8-85.8) 
11.5 
(8.1-16.7) 
1.24* 12.3 
(9.4-18.5) 
11.9 
(7.9-18.7) 
1.03 
¶ RCF: Red blood cell folate; † PLP: Pyridoxal-5’-Phosphate; ‡ tHcy: Total homocysteine; * P 
≤ 0.05  
 
 
Discussion 
 
This study demonstrates that a maternal serum vitamin B12 concentration of ≤ 
185 pmol/L is associated with a 3.5-fold increased risk of spina bifida offspring. 
Mean vitamin B12 concentrations in mothers of spina bifida offspring were 21% 
lower compared with controls, while no differences were observed for serum 
folate, RCF, PLP and total homocysteine concentrations. This finding confirms 
the multifactorial origin of NTD and is in contrast to our earlier studies (4,5), 
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and in line with our more recent study and that of others (7,20). Heterogeneity 
of NTDs may explain this discrepancy. In the current study only mothers of 
spina bifida children were included while in the previous studies mothers of 
offspring affected with anencephaly, encephalocele and spina bifida were 
included. Although the difference in laboratory methods may explain the 
differences in B12 concentrations between the studies, this is very unlikely 
given the results of the control group in the present study: median 280 pmol/L 
(P5-P95: 155-550) vs. the previous study: mean 288 pmol/L (SD: 107).  
 
Table V. Pearson correlation coefficient matrix between the log-transformed blood parameters 
of B vitamins and total homocysteine in mothers and in children and between mothers and 
children. 
  
 
PLP_m B12_m tHcy_m RCF_m FS_m PLP_c B12_c tHcy_c RCF_c FS_c 
PLP_m 1.00 
 
         
B12_m 0.16 
 
1.00         
tHcy_m -0.17 
(*) 
-0.39 
** 
1.00        
RCF_m 0.09 0.25 
** 
-0.31 
** 
1.00       
FS_m 0.18 
* 
0.07 -0.35 
** 
0.45 
** 
1.00      
PLP_c 0.15 
 
-0.08 0.04 0.09 -0.05 1.00     
B12_c 0.02 0.22 
* 
-0.01 0.08 -0.08 -0.11 1.00    
tHcy_c 0.03 
 
-0.02 0.15 0.06 0.16 -0.03 -0.15 1.00   
RCF_c 0.08 0.14 -0.12 0.46 
** 
0.19 
(*) 
0.49 
** 
-0.02 -0.12 1.00  
FS_c -0.02 0.12 -0.13 0.20 
(*) 
0.18 
(*) 
0.37 
** 
-0.15 -0.19 
(*) 
0.71 
** 
1.00 
PLP: Pyridoxal-5'-Phosphate, whole blood; B12: Vitamin B12, serum; tHcy: Total 
homocysteine, plasma; RCF: Folate, red blood cell; FS: Folate, serum; _m refers to maternal 
concentrations; _c refers to child concentrations; (*) : P≤0.10; *: P≤0.05; ** : P≤0.01  
 
Although the differences are more pronounced between the case groups in both 
studies, the results are within the observed ranges and more importantly, are 
within the reference ranges, median 223 pmol/L, P5-P95: 119-413 vs. mean 
268 pmol/L, SD: 100, respectively. We showed earlier that despite normal 
fasting vitamin levels, hyperhomocysteinemia is present in a subgroup of 
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mothers with NTD offspring (4,5). Mills et al. confirmed this finding and 
demonstrated that mothers of NTD children had elevated homocysteine levels 
compared to B12-matched controls pointing to an abnormality in methionine 
synthase in which vitamin B12 acts as a cofactor (21). Brouwer et al. did not 
show a vitamin B12 shortage in spina bifida patients compared to controls (22). 
Homocysteine levels can be lowered by folic acid supplementation. Carmel et 
al. showed that vitamin B12 supplementation normalized homocysteine 
concentrations in a vitamin B12 deficient state (10). These findings suggest that 
an underlying metabolic derangement can be present, however this does not 
always become manifest by showing increased homocysteine levels.  
An inverse correlation (-0.39; p<0.01) between vitamin B12 and homocysteine 
concentrations confirmed data of previous studies and may partially reflect the 
activity of vitamin B12-dependent methionine synthase (5,20,21). We did not 
observe higher total homocysteine concentrations in cases with low B12. This 
may be due to the combination of an adequate PLP status, cystathione-β-
synthase activity and folate status counteracting the effect on homocysteine 
levels of the women with a compromised vitamin B12 status. Moreover, a 
shortage of vitamin B12 leads to a folate trap and it is therefore not very likely 
that the folate status plays a significant role in this respect.  
This study suggests that mothers with a low vitamin B12 concentration could 
benefit from the use of a periconceptional multivitamin supplement. However, 
the benefit of this oral treatment depends on the cause of vitamin B12 shortage 
and dosage. Mothers of a spina bifida child who did not use a periconceptional 
supplement showed a 27% lower concentration of vitamin B12. In contrast, in 
vitamin-supplemented case-mothers no substantial difference in vitamin B12 
concentrations but a 24% higher total homocysteine concentration was 
observed compared to vitamin supplemented users in the control group.  
In this study, the educational level was lower in case-mothers than in controls, 
which has been shown before a risk factor for spina bifida offspring (23). 
Adjusting the OR estimates presented in Table III for educational level, the use 
of oral contraceptives, alcohol and tobacco did not result in substantially 
different OR estimates.  
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Of interest are the 32% and 24% lower geometric mean concentrations of serum 
folate and RCF in spina bifida children, respectively. Together with the lower 
vitamin B12 concentrations in mothers of these children this may point to the 
involvement of both nutritional and genetic factors in children (24). Both folate 
concentrations in children were comparable after adjustment for age at blood 
sampling. Therefore, we suggest that the lower folate concentrations are due to 
differences in nutritional intake and maturation of the internal organs during the 
first years of life. Minet et al. demonstrated significant differences in vitamin 
B12 and homocysteine blood concentrations between breast-fed and formula-
fed infants at the age of 12 weeks (25). Formulas are enriched with vitamin B12, 
whereas human milk contains a lower amount of vitamin B12 (26). In our study, 
the number of children who were breast-fed was not significantly different from 
controls. Therefore, this is not a likely explanation. Nevertheless, the age 
difference may be related to differences in amount and content of nutritional 
intake. Meals prepared from fresh foods generally contain more B-vitamins 
compared to pre-prepared meals.  
In summary, this study demonstrates that a marginal maternal vitamin B12 status 
is associated with an increased risk of spina bifida offspring. This data may 
suggest that adjuvant vitamin B12 therapy to the current folic acid therapy might 
be considered in the future. 
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C H A P T E R   7 
 
Periconceptional health and lifestyle factors  
in parents of spina bifida offspring 
 
Pascal MW Groenen, Petronella GM Peer, Jetty van Meeteren,  
Reinier Mullaart, Gerhard A Zielhuis, Régine PM Steegers-Theunissen 
 
 
OBJECTIVE: This study evaluates periconceptional health and lifestyle factors and the 
risk of spina bifida offspring.  
STUDY DESIGN: In a retrospective case-control study of 128 parents of spina bifida 
and 233 parents of healthy non-malformed offspring, questionnaire data were obtained 
at approximately 24 months after the index-pregnancy on periconceptional health 
aspects as illnesses, pregnancy planning, use of folic acid and a health promoting diet. 
Lifestyle factors included smoking and alcohol use. Data were dichotomized, a multiple 
logistic regression model was fitted and odds ratios (OR), 95 percent confidence 
intervals (CI) were calculated.  
RESULTS: The final model identified as risk factors periconceptional maternal use of a 
health promoting diet, OR: 0.3, 95 percent CI: 0.1-1.0, medication, OR: 1.8, 95 percent 
CI: 1.1-3.1, illnesses, OR: 2.3-95 percent CI, 1.0-5.2, and preconceptional oral 
contraceptive use, OR: 2.1, 95 percent CI: 1.2-3.8. A parental familial history of 
congenital malformations more than 4-fold increased spina bifida risk, OR: 4.4, 95 
percent CI: 2.2-8.9, and those who had planned pregnancy showed a 60 percent lower 
risk, OR: 0.4, 95 percent CI: 0.2-0.9. Periconceptional folic acid use reduced all ORs 
except the congenital malformation family risk, OR: 6.5, 95 percent CI, 1.8-22.9.  
CONCLUSION: Preconceptional counseling may contribute to the primary prevention of 
spina bifida. 
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Introduction 
 
Spina bifida and anencephaly are severe malformations of the central nervous 
system and both are due to a failure of closure of the neural tube. Spina bifida 
has a complex etiology in which environmental and genetic factors play a role. 
Its birth prevalence rate is approximately 0.5 per 1,000 live births in The 
Netherlands (1). In order to achieve the primary prevention of spina bifida 
environmental factors in particular should be identified because they can be 
amended in contrast to most genetic factors. 
Nutrition is an important environmental factor and periconceptional 
malnourishment, that of folate in particular, is a risk factor for congenital 
malformations with a neural crest contribution such as spina bifida, orofacial 
clefts and cardiac outflow defects (2-4). A gene-environment interaction as a 
risk factor for these malformations is demonstrated by the finding that the 
combination of a low maternal periconceptional folate intake and carriership of 
the 677C>T polymorphism in the methylenetetrahydrofolate reductase gene 
leading to a reduced availability of folate and mild hyperhomocysteinemia, is 
associated with a higher risk than the separate factors (3-7).  
Several other environmental factors have been associated with spina bifida risk 
of which some interact with folate uptake and metabolism. Alcohol abuse, 
smoking, caffeine intake, use of anticonvulsants and oral contraceptives 
decrease folate status and increase homocysteine plasma concentrations 
suggested by the impairment of the activity of folate reductase or methionine 
synthase or by the induction of folate clearance (8-12). Besides, the 
consumption of alcohol, tobacco and caffeine could be teratogenic independent 
of interactions with folate (13-15). Of interest is that Marret et al. 
demonstrated that caffeine exposure even at physiological concentrations 
induces neural tube defects in NMRI mice (16). Moreover, in curly tail mice, an 
experimental animal model for spina bifida, exposure to tobacco was associated 
with a mildly increased frequency of spina bifida (15). In man however, reports 
about smoking and spina bifida are conflicting (17). This may be explained in 
part by the higher frequency of spontaneous miscarriages in smoking mothers 
without examination of the pregnancy product through which many cases of 
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spina bifida can be missed (18,19). The maternal use of anticonvulsants, such as 
valproic acid, carbamazepine and phenobarbital, has also been associated with 
spina bifida offspring (9,20,21). The underlying mechanisms of the teratogenic 
effects of these drugs have not been clarified. Several reports however suggest 
that exposure to high levels of epoxides as well as the induction of low folate 
and mildly elevated homocysteine concentrations could affect neural tube 
closure (22-24).  
It is known for a long time that a low social economic status is associated with a 
higher risk of spina bifida (25,26). Socioeconomic status is strongly determined 
by education and occupation. The cause of the association between low social 
class and malformed offspring could arise from the findings that less educated 
couples more often suffer from health problems, use more medication, are less 
health conscious partially reflected by the use of an unbalanced diet, and more 
frequently are exposed to harmful occupational exposures compared to higher 
educated couples (27). The latter can be illustrated by the increased risk of 
spina bifida offspring among female hair dressers, employee's working with 
glycol ethers and those working in health care (28,29).  
Therefore, the purpose of this study was to retrospectively evaluate risk 
factors for spina bifida that could have been prevented if these couples had 
planned their pregnancy and had received preconceptional care. 
 
 
Subjects and Methods 
 
Design & subjects 
Between August 1999 and December 2001 we designed a case-control study, in 
which 128 parents of a child with spina bifida and 233 control parents were 
enrolled in collaboration with the Dutch Spina Bifida Teams of the University 
Medical Centers in Nijmegen, Utrecht, Groningen, Rotterdam, Leiden, 
Amsterdam and the local hospitals in Tilburg and Zwolle. In order to reduce 
recall bias and to obtain homogeneity of the study group, parents of Dutch 
Caucasian children with an age between one and three years and diagnosed 
with a nonsyndromic meningo(myelo)cele, i.e. spina bifida, by a pediatric 
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neurologist and geneticist were eligible to participate. At the same time control 
parents were recruited from acquaintances of the case-parents and from public 
nurseries and health centres in Nijmegen and surroundings as previously 
described by Groenen et al. (30,31) and Van Rooij et al. (4,32). Exclusion 
criteria were consanguinity, a familiar relationship between the spina bifida and 
control parents. 
The eligible parents were invited to participate at approximately 24 months 
after the periconceptional period of the index-pregnancy. They received oral 
and written information about the study and were included after having received 
their written informed consent. A self-administered questionnaire with 
standardized questions was mailed to the participants. Information of both 
parents was obtained on four categories: demographic features, 
periconceptional lifestyles, periconceptional health, and miscellaneous. During a 
hospital visit or by telephone interview the questionnaires were checked for 
consistency and completeness by the investigator. The periconceptional period 
of the index-pregnancy was defined as three months prior to conception until 3 
months after conception. However, conform the Dutch Health Council 
recommendation periconceptional folic acid supplement use was defined as the 
daily use of one folic acid containing vitamin supplement 4 weeks prior to 
conception until 2 months after conception. In mothers the use of alcohol and 
tobacco was defined as any use, stopped using or no use. Fathers were 
classified as user or non user. Caffeine use has been defined as drinking one or 
more cups of caffeine containing coffee per day. Medication and illnesses were 
reported by the participants and this information was checked by the general 
practitioner or otherwise if necessary. 
The study protocol was approved by the Institutional Review Board of the 
University Medical Center Nijmegen in the Netherlands. 
 
Data extraction 
The category of 'demographic features' comprised maternal and paternal age, 
education, family history of congenital malformations up to the 4th generation, 
with a specific  focus on neural tube defects and orofacial clefts, and obstetrical 
history as the occurrence of spontaneous abortion. The education level was 
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divided into a group with a high education, when at least one of the parents had 
finished higher secondary or higher vocational training (college) or university, 
and a group with a low education, when both parents finished primary school, 
lower and intermediate secondary school and lower and intermediate vocational 
school. In the category of 'periconceptional lifestyle factors' the maternal use of 
folic acid, zinc and iron containing supplements, the use by both parents of 
alcohol, tobacco, caffeine and a health promoting diet, e.g. macrobiotic, 
vegetarian or vegan, was evaluated. The third category 'periconceptional health 
factors' comprised illnesses, such as gastro-intestinal, dermatological and 
respiratory tract diseases, diabetes mellitus and epilepsy, and the use of 
medication. In the fourth category on 'miscellaneous factors' information was 
obtained on the planning of pregnancy, method of conception (natural vs. 
'assisted'), the use of oral contraceptives, hyperemesis gravidarum, maternal 
anemia and weight loss, and exposure of both parents to X-ray.  
 
Statistical analysis 
Except for maternal and paternal age all determinants were dichotomized, and 
divided into the four categories. Univariate odds ratios (OR) with 95 percent 
confidence intervals (95 percent CI) were calculated. A forward selection 
procedure was performed. For each category multiple logistic regression 
models were constructed to identify the significant factors while simultaneously 
adjusting for the other factors in the category. A p-value of less than 0.05 was 
used as selection criterion. Significant factors only for each category were 
entered in a final multiple logistic regression model of which a ROC-curve and 
an area under the curve (AUC) was calculated as a summary measure of the 
predictive value. Moreover, this logistic model allowed for the estimation of OR 
and 95 percent CI for the adjusted association between a determinant and spina 
bifida risk.  
To compare the low frequencies of the combined variables, such as the familiar 
history of neural tube defects and orofacial clefts, periconceptional illnesses 
and use of medication, Fisher's exact test was employed. 
All statistical analyses were performed using the SAS System for Windows 
version 8 (SAS institute Inc, Cary, NC). 
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Results 
 
For each category the distribution parameters of each factor as well as 
univariate and adjusted ORs with 95 percent CI are presented in Tables I to IV. 
A low maternal and paternal age, a low parental education, and a high frequency 
of congenital malformations in the family increased the risk of spina bifida 
offspring (Table I).  
 
Table I. Category I: Demographic features of parents of a spina bifida or healthy nonmalformed control child, expressed as median (5th – 95th percentile) or 
frequency, and relative risks for spina bifida offspring. 
 
Determinant 
Spina bifida group 
N=128 
Control  
group 
N=233 
OR 95% CI Multivariate ORa 95% CI 
Mother       
 age (years)b 
  
29.8 (23.9–36.3) 31.5 (25.5–37.5) 0.57 (0.42-0.78) 0.78 (0.51-1.19) 
 spontaneous  
 miscarriage (yes) 
28.1% 22.8% 1.3 (0.8-2.2) 1.4 (0.8-2.5) 
       
Father       
 age  (years)b 
  
32.2 (25.3–39.6) 34.0 (28.5–43.2) 0.60 (0.46-0.79) 0.69 (0.48-0.99) 
       
Parental       
Family history of congenital malformations (yes) 25.0% 7.7% 4.0 (2.1-7.4) 4.3 (2.2-8.3) 
 Low educational level 46.9% 32.6% 1.8 (1.2-2.8) 1.6 (1.0-2.7) 
Univariate and multivariate Odds Ratio (OR) with 95% Confidence Intervals (CI) calculated from  univariate analysis and multiple regression models; a) Adjusted 
Odds Ratios for all other factors in the model; b) Odds Ratios for maternal and paternal age at child birth are given as change in risk of spina bifida offspring 
per 5 years.  
 
Maternal age was not significant in the multiple regression model, because of 
the correlation with paternal age (rSpearman=0.65). Therefore, in the final model 
paternal age was replaced by maternal age. Of the periconceptional lifestyle 
factors the maternal use of a health promoting diet and paternal smoking were 
the most prominent risk factors. Periconceptional use of alcohol by the mother 
tended to reduce spina bifida risk (Table II). Most pronounced risk factors for 
periconceptional parental health were maternal illnesses and use of medication 
(Table III). In the category of 'miscellaneous factors' most interesting was the 
finding that planned pregnancy significantly decreased spina bifida risk by 
approximately 60 percent and oral contraceptive use prior to the index-
pregnancy more than two-fold increased spina bifida risk (Table IV).  
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Table II. Category II: Periconceptional lifestyle factors given in frequencies, and relative risks for spina bifida offspring. 
 
Determinant 
Spina bifida group 
N=128 
Control group 
N=233 
OR 95% CI Multivariate 
ORa 
95% CI 
Mother        
Health promoting dietb (yes) 3.1% 9.4% 0.3 (0.1-0.9) 0.2 (0.1-0.7) 
Folic acid supplement (yes) 32.8% 42.1% 0.7 (0.4-1.1) 0.7 (0.4-1.2) 
Zinc supplement (yes) 12.5% 14.2% 0.9 (0.5-1.6) 0.6 (0.2-2.0) 
Iron supplement (yes) 17.2% 17.2% 1.0 (0.6-1.8) 1.9 (0.6-6.0) 
       
Smoking (yes) 24.2% 22.3% 1.1 (0.7-1.9) 0.9 (0.5-1.5) 
Alcohol (yes) 32.3% 43.4% 0.6 (0.4-1.0) 0.6 (0.4-1.0) 
Caffeine (yes) 57.8% 65.7% 0.7 (0.5-1.1) 0.8 (0.5-1.2) 
       
Father       
Health promoting diet* (yes) 2.4% 2.2% 1.1 (0.3-4.7) 3.1 (0.6-16.6) 
Smoking (yes) 42.9% 32.3% 1.6 (1.0-2.5) 1.8 (1.1-2.9) 
Alcohol use (yes) 81.8% 85.8% 0.7 (0.4-1.3) 1.0 (0.5-1.8) 
Caffeine use (yes) 83.3% 86.6% 0.7 (0.4-1.4) 0.8 (0.4-1.4) 
Univariate and multivariate Odds Ratio (OR) with 95% Confidence Intervals (CI) calculated from the univariate analysis  
and multiple regression models; a) Adjusted Odds Ratios for all other factors in the model;  
b) The health promoting diet includes vegetarian, vegan or macrobiotic diets.  
 
Table III. Category III: Periconceptional health and relative risk of spina bifida offspring given in relative risks. 
 
Determinant 
Spina Bifida group 
N=128 
Control group 
N=233 
OR 95% CI Multivariate ORa 95% CI 
Maternal illness (yes) 18.0% 7.3% 2.8 (1.4-5.4) 2.3 (1.1-4.6) 
 medication (yes) 39.1% 24.9% 1.9 (1.2-3.1) 1.7 (1.1-2.8) 
Paternal  illness (yes) 13.3% 8.2% 1.7 (0.9-3.5) 1.3 (0.6-2.8) 
 medication (yes) 18.0% 10.7% 1.8 (1.0-3.4) 1.8 (0.9-3.6) 
Univariate or adjusted Odds Ratio (OR) with 95% Confidence Intervals (CI) calculated from the univariate and 
multiple regression models; a) Multivariate Odds Ratios for all other factors in the model.  
 
In the final model ten potential risk factors were entered and presented in Table 
V. A ROC-curve of the risk profile is depicted in Figure 1 in order to reflect the 
sensitivity and specificity of the final model at different risk profile levels. The 
overall discriminating power of the model is moderate as can be inferred from 
the AUC-value of 0.74. At a sensitivity of 80 percent, a specificity of 60 
percent can be inferred. The use of a periconceptional folic acid containing 
supplement partially prevents spina bifida, it may therefore also reflect the 
health consciousness of the parents. Therefore we stratified the most relevant 
determinants in the final model for the use of folic acid (Table V). Although no 
significant differences in the associations between both strata were 
demonstrated, remarkable was that in folic acid users the ORs for most risk 
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factors tended to be lower with the exception of maternal medication use and 
congenital malformations in the family history. The beneficial effect of 
supplement use was even more pronounced in mothers who had used a health 
promoting diet and reported to have used alcohol in the periconceptional period. 
Whether parents who carefully planned pregnancy and used a supplement were 
at a lower risk than those who did not use a supplement could not be calculated 
due to the fact that all couples in the case group reported that they had planned 
the index-pregnancy. 
 
Table IV. Category IV: Miscellaneous risk factors and the relative risks for spina bifida offspring given in relative risks. 
 
Determinant 
Spina Bifida group 
N=128 
Control group 
N=233 
OR 95% CI Multivariate ORa 95% CI 
Mother       
 Use of OCb (yes) 72.4% 58.6% 1.9 (1.2-3.0) 2.3 (1.4-3.8) 
 Hyperemesis < 12 weeks (yes) 58.6% 52.4% 1.3 (0.8-2.0) 1.3 (0.8-2.1) 
 Anemia < 12 weeks (yes) 3.1% 7.3% 0.4 (0.1-1.2) 0.4 (0.1-1.4) 
 Weight loss < 12 weeks (yes) 19.5% 14.6% 1.4 (0.8-2.5) 1.6 (0.9-2.9) 
 X-rays (yes) 2.3% 2.2% 1.1 (0.3-4.7) 1.2 (0.2-5.8) 
       
Father       
 X-rays (yes) 3.2% 4.4% 0.7 (0.2-2.3) 0.9 (0.2-3.0) 
       
Parental       
 Planned pregnancy (yes) 85.2% 91.4% 0.5 (0.3-1.1) 0.4 (0.2-0.9) 
Univariate or multivariate Odds Ratio (OR) with 95% Confidence Intervals (CI) calculated from the univariate and multiple  
regression models; a) Adjusted Odds Ratios for all other factors in the model; v) Use of oral contraception until conception. 
  
 
Discussion 
 
The objective of this study was to retrospectively evaluate parental health and 
lifestyle factors in the periconceptional period of pregnancies complicated by 
spina bifida and in unaffected control pregnancies. It reveals that the presence 
of a genetic factor defined as a family history of neural tube defects or orofacial 
clefts in particularly is associated with a more than 4-fold higher spina bifida 
risk. Moreover, the same risk was 6 to 7-fold higher in periconceptional folic 
acid supplement users compared to nonusers. This suggests that folic acid 
treatment is not beneficial in the primary prevention of spina bifida, in which a 
major genetic compound is involved. We consider polymorphisms in folate 
genes as minor genetic factors. The combination of these polymorphisms with 
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other environmental factors as low folate intake and the use of a folate 
antagonist can have a significant effect on spina bifida risk. 
 
Table V. The most contributing factors towards spina bifida risk in the final model and stratified by the 
periconceptional use of folic acid supplements. 
 Overall Periconceptional folic acid use 
 N=361 No (N=216) Yes (N=140) 
 Spina bifida/ Control 
 128 / 233 
Spina bifida/ Control 
83 / 133 
Spina bifida/ Control 
42 / 98 
 OR † 95% CI OR † 95% CI OR † 95% CI 
Determinant       
Maternal       
 Age (years) 0.94¶ 0.88-1.01 0.95¶ 0.87-1.03 0.94¶ 0.82-1.07 
 Health promoting diet (% yes) 0.3 0.1-1.0 0.4 0.1-1.9 0.1 0.02-1.4 
 Alcohol use (% yes) 0.6 0.4-1.1 0.7 0.4-1.5 0.4 0.2-1.1 
 Illness (% yes) 2.3 1.0-5.2 2.9 0.8-10.3 2.3 0.7-7.0 
 Use of medication (% yes) 1.8 1.1-3.1 1.6 0.8-3.6 2.1 0.9-5.0 
 Use of OC (% yes) 2.1 1.2-3.8 2.8 1.3-5.9 1.6 0.6-4.1 
       
Paternal       
 Smoking (% yes) 1.2 0.7-2.0 1.2 0.6-2.2 1.0 0.4-2.6 
        
Parental       
 Family history of  
 congenital malformations (%yes) 
4.4 2.2-8.9 4.0 1.1-9.7 6.5 1.8-22.9 
 Low level of education (% yes) 1.3 0.8-2.2 1.4 0.8-2.7 1.1 0.4-2.6 
 Planned pregnancy (% yes) 0.4 0.2-0.9 0.4 0.1-1.0 N.S.*  
Odds Ratio (OR) with 95% Confidence Intervals (CI) calculated from the multiple logistic regression models.  
†) Multivariate Odds Ratios for all other factors in the model. 
¶) Odds Ratio for maternal age at child birth  is given as change in risk of spina bifida offspring per 5 year 
*) In the case group all couples reported that they had planned their pregnancy. A Likelihood ratio test was applied to 
ascertain the statistical significance of this parameter, N.S. = not significant.  
 
We did not determine polymorphisms in folate genes, because we already knew 
from our previous studies and that of others that the biochemical consequences 
of for example the 677C>T polymorphism in the MTHFR gene can beneficially 
be treated by folic acid supplements. Of interest is that the family history effect 
is mainly due to a significant difference in the occurrence of orofacial clefts 
being 21.9 percent in spina bifida families and 3.5 percent in control families. 
Both neural tube defects and orofacial clefts originate from a disturbed 
migration and differentiation of neural crest cells in early pregnancy and 
therefore support the existing evidence that these congenital malformations 
share some genetic and/or life style factors (26). To prevent spina bifida, 
couples with such family histories should consider refraining from pregnancy, to 
choose for donor insemination, oocyte donation, adoption or prenatal diagnostic 
procedures with the option of pregnancy termination. 
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Figure 1. ROC-curve of the final model for the most contributing determinants i.e., maternal age, peri-
conceptional use of a health promoting diet, alcohol, oral contraceptives, and medication, illness, paternal 
smoking, congenital malformations in the family, low parental level of education, planning of pregnancy, and 
spina bifida risk in the offspring; AUC = 0.74. 
 
More hopeful with regard to the primary prevention of spina bifida is the 
identification of some amendable independent health and lifestyle risk factors 
from the logistic regression model. The relatively high percentages of false-
positives and false-negatives makes this model not very suitable for 
preconceptional screening. However, the model would substantially be 
improved when genetic data, in particular polymorphisms, are incorporated as 
well. Nevertheless, it may be a useful instrument to preconceptional identify 
and consecutively handle some of the risk factors.  
In line with our expectations is that more health consciousness couples, 
reflected by the maternal periconceptional use of a health improving diet, folic 
acid supplement use, the planning of pregnancy, less alcohol and tobacco use, 
show a 70 percent lower spina bifida risk than those who are not concerned 
with their health and lifestyles. Although, we had expected more 
periconceptional folic acid users in the diet group, the distribution of spina 
bifida and control mothers using periconceptional supplements stratified by the 
periconceptional use of the diet was comparable. It has been reported that 
individuals following a strict macrobiotic diet without the use of vitamin 
supplements more often show hyperhomocysteinemia and vitamin B12 deficiency 
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(33). Both determinants are risk factors for spina bifida offspring and therefore 
we suppose that the mothers in our study did not use a very strict diet or the 
subgroup was too small to effect the risk estimates. Further investigation 
however, is needed to disentangle the underlying mechanism of the association 
between the maternal diet and spina bifida offspring. 
Illnesses and the use of prescribed medication more often occurred in parents 
of spina bifida offspring but was most pronounced in the mothers. This is in line 
with previous reports showing associations between maternal epilepsy, diabetes 
mellitus, acrodermatitis enteropathica, fever and spina bifida risk (34-36). From 
the subgroup analysis revealed that significantly more mothers of a spina bifida 
child suffered from epilepsy compared to the control mothers, 3.1 percent and 0 
percent, respectively, and used anticonvulsants that can induce spina bifida by 
exposure to epoxides and/or imparing folate metabolism (9,23,35). In addition, 
asthma, i.e. 8.6 percent and 3.9 percent, respectively, and dermatological 
diseases, i.e. 3.9 percent and 1.3 percent, respectively, occurred more 
frequently in spina bifida mothers than in controls. Herewith in line is the more 
frequent use of antihistaminic drugs, corticosteroids and sympaticomimetics in 
spina bifida mothers, i.e. 13.3 percent and 5.6 percent, respectively. So far no 
studies demonstrated the association between a maternal allergic constitution 
and spina bifida offspring before. Of interest however is that latex allergy may 
be more prevalent in spina bifida children (37,38). Moreover, corticosteroid use 
in early pregnancy has been associated with congenital malformations, in 
particular cleft palate (39). Future research is needed to unravel whether the 
disease and/or the medication is the most important risk factor. In 
preconceptional counseling these women should be referred to their consultant 
to temporarily stop or change their medication. 
From this study reveals a two-fold increased spina bifida risk in mothers who 
reported to have used oral contraceptives prior to the index-pregnancy 
compared to those who used other contraceptive methods. Although the 
subgroup analysis demonstrated that 4 spina bifida mothers used the oral 
contraceptives until the 4th week of amenorrhea and two till the 10th week of 
amenorrhea, the increased spina bifida risk was significantly due to mothers 
who reported to have stopped oral contraceptive use before conception being 
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5.4 percent compared to the 0.7 percent post-conceptional users. This supports 
the earlier findings that long term oral contraceptive use may compromise 
vitamin status in particular that of folate, cobalamin and pyridoxine. Moreover, 
we demonstrated before that oral contraceptives directly affect folate kinetics 
(40) and compromised folate and cobalamin status is associated with spina 
bifida risk (2,31). Herewith in line is that a mild hyperhomocysteinemia as a 
result of folate and/or cobalamin shortage is a risk factor for spina bifida 
offspring as well (5,41). Inference about the causality of folate shortage and 
spina bifida offspring is difficult because the six mothers who used oral 
contraceptives after conception also did not use periconceptional folic acid 
supplements. On the other hand both factors compromise folate status. These 
findings are in agreement with that of the group of Stoll et al. (1992) who 
observed that mothers of children with hydrocephalus and multiple 
malformations had more frequently used oral contraceptives during the first 
trimester of pregnancy (42), and in contrast to the data of Cuckle et al. (43). 
The conflicting evidence may be explained by the heterogeneity of the oral 
contraceptives with varying effects on folate status, the definitions of the study 
groups and the sample sizes. 
A methodological issue to be considered in case-control studies on risk factors 
for congenital malformations is information bias, which may have occurred due 
to the retrospective design of the study and social undesirable or harmful 
behavior. This may explain a possible underestimation of smoking and alcohol 
abuse. Nevertheless, the fact that several independent data point to the same 
direction, namely that a healthier life-style reduces the risk of spina bifida 
offspring, support the validity of our findings.  
In contrast to most other studies we standardized the moment of data collection 
in both spina bifida and control parents at around 24 months after the 
periconceptional period of the index-pregnancy to improve the comparability of 
the data. The recall period of 24 months is relatively short compared to other 
studies, in which periods of 5-10 years are covered. Two years was chosen 
also to improve the validity of data related to the season, such as the 
occurrences of illnesses such as the flu and allergies. 
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A considerable part of the control group (83 percent) was recruited by leaflets 
via public nurseries and health centers. This approach may have lead to an 
overrepresentation of higher educated parents in the control group that are 
more aware of the importance of a healthier life-style towards pregnancy 
through which an overestimation of risk factors such as the use of a health 
promoting diet may have occurred. In addition, lower educated parents may 
have had more difficulties in filling out the questionnaires. To reduce this 
potential source of confounding, all questionnaires were checked and validated 
in a personal interview. Nevertheless, we adjusted ORs for the level of 
education in the final model.  
It is very likely that information bias concerning maternal use of alcohol has 
occurred, because case mothers may have underreported social unwanted 
behavior thus leading to information bias. Nevertheless, if this is a valid finding 
we would have expected that periconceptional smoking and caffeine use 
demonstrated similar trends, which was not the case. The frequency of 
periconceptional folic acid supplement use was not significantly different 
between cases and controls and is likely due to over reporting by the spina 
bifida mothers due to social desirable answers. The frequency of folic acid 
supplement use is comparable to other studies performed in the same period in 
the Netherlands (44,45). 
In summary, our study provides some amendable health and life-style factors in 
parents that are associated with spina bifida risk. They underline the 
multifactorial origin of spina bifida and should be targeted in preconceptional 
counseling to contribute to the primary prevention of spina bifida.  
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OBJECTIVE: Myo-inositol plays a key role in an important intracellular 
signaling pathway. A deranged myo-inositol metabolism has been associated 
with neural tube defects. A myo-inositol loading test was performed to 
investigate the kinetics of myo-inositol in healthy women of reproductive age. 
STUDY DESIGN: Five healthy non-obese females (mean age (SD); 22.8 (2.2) 
years) were recruited at the University Medical Center Nijmegen. Blood 
samples were drawn fasting and at 20, 40, 60, 90, 180 and 270 minutes after 
ingestion of 100 mg/kg body weight of myo-inositol. Urine samples were 
collected before myo-inositol loading and at 180 and 270 minutes post loading. 
Samples were analysed for serum myo-, epi- and scyllo-inositol and glucose 
concentrations by gas chromatography. Plasma insulin concentrations were 
determined by radioimmunoassay. Random intercept models were fitted to 
evaluate the data. 
RESULTS: The estimated myo-inositol and scyllo-inositol concentrations both 
reached maximum values at 180 minutes post loading, respectively, mean (SD) 
101.5 (9.2) µmol/L and 1.09 (0.11) µmol/L. The estimated plasma insulin and 
serum glucose concentrations decreased slightly, but significantly during the 
experiment, p<0.0001 and p<0.05, respectively. At 180 and 270 minutes post 
loading, urinary myo-inositol concentrations were increased and urinary 
glucose concentrations were unchanged. 
CONCLUSIONS: Myo-inositol enters the bloodstream quickly after oral 
ingestion and a small amount of myo-inositol is converted to scyllo-inositol. 
The synthesis of glucose from myo-inositol could not be detected by serum 
measurements. This data can be used in further research into the association 
between myo-inositol and neural tube defects. 
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Introduction 
 
Myo-inositol is a hexahydroxycyclohexane and one of the nine stereoisomers 
of inositol. It plays a key role in the intracellular inositol-1,4,5-triphosphate 
signaling pathway. Myo-inositol is a constituent of phosphatidylinositol-4,5-
biphosphate, which can be cleaved into inositol-1,4,5-triphosphate and 
diacylglycerol after receptor activation by phospholipase C. Inositol-1,4,5-
triphosphate triggers calcium release from the endoplasmic reticulum, resulting 
in cellular reactions such as DNA transcription and muscle contraction (1).  
Adult food intake contains approximately 1 g of inositol per day either as free 
inositol, inositol-containing phospholipids, or as phytic acid, e.g. inositol 
hexaphosphate (1). Experimental data has shown that myo-inositol is taken up 
by sodium- and energy-dependent cotransporters located in the cell 
membranes of most tissues (2,3). Aside from dietary intake, several mammalian 
tissues are able to synthesise myo-inositol de novo from glucose-6-phosphate 
(4). The initial reaction is catalysed by 1L-myo-inositol 1-phosphate 
synthetase (see Figure. 1) (5). The human kidney is the primary site of myo-
inositol clearance by conversion of 1L-myo-inositol into glucuronate by myo-
inositol oxygenase (EC 1.13.99.1) followed by urinary excretion (5). In humans, 
the urinary disposal of myo-inositol is 1 g/day, which can rise to 21 g/ day 
during hypermyo-inositolaemia (5).  
Myo-inositol is a constituent of membrane-bound phosphoinositides. These 
compounds are involved in intracellular signalling processes which play a role 
in embryogenesis (1,3). In healthy subjects, the free myo-inositol blood plasma 
concentration is approximately 30 µmol/L (1). Brain and cerebrospinal fluid 
myo-inositol concentrations have been reported to be higher than in peripheral 
blood (1,6). Beside active transport across the blood-brain barrier, de novo 
synthesis of myo-inositol has been reported in the rabbit brain (6).  
The disturbances in glucose myo-inositol metabolism in diabetic patients cause 
cellular dysfunction leading to atherosclerosis and neuropathy (7). Infants of 
diabetic mothers have a three- to fivefold increased risk of congenital 
malformations, especially of the central nervous system, i.e. neural tube 
defects, and the heart (8,9). These findings are confirmed in experimental 
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animal studies (10,11). The mechanism whereby hyperglycaemia induces 
embryopathy is not well understood. An explanation could be that, due to 
competitive inhibition of cellular myo-inositol uptake by hyperglycaemia, 
tissue-specific shortages of myo-inositol occur (7,12). Of interest is that 
supplementation with myo-inositol has been shown to reduce the birth 
prevalence of neural tube defects in streptozotocin-induced diabetic Sprague-
Dawley rats and curly tail mice (10,11). A similar effect could be expected in 
humans (13).  
To gain insight in the metabolism of myo-inositol, we performed a kinetic 
study, in which the uptake of myo-inositol, its conversion into the 
stereoisomers epi- and scyllo-inositol, urinary excretion and insulin response 
were studied after myo-inositol loading in women of reproductive age.  
 
Figure 1. The biosynthesis and degradation of myo-inositol in mammalian tissues, such as liver, kidney, brain 
and glands.  The conversion of 1D-Myo-inositol into D-glucuronate primarily takes place in the kidneys.  
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Subjects and Methods 
 
Subjects 
Five healthy non-obese female subjects in reproductive age participated in the 
study after having given written informed consent. Participants did not use any 
medication except for the use of oral contraceptives. The study protocol was 
approved by the Institutional Review Board of the University Medical Center 
Nijmegen in the Netherlands. 
 
Study protocol 
Participants fasted from 11 pm the day prior to the experiment. On the day of 
the experiment the participants came in at 8 am and venous blood samples were 
drawn for the determination of serum myo-, epi-, scyllo-inositol, glucose and 
plasma insulin concentrations. The blood samples for the measurements of 
serum myo-, epi-, scyllo-inositol and glucose were collected into a 2 mL 
Vacutainer tube containing sodium fluoride and potassium oxalate. A 4.5 mL 
Vacutainer tube containing lithium heparin was used for collection of blood for 
the determination of plasma insulin. Each subject ingested an aqueous solution 
of 100 mg/kg bodyweight of myo-inositol. Subsequently, blood was drawn at 
20, 40, 60, 90, 180 and 270 minutes after myo-inositol intake. At 0, 180 and 
270 minutes urine specimens were collected. After blood sampling and urine 
collection, the samples were immediately placed on ice and centrifuged for 10 
minutes at 1,550xg in a Hettich Rotanta/AP centrifuge and stored at -20 °C until 
assayed. The samples were assayed in one run within 1 year of collection. 
During the experiment no side effects of myo-inositol loading were observed. 
 
Laboratory analysis 
Serum myo-, epi- and scyllo-inositol and glucose concentrations were 
determined by trimethylsilylation and gas chromatography according to Jansen 
et al (14). Five hundred µL of serum was pipetted into an Eppendorf tube and 
100 nmol of mannoheptulose and 100 nmol of trehalose were added as internal 
standards. Then 25 µL of 8 M perchloric acid was added. After the tube was put 
on ice for 10 minutes, the samples were centrifuged for 5 minutes at 10,000xg 
in an Eppendorf centrifuge (model 5414). The supernatants were transferred 
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into new Eppendorf tubes and 50 µL of 4 M K2HPO4 was added. After 10 
minutes on ice the samples were again centrifuged for 5 minutes at 10,000xg. 
The supernatants were transferred into glass tubes and frozen until dry 
overnight in a Lyovac GT II (Leybold-Heraeaus, Utrecht, The Netherlands).  
Urinary creatinine determination was based on the Jaffé reaction and analysed 
on a Hitachi 747 (Roche Diagnostics Nederland BV, Almere, The Netherlands). 
The volume of the urine sample was chosen such that it contained 1 mmol of 
creatinine. Subsequently, the samples were transferred into glass tubes and 
frozen until dry overnight. 
Five hundred µL of Tri-SIL® TBT, a powerful silylating agent from Pierce 
Omnilabo International (Breda, The Netherlands, No. 49016) was added to the 
residues of the serum and urine samples and the mixtures were put in a heating 
block (Marius Instrumenten, Utrecht, The Netherlands) for 30 minutes at 100 
°C. One mL of MilliQ and 1 mL of hexane were added to the solutions. The 
mixtures were then shaken for 5 minutes (Gyrotory Shaker Model G2, New 
Brunswick Scientific Co., Inc. Edison, New Jersey, USA) and centrifuged for 5 
minutes at 1,000xg. The supernatants were transferred to clean glass tubes and 
1 mL of 0.1 M HCl was added, shaken again for 5 minutes and centrifuged at 
1,000xg for 10 minutes. The supernatants were transferred to new tubes and 
200 mg of Na2SO4 added. Samples were left at room temperature for 15 minutes 
and centrifuged at 1,000xg for 10 minutes. The supernatants were decanted 
into new tubes and 1 drop of bis(trimethylsilyl)trifluoracetamide was added, 
mixed and the tubes were then centrifuged at 1,000xg for 10 minutes. The 
supernatants were then decanted into clean glass tubes and evaporated under a 
stream of nitrogen. Finally, the residues were dissolved in 100 µL of hexane 
and analysed on a gas chromatograph (Hewlett Packard 5890 series II). The 
detection limits of glucose and the inositol-stereoisomers were ( 0.5 (mol/L. 
The intra-assay coefficients of variation (CV) for myo-inositol and glucose 
were 10.4% and 4.3%, respectively. 
Plasma insulin was assessed by a direct radioimmunoassay (RIA) using 125I-
labelled human insulin and anti-human antiserum, raised in a guinea pig against 
a human insulin-bovine serum albumin conjugate. Sheep anti-guinea pig 
antiserum was used for separation of bound and free tracer. Human Insulin 
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(Novo Biolabs, Bagsvaerd, Denmark, No. 471) was used for standards. The 
intra-assay CV was 8.1%, 8.8% and 9.0% at insulin concentrations of 123.0, 
245.4, and 336.0 pmol/L and the inter-assay CV at these concentrations were 
15.2%, 10.7% and 12.4%. 
 
Statistical analysis 
Concentrations per sampling point were pooled and mean (SEM) concentrations 
were calculated for myo-, epi- and scyllo-inositol, glucose and insulin.  
To describe the kinetics of the serum concentrations of myo-inositol, epi-
inositol, scyllo-inositol, glucose and insulin, random intercept models were 
fitted. The models included the serum concentration as a dependent variable, 
time and time-squared, when appropriate, as independent variables and a 
random intercept. The serum myo- and scyllo-inositol concentrations were 
best described by a second-order polynomial function, whereas a first-order 
model best described the glucose and insulin concentrations. The epi-inositol 
concentration did not change during the experiment and, therefore, no model 
was fitted. 
Let Yij denote the myo-inositol measurement of individual i (i=1,...,5) at time Tj 
(j=1,...,7). A random intercept model with a second-order (fixed) polynomial 
term for time is given by: 
 
Yij = α + β1Tj + β2T2j + µi + εij 
    
The second-order polynomial term α + β1Tj + β2T2j describes a parabola and 
gives the (estimated) population mean concentration of myo-inositol. The term 
µi is the random intercept and gives the deviation of subject i from the 
population mean and is assumed to be normally distributed with variance σ2µ and 
expectation 0. The εij are the residuals and these follow a normal distribution 
with variance σ2ε and expectation 0. The variance σ2µ is also known as the 
between-subjects variance, whereas the variance σ2ε is known as the within-
subjects variance. All analyses were performed using the SAS System for 
Windows Version 6.12. 
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Results 
 
On the day of the experiment the mean (SD) age and bodyweight of the women 
were 22.8 (2.2) years and 64.3 (12.6) kilograms, respectively.  
After myo-inositol ingestion, the observed mean (SEM) serum concentration 
increased from 19.9 (2.5) µmol/L to a maximum of 96.5 (16.6) µmol/L after 90 
minutes. The estimated mean (SEM) serum myo-inositol concentration 
significantly increased from 20.8 (9.4) µmol/L to an estimated maximum of 
101.5 (9.2) µmol/L (p<0.001) after 180 minutes. This indicates that the actual 
maximum of the myo-inositol serum concentration is located between 90 and 
180 minutes after ingestion of myo-inositol. Subsequently, the observed and 
estimated concentrations decreased to, respectively, 77.3 (17.7) µmol/L and 
72.5 (10.6) µmol/L after 270 minutes. The results are summarised in Table I 
and Figure 2. 
 
Table I. Parameter estimates in the random intercept model for myo-inositol, scyllo-inositol, 
glucose and insulin measurements. 
Parameter α (SE) β1 (SE) β2 (SE) σ2µ (SE) σ2ε (SE) 
Myo-inositol 20.8 (9.4) 
p>0.05 
0.96 (0.12) 
p<0.0001 
-2.8x10-3 (0.44x10-3) 
p<0.0001 
287 (208) 
p>0.05 
293 (76) 
p<0.0001 
Scyllo-inositol 0.39 (0.10) 
p≤0.05 
7.4x10-3 (1.2x10-3) 
p<0.0001 
-19.1x10-6 (4.3x10-6) 
p<0.0001 
0.043 (0.030) 
p>0.05 
0.027 (0.007) 
p<0.0001 
Glucose 3.76 (0.06) 
p<0.0001 
-8.6x10-4 (4.3x10-4) 
p≤0.05 
- 3.0x10-3 (6.9x10-3) 
p>0.05 
0.052 (0.013) 
p<0.0001 
Insulin 58 (2.5) 
p<0.0001 
-0.09 (0.02) 
p<0.0001 
- 4.2 (10.9) 
p>0.05 
86 (22) 
p<0.0001 
Parameter estimates are presented with their standard error (SE). P-values are calculated for 
test parameter=0. The t-distribution is used for α, β1 and β2 and the Z-distribution is used for 
σ2µ and σ2ε.  
 
Similar to serum myo-inositol concentrations, serum scyllo-inositol 
concentrations increased after myo-inositol ingestion from an observed and 
estimated mean (SEM) concentration of respectively 0.46 (0.13) µmol/L to 1.09 
(0.17) µmol/L and 0.39 (0.11) µmol/L to 1.09 (0.11) µmol/L at 180 minutes 
(p<0.0001) (see Table I and Figure 3).  
The coefficient for time in the model for epi-inositol was not significant (β1; 
p>0.05). This concludes that the observed epi-inositol concentration did not 
significantly change during the experiment (Table II). The estimated serum 
glucose and plasma insulin concentrations, slightly, but significantly declined 
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during the experiment (time coefficients glucose p≤0.05 and insulin p<0.001) 
(Table I).  
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Figure 2. Observed and estimated serum myo-inositol concentrations (µmol/L) in five healthy subjects. The 
dots, squares, diamonds, triangles and circles represent individual samples, whereas the solid line represents 
the mean with standard error of the mean at each sampling point. The dashed line represents the mean serum 
myo-inositol concentrations as estimated by the random intercept model.  
 
Table II. Epi-inositol, glucose and insulin  
concentrations after myo-inositol loading. 
Serum Plasma 
Epi-Inositol 
(µmol/L) 
Glucose 
 (mmol/L) 
Insulin 
(pmol/L) 
0.38 ± 0.23 3.8 ± 0.1 54.0 ± 4.2 
0.29 ± 0.15 3.7 ± 0.2 62.4 ± 5.2 
0.41 ± 0.25 3.7 ± 0.1 51.6 ± 3.1 
0.33 ± 0.19 3.7 ± 0.1 52.5 ± 5.9 
0.26 ± 0.15 3.8 ± 0.1 51.6 ± 5.9 
0.27 ± 0.20 3.5 ± 0.1 38.4 ± 3.1 
0.19 ± 0.19 3.6 ± 0.1 34.8 ± 2.9 
Results are presented in mean ± SEM.   
Urinary excretion of myo-inositol increased. However, the amount excreted 
differed between the subjects (see Figure 4). In urine both scyllo- and epi-
inositol were at the detection limit. The urinary glucose concentrations 
remained at approximately 20 µmol per mmol of creatinine throughout the 
experiment.  
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Figure 3. Observed and estimated serum scyllo-inositol concentrations (µmol/L) in five healthy subjects. The 
dots, squares, diamonds, triangles and circles represent individual samples, whereas the solid line represents 
the mean with standard error of the mean at each sampling point. The dashed line represents the mean serum 
scyllo-inositol concentrations as estimated by the random intercept model.  
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Figure 4. Urinary myo-inositol concentrations given in µmol/mmol creatinine in the five healthy subjects. 
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Discussion 
 
Myo-inositol was readily taken up following oral loading and maximum serum 
concentrations were reached between 90 and 180 minutes. This was faster than 
was previously described by Clements et al., who reported maximum 
concentrations 3 hours following oral intake in fasting control subjects (15). 
This can be explained by the lower dose of myo-inositol administered, i.e. 3.0 
g, independent of body weight. In our study, we administered 100 mg of myo-
inositol per kg body weight, resulting in a load of at least 5 grams of myo-
inositol. However, the maximum serum myo-inositol concentrations obtained of 
approximately 100 µmol/L were comparable in both studies. An explanation 
could be that due to the higher myo-inositol load the maximum serum 
concentration is reached sooner. The anticipated twofold increase in maximum 
serum concentration was not reached, possibly because of saturation of the 
sodium- and energy-dependent myo-inositol transporter protein at 100 µmol/L. 
This is supported by a review of Gani et al. which described sodium- and 
energy-dependent myo-inositol transporters as having myo-inositol affinities 
ranging from 50 to 200 µmol/L (16).  
Serum scyllo-inositol concentrations were also found to increase; on average 
2.5-fold. This has not been reported previously. This suggests that around 1% 
of myo-inositol is converted into scyllo-inositol, but not into epi-inositol. This 
is supported by the random intercept models for myo-inositol and scyllo-
inositol, which reveal that the estimated maximum serum scyllo-inositol 
concentration is reached at a later time point than the estimated serum myo-
inositol maximum, respectively 168 and 190 minutes after myo-inositol 
ingestion.  
Although a balance seems to exist between the metabolism of glucose and 
myo-inositol, no increase in serum or urinary glucose concentrations were 
observed after myo-inositol loading. This can be explained by the intracellular 
conversion of myo-inositol into glucose and its immediate metabolism. The 
administered myo-inositol dose may therefore have direct effects on cellular 
level that may not be detected in blood and urine. Moreover, as a consequence 
of prolonged fasting, the estimated serum glucose concentrations decreased 
slightly, but significantly. It is not very likely that the pattern of responses are 
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confounded by diet, because a very high myo-inositol dose was used to trigger 
glucose-myo-inositol metabolism. Besides the participants were fasting at 
entry.  
These data show that myo-inositol is excreted into the urine as previously 
described in diabetics and controls (15). Following myo-inositol loading, 
individual urinary myo-inositol concentrations increased 2 to 90 times 
compared to the fasting baseline levels, whereas the glucose concentration was 
unchanged. Of interest is the observation of two different excretion patterns 
(Figure 4). Three subjects showed urinary myo-inositol excretions starting 
from approximately 5 µmol/mmol of creatinine and rising to around a mean of 
40 µmol/mmol of creatinine at 270 minutes. The urinary myo-inositol 
concentrations of the two other subjects rose from 5 µmol/mmol of creatinine to 
a mean of 550 µmol/mmol of creatinine at 270 minutes. We suggest that there 
are two isoforms of the enzyme myo-inositol oxygenase, a slow and a fast 
isotype. After myo-inositol loading, the fast isotype will cleave myo-inositol 
quickly to glucuronate resulting in low urinary concentrations of myo-inositol 
and vice versa for the slow isotype (see Figure 4). 
In conclusion, this study shows that myo-inositol is readily taken up after 
ingestion and around 1% seems to be converted into scyllo-inositol. Of interest 
is that two patterns of myo-inositol excretion were shown. Future experiments 
may involve the myo-inositol loading in mothers with neural tube defect-
affected offspring and in patients with neural tube defects themselves. 
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OBJECTIVE: The aim of this study was to longitudinally determine the blood 
concentrations of these myo-inositol, glucose and zinc before, during and after 
pregnancy. The results may be used for future studies into the role of myo-inositol, 
glucose and zinc in human reproduction. 
STUDY DESIGN: Thirty-seven women who were planning pregnancy were recruited at 
the University Medical Center Nijmegen in The Netherlands. In blood samples of 18 
nulliparae and 19 multiparae, concentrations were determined of serum inositol and 
glucose, and red blood cell zinc concentrations preconceptionally, at 6, 10, 20, 30 and 
37 weeks amenorrhea, and 6 weeks after delivery. The data were analyzed using a 
linear mixed model. 
RESULTS: The preconceptional mean (SE) inositol concentration of 21.7 (1.03) μmol/L 
was comparable to the concentrations at 6 and 37 weeks amenorrhea, 22.2 (1.03) 
μmol/L, and 19.9 (1.10) μmol/L, respectively. However, the preconceptional inositol 
concentration was significantly lower at 10 and 20 weeks amenorrhea and post partum, 
p<0.05. The preconceptional mean (SE) glucose concentration of 3897 (103) μmol/L 
was comparable to the concentration at 6 and 10 weeks amenorrhea, 3946 (104) μmol/L 
and 3750 (104) μmol/L respectively. The preconceptional glucose concentration also 
was significantly lower at 20 weeks amenorrhea as well as at 30 and 37 weeks 
amenorrhea and after delivery, p<0.05. Preconceptional red blood cell zinc 
concentrations were comparable to concentrations at 6, 10 and 20 weeks amenorrhea. 
At 30 and 37 weeks amenorrhea and post partum, the zinc concentrations were 
significantly higher than in the preconceptional period (p<0.01). 
CONCLUSION: The concentrations of inositol, glucose and zinc significantly change 
during pregnancy. However, the preconceptional blood concentrations reflect the 
concentrations determined in the first pregnancy trimester rather well, which is 
important information to be used in the design of future studies into the role of inositol, 
glucose and zinc in reproductive disorders. 
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Introduction 
 
Myo-inositol (inositol), a six-carbon sugar-alcohol is the most abundant of the 
nine isomers of inositol in cells. Myo-inositol and its derivatives such as 
phosphatidyl-inositol-4,5-biphosphate play a key role in intracellular signaling 
pathways, steroid synthesis, intracellular calcium regulation and membrane 
integrity (1-3). Following G-coupled-receptor activation phosphatidyl-inositol-
4,5-biphosphate is cleaved by phospholipase C resulting in myo-inositol-1,4,5-
triphosphate and diacylglycerol. Subsequently, these molecules trigger calcium 
release from intracellular stores and activate protein kinase C (PKC). The 
increase of calcium-ions and activation of PKC leads to cellular responses such 
as muscle contraction and up or down regulation of genes. Humans are able to 
synthesize inositol from D-glucose-6-phosphate. Additionally, approximately 1 
gram of inositol per day is provided by the diet (4). Myo-inositol is taken up 
from the intestinal lumen by sodium or proton and energy dependent 
cotransporters and subsequently transported by the blood at a concentration of 
20-100 µmol/L. One of the sodium-myo-inositol transporters, SMIT1, is also 
capable of transporting glucose. Competitive inhibition of inositol uptake by high 
glucose concentrations as observed in diabetes mellitus can result in tissue-
specific inositol shortages. This is of interest because myo-inositol has been 
implicated in the pathogenesis of reproductive disorders as fertility, 
spontaneous miscarriages, preeclampsia, and congenital malformations as spina 
bifida and Down's syndrome (3,5,6). Inositol, in particularly inositol 
supplementation, has been investigated with respect to fetal lung maturation and 
respiratory distress syndrome (7,8). 
Since glucose is the main energy source of the embryo and fetus, a deranged 
maternal glucose metabolism may interfere with normal fetal development, as 
can be seen from women suffering from diabetes and the occurrence of spina 
bifida and other congenital malformations (9). We have recently demonstrated 
that low maternal serum inositol and mildly increased glucose concentrations 
are associated with the occurrence of spina bifida offspring (10). However, the 
mechanisms by which inositol and glucose are involved in the pathogenesis of 
these congenital malformations have yet to be elucidated.  
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Another nutrient reported to be associated with spina bifida is zinc and more 
specifically zinc deficiency. Both experimental and human studies revealed 
deficiencies of this trace element as a risk factor for several congenital 
malformations among them being spina bifida and anencephaly (11-13). Zinc is 
involved in the structure and functioning of many enzymes, hormones and 
neuropeptides. Of interest is the observation that maternal zinc deficiency can 
exacerbate the teratogenic effect of diabetes mellitus in Streptozotocin-induced 
diabetic Sprague-Dawley rats (13). This is in line with the study by Leushner et 
al. suggesting that a thickening of the basal membrane of the trophoblast in 
diabetic patients result in reduced placental transfer of nutrients such as zinc to 
the developing fetus (14). The underlying deranged pathways due to zinc 
deficiency, however, remain to be elucidated.  
From this background we determined and evaluated the longitudinal 
concentrations of serum inositol, glucose and red blood cell zinc before and 
during uncomplicated pregnancy and 6 weeks after delivery. The results can be 
used for future studies into the role of inositol, glucose and zinc in human 
reproduction. 
 
 
Subjects and Methods  
 
Subjects 
A longitudinal study was designed in which blood sampling for myo-inositol, 
glucose and zinc took place preconceptionally, at 6, 10, 20, 30, 37 weeks 
amenorrhea and around 6 weeks after delivery. Between September 1999 and 
February 2001, 37 women who were planning pregnancy and were living in 
Nijmegen and surroundings in The Netherlands were enrolled for this 
investigation. The participants were recruited by advertisements in local 
newspapers, posters at the clinics of general practitioners, pharmacies, child 
day care centers and public health centers. All native-Dutch women who were 
planning pregnancy and were not participating in an assisted reproductive 
program were eligible to participate. We excluded women who were smoking, 
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taking medication that is known to interfere with inositol, glucose or zinc, or 
who had experienced two repeated miscarriages.  
After obtaining written informed consent, appointments were made at the 
Department of Obstetrics and Gynecology of the University Medical Center in 
Nijmegen for blood sampling. At the end of each appointment the woman 
received a small questionnaire concerning information about current lifestyle, 
demographic factors and pregnancy, which was filled out at home and returned 
by mail. The study protocol was approved by the Institutional Review Board of 
the University Medical Center Nijmegen in the Netherlands. 
Thirty-seven healthy women were included of which 18 were nulliparae and 19 
multiparae. Five women experienced preeclampsia in a previous pregnancy and 
3 had been diagnosed with preexistent hypertension. 
 
Blood sampling 
The women fasted from 10 p.m. the day prior to blood sampling. Two mL of 
venous blood was drawn into a potassium oxalate and sodium fluoride 
containing vacutainer tube for inositol and glucose measurement and stored on 
ice until processed. In addition, 4 mL of venous blood was drawn into an EDTA 
containing vacutainer tube for the measurement of zinc. 
 
Measurement of inositol and glucose 
The inositol and glucose concentrations were determined by trimethylsilylation 
and gas chromatography according to a modification of the procedure used by 
Jansen et al. (15), which has been described elsewhere (16). The detection limit 
of both inositol and glucose was 0.5 µmol/L. The intra-assay coefficient of 
variation (CV) for inositol and glucose was 10.4% and 4.3%, respectively. 
 
Measurement of zinc 
Red blood cell zinc concentrations were determined by flame atomic absorption 
spectrophotometry (AAS) (Perkin Elmer 4100; Norwalk, Connecticut, USA). To 
1 mL of venous blood 9 mL of a physiological salt solution was added and the 
sample was centrifuged for 10 minutes at 400x g at 4 °C. The supernatant was 
removed, the cell pellet resuspended into 10 mL of a physiological salt solution 
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and centrifuged for 10 minutes at 400x g at 4 °C. After removal of the 
supernatant, the red blood cells were lysed by adding 2 mL of MilliQ. The lysed 
red blood cell samples were stored at -20 °C until assayed. The intra- and 
inter-assay CV for zinc were 3.4% and 3.5%, respectively (level 12 µmol/L). 
 
Statistical analysis 
The data were analyzed using a linear mixed model. In this model the 
dependency of the measurements within the same subject was accounted for by 
a subject-specific random coefficient. Separate means for each of the seven 
sampling time-points were assumed. To investigate differences between 
women due to parity, preeclampsia and the use of folic acid containing 
multivitamins, indicator variables were taken up into the model. Because neither 
indicator variable reached significance, all women were treated as one group.  
The concentrations are summarized by estimated mean concentrations with 
standard errors at the seven time-points.  
Pearson correlation coefficients were calculated between concentrations of 
inositol, glucose and zinc at any of the seven time-points and birth weight. 
Probability values of < .05 were considered statistically significant. All 
statistical analyses were performed with the SAS software (version 8; SAS 
Institute Inc, Cary, NC). 
 
 
Results 
 
The median age (range) was 31.5 years (24.2 – 37.5) and median birth weight 
(range) was 3245 grams (2203 – 4690). Five monitored pregnancies were 
complicated by preeclampsia of which 2 in women who suffered from 
preexistent hypertension. Seventy-three percent of the women reported the 
use of folic acid containing multivitamin supplements from preconception until at 
least 8 weeks amenorrhea.  
Figures 1 –  3 show the observed inositol, glucose and zinc mean (SEM) 
concentrations and the estimated means according to the model. For inositol a 
markedly significant decrease occured after 6 weeks of gestation from 22.2 
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µmol/L to 16.9 µmol/L, followed by a steady increase to 19.9 µmol/L at the end 
of pregnancy. Glucose concentrations decreased markedly after 6 weeks of 
gestation from 3897 µmol/L to 3537 µmol/L at 20 weeks amenorrhea and from 
where it remains rather constant. Red blood cell zinc concentrations gradually 
increased during pregnancy reaching statistical significance at 30 weeks 
amenorrhea.  
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Figure 1. Serum myo-inositol concentrations during pregnancy. Circles (bars) represent observed mean (SEM) 
and dotted line represent the estimated means; N=37. 
 
Table I summarizes the preconception inositol, glucose and zinc concentrations, 
as well as the concentrations during pregnancy and after delivery. P-values are 
shown for the differences in concentrations between the preconception 
concentrations versus the concentrations during pregnancy and around 6 weeks 
after delivery. A P-value is also presented in Table I for the first time-point 
that shows the lowest inositol and glucose concentrations and the highest zinc 
concentration versus the other concentrations. Additionally, we studied changes 
in the concentrations of inositol, glucose and zinc during pregnancy. Using the 
different time points as reference it revealed that breakpoints occurred at 10 
weeks amenorrhea for inositol and glucose and at 20 weeks amenorrhea for 
zinc.  
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Figure 2. Serum glucose concentrations during pregnancy. Circles (bars) represent observed mean (SEM) and 
dotted line represent the estimated means; N=37. 
  
Table I. Estimated serum myo-inositol and glucose and red blood cell zinc concentrations in 37 women before, during and after pregnancy. 
Moment of blood sampling 
Weeks amenorrhea 
Myo-inositol 
(µmol/L) 
mean (SE) 
P0 PL Glucose 
(µmol/L) 
mean (SE) 
P0 PL Zinc 
(µmol/L) 
mean (SE) 
P0 PH 
Preconceptional 21.7 (1.03) . <0.01 3897 (103) . <0.01 217.8 (4.65) . 0.54 
6  22.2 (1.03) 0.68 <0.01 3946 (104) 0.64 <0.01 218.8 (4.95) 0.85 0.44 
10 16.9 (1.03) <0.01 . 3750 (104) 0.17 0.05 214.4 (4.82) 0.54 . 
20 17.1 (1.09) <0.01 0.90 3537 (108) <0.01 . 224.0 (4.99) 0.28 0.09 
30 17.9 (1.07) <0.01 0.43 3622 (107) 0.01 0.43 232.6 (5.33) 0.02 <0.01 
37 19.9 (1.10) 0.16 0.02 3538 (109) <0.01 0.99 246.2 (5.55) <0.01 <0.01 
6 after delivery 18.9 (1.11) 0.03 0.13 3667 (109) 0.04 0.24 241.7 (5.95) <0.01 <0.01 
PL/H: P-values for differences between the lowest concentrations (L) of inositol (10 weeks) and glucose (20 weeks)  
and the highest concentration (H) of zinc (10 weeks) versus the other time points.  
 
To investigate a possible association between preeclampsia and the biochemical 
parameters inositol, glucose and zinc, the study population was divided into a 
group of women who suffered from preeclampsia in the index-pregnancy and 
women with a normal pregnancy. No significant differences between these 
groups revealed from this analysis.  
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Figure 3. Red blood cell zinc concentrations during pregnancy. Circles (bars) represent observed mean (SEM) 
and dotted line represent the estimated means; N=37. 
 
Statistically significant Pearson correlation coefficients of 0.52 and 0.51, 
respectively, were observed between the serum inositol concentrations at 30 
and 37 weeks amenorrhea and birth weight, Table II.  
 
Table II. Pearson correlation coefficients for the associations between serum myo-inositol, glucose, red blood 
cell zinc concentrations and birth weight dependent on gestational age in weeks amenorrhea. 
 preconception 6 10  20  30 37 
Inositol 0.17 0.31 0.30 0.20 0.52* 0.51* 
Glucose -0.11 -0.20 0.01 -0.13 -0.26 -0.09 
Zinc 0.05 -0.15 -0.24 -0.09 0.05 -0.31 
*) P < 0.05 
 
 
 
Discussion 
 
This longitudinal study characterizes the inositol, glucose and zinc 
concentrations in women prior to conception, during pregnancy and around 6 
weeks after delivery. It clearly demonstrates that serum inositol and glucose 
concentrations decrease during the first trimester after which the 
concentrations gradually increase. Our data are comparable to our previous data 
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(10). Quirk et al. reported unchanged inositol concentrations of 21.4 µmol/L 
during pregnancy, ranging from 22.9 µmol/L in the first trimester to 17.9 µmol/L 
in the third trimester (17). The difference may be explained by the larger 
number of women included in our study, the methodology used to determine 
inositol and the statistical methods applied. They used the Newman-Keuls test 
that is similar to Tukey's pair-wise comparison but may be less suitable for 
describing repeated measurements as compared to the random intercepts model 
in our study. Moreover, they used cross-sectional data in a longitudinal manner 
bearing the risk of a distorted impression of the true pattern of the 
concentrations during pregnancy (18).  
The rising maternal inositol concentrations in the third trimester may be due to 
the increased need of inositol for surfactant synthesis necessary for fetal lung 
maturation during this period. Interestingly, Quirk et al. reported decreasing 
fetal serum inositol concentrations towards the end of gestation (17). They 
suggested that the diminishing inositol concentrations represents a decreasing 
availability of myo-inositol to the fetal lungs and could be important in the 
mechanism whereby the amounts of phosphatidylglycerol and phosphatidyl-
inositol in lung surfactant are regulated during fetal lung development (17). The 
importance of inositol for fetal lung maturation is strengthened by a review of 
Howlett et al. in which they conclude that inositol supplementation significantly 
reduces the occurrence of adverse neonatal outcomes such as respiratory 
distress syndrome which frequently occurs in preterm infants (19). 
Interestingly, the inositol concentrations at 30 and 37 weeks amenorrhea in our 
study were significantly associated with birth weight. This new finding may 
refer to the maturation of the fetus and therefore may be of clinical importance. 
Moreover, this finding is of interest with regard to the fetal origins of disease 
hypothesis (20). Inositol is known to support the growth of lower organisms and 
mammalian cells in culture (21,22). Therefore, the biological significance of this 
association needs further investigation.  
Like inositol, serum glucose concentrations decrease during gestation reaching 
the lowest level at the 20th week of gestation. This corresponds to the observed 
decrease in amniotic fluid concentrations of both compounds from 
approximately 15 weeks to 38 weeks amenorrhea (23,24). A good explanation 
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for the decreasing concentrations may be the plasma expansion that occurs 
early in gestation and has been described for other constituents of the blood as 
well (25). On the other hand glucose is the main energy source for the embryo 
and fetus during this period through which the maternal glucose concentrations 
may be affected. 
In contrast to the serum inositol and glucose concentrations, we determined 
zinc in red blood cells as zinc concentrations, a long-term parameter reflecting 
the tissue zinc status. The zinc concentrations increased during pregnancy after 
the 20th week of pregnancy, which is in agreement with the findings by Lao et al 
(26). An explanation could be the gradual hemo concentration from 20 weeks 
amenorrhea onwards. The zinc concentration is determined in a hemolysate of 
red blood cells through which the calculated zinc concentration per red blood 
cell may be increased. Previous studies investigating zinc concentrations during 
pregnancy determined zinc concentrations in plasma and established declining 
zinc concentrations in plasma during the course of pregnancy as well. They 
suggested that this decline was attributed to the plasma volume expansion 
(12,25). Although the study performed by Lao et al. suggested no correlation 
between red blood cell and plasma zinc concentrations, a zinc-shift from the 
plasma to the red blood cells may explain the decreasing plasma and increasing 
red blood cell zinc concentrations (27). We hypothesized that the use of multi-
vitamins may have contributed to the produce increased red blood cell zinc 
concentrations as well. This appeared however not very likely because the use 
of multivitamins did not significantly affect the red blood cell zinc 
concentrations. This is in agreement with our previous experiences and that of 
Wong et al. showing that zinc supplementation is not affecting plasma and red 
blood cell zinc concentrations (10,18). 
This study demonstrates that the concentrations of inositol, glucose and zinc 
significantly change during pregnancy. However, concentrations of inositol, 
glucose and zinc determined preconceptionally are comparable to those 
determined at 6 weeks amenorrhea and those at 24 months after the 
conceptional period determined in a previous study (10). These new data are 
important because they can be used as reference values for future research 
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focused on adverse pregnancy course and outcome originating in the first 
pregnancy trimester.  
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OBJECTIVE: Associations are reported between myo-inositol, glucose, zinc and the 
occurrence of spina bifida. To gain more insight into the pathogenesis of spina bifida, 
the concentrations of myo-inositol, glucose and zinc were determined in amniotic fluids 
from pregnancies with a spina bifida or an unaffected control fetus. 
STUDY DESIGN: Amniotic fluids of 27 pregnancies complicated by spina bifida and 49 
controls were collected at the Department of Obstetrics and Gynecology of the 
University Medical Center Nijmegen in The Netherlands. Myo-inositol, glucose and zinc 
concentrations were determined. By indication, the samples were taken at different 
gestational ages. Therefore, the data were evaluated using multiple linear regression 
analysis to adjust for gestational age. 
RESULTS: Amniocentesis was performed at a more advanced gestational age in the 
spina bifida group than in controls. In the spina bifida group, amniotic fluid myo-inositol, 
glucose and zinc concentrations gradually declined throughout pregnancy. At a 
gestational age of 15 weeks, the estimated mean amniotic fluid glucose and zinc 
concentrations in the spina bifida group were, respectively, significantly lower (p≤0.5) 
and higher (p≤0.5) compared with the control group. At the same gestational age, the 
estimated mean myo-inositol concentrations were comparable in both groups. At a 
gestational age of 38 weeks, the estimated mean myo-inositol, glucose and zinc 
concentrations were not significantly different in the spina bifida group compared with 
the control group. 
CONCLUSION: This study may suggest that a derangement in zinc and glucose transfer 
or metabolism is associated with spina bifida. Since compounds in amniotic fluid are 
only a very crude marker of the actual fetal condition, studies that focus on the 
metabolism of these compounds on tissue or even cellular level should be performed to 
clarify their role in the pathogenesis and future prevention of spina bifida.  
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Introduction 
 
Spina bifida is classified as a neural tube defect and has a multifactorial 
etiology. Evidence is increasing that folate is involved in the pathogenesis and 
prevention of neural tube defects (1). Recent data also suggest that independent 
of folate, a derangement in the metabolism of the carbohydrate myo-inositol 
could play a role in the causation of spina bifida (2). Myo-inositol is 
endogenously synthesized from glucose and can be taken from the diet (3). 
Several studies have shown that myo-inositol is crucial for normal embryonic 
and fetal development (4,5). Myo-inositol is a precursor for phosphatidyl-
inositol, which is an important compound of biomembranes and lung surfactant. 
In addition, it is a substrate for phospholipase C in the inositol-1,4,5-
triphosphate signaling pathway. During the 15th through 28th day of gestation 
in which the neural tube develops, glucose is the main energy source to drive 
embryonic metabolism. Data from human and animal studies show that diabetic 
females have a three- to five-fold higher risk for having an offspring with 
congenital malformation such as spina bifida (6,7). It has been postulated that 
the high glucose concentration in these patients interferes with the cellular 
uptake of myo-inositol resulting in a tissue specific myo-inositol shortage (8,9). 
Our hypothesis is that this lack of myo-inositol may result in a derangement of 
DNA transcription and in disturbances of migration and differentiation of neural 
crest cells, which are important processes in the formation of the neural tube. 
Furthermore, hyperglycemia is associated with changes in the membrane of the 
yolk sac (10). Impairment of the function of the visceral yolk sac cells during 
organogenesis may severely compromise embryonic nutrition and thus affect 
embryonic development and survival. 
Experimental animal and human studies reveals that maternal zinc deficiency is 
a risk factor for having offspring with spina bifida. Bergmann et al. and recently 
Srinivas et al. reported lower hair zinc concentrations in fetuses with a neural 
tube defect and their mothers compared to controls (11,12). Zinc is essential for 
cell proliferation and differentiation because of its role as a constituent of 
enzymes, hormones and neuropeptides (13). Interestingly, it has been shown in 
Streptozotocin-induced diabetic Sprague-Dawley rats that diabetes during 
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pregnancy amplifies the teratogenic effect of a maternal zinc deficiency (14). 
This may suggest that an interaction exists between zinc and diabetes-induced 
hyperglycemia. Leushner et al. showed a thickening of the trophoblastic basal 
membrane in diabetic patients, which may result in a reduced placental transfer 
of nutrients such as zinc to the developing fetus (15). The exact mechanism, 
however, remains to be elucidated. 
To gain more insight in the pathogenesis of spina bifida, the aim of this 
explorative study was to determine the myo-inositol, glucose and zinc 
concentrations in amniotic fluids of fetuses with spina bifida and controls.  
 
 
Subjects and Methods 
 
Patients and controls 
Between January 1991 and January 2000, amniotic fluid samples were obtained 
from 76 women aged 20-44 years who underwent amniocentesis at the 
outpatient clinic of the Department of Obstetrics and Gynecology of the 
University Medical Center Nijmegen in the Netherlands. Twenty-seven women 
carried a fetus with a spina bifida, i.e. memingo(myelo)cele, diagnosed after 
ultrasonography and determination of α-foetoprotein and postpartum confirmed 
by pregnancy outcome. The control group comprised a random sample of 49 
women who underwent amniocentesis indicated for high maternal age (≥  36 
years). The postpartum physical examination of the control neonates by the 
gynecologist as well as the examination after 6-8 weeks follow up revealed no 
major congenital malformations. Four amniotic fluids of spina bifida cases and 
two of controls were not derived from Caucasian women. 
 
Sample handling 
Amniotic fluid samples were obtained randomly either by routine 
transabdominal amniocentesis or by aspiration through membranes during 
cesarean section. The samples were centrifuged for 10 minutes at 1,550xg in a 
Hettich Rotanta/AP centrifuge and stored at -20°C until assayed.  
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Measurement of the inositols, glucose and zinc 
Serum myo-, epi- and scyllo-inositol and glucose concentrations were 
determined by trimethylsilylation and gas chromatography according to Jansen 
et al. (16). To 500 µL of amniotic fluid, 25 µL of 8 M PCA, 200 nmol of 
mannoheptulose and 200 nmol of trehalose were added as internal standards in 
an Eppendorf tube and placed on ice for 10 minutes. The samples were 
centrifuged for 5 minutes at 10,000xg in an Eppendorf centrifuge (model 5414). 
The supernatant was transferred into a new Eppendorf tube and 50 µL of 4 M 
K2HPO4 was added. After 10 minutes on ice, the samples were again 
centrifuged for 5 minutes at 10,000xg. The supernatant was transferred into a 
glass tube and frozen until dry overnight in a Lyovac GT II (Leybold-Heraeaus, 
Utrecht, The Netherlands). Five hundred µL of Tri-SIL® TBT, a powerful 
silylating agent from Pierce Omnilabo International (Breda, The Netherlands, 
No. 49016) were added to the residues and the mixtures were put in a heating 
block (Marius Instrumenten, Utrecht, The Netherlands) for 30 minutes at 100°C. 
One mL of aquadest and 1 mL of hexane were added, shaken for 5 minutes 
(Gyrotory Shaker Model G2, New Brunswick Scientific Co., Inc. Edison, New 
Jersey, USA) and centrifuged for 5 minutes at 1,000xg. The supernatant was 
transferred to a clean tube and 1 mL of 0.1 M HCl was added, again shaken for 
5 minutes and centrifuged at 1,000xg for 10 minutes. The supernatant was 
transferred to a new tube and 200 mg of Na2SO4 added. Samples were left at 
room temperature for 15 minutes and centrifuged at 1,000xg for 10 minutes. 
The supernatant was decanted into another tube and one drop 
bis(trimethylsilyl)trifluoracetamide was added, mixed and centrifuged at 
1,000xg for 5 minutes. The supernatant was then decanted into a clean tube and 
evaporated under a stream of nitrogen. Finally, the residue was dissolved in 
100 µL hexane and analyzed on a Hewlett Packard 5890 Series II. Inositol-
isomers, epi- and scyllo-inositol, were found to be below the detection limit. 
Zinc concentrations were determined by Atom Absorption Spectroscopy (AAS) 
as previously described (17).  
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Statistical analyses 
The Mann-Whitney U-test was used to estimate differences between 
gestational age and maternal age between the two groups. Results are 
presented as means with standard errors unless otherwise stated.  
In the spina bifida group, linear associations between the determinants in 
amniotic fluid and gestational age were assumed. Multiple linear regression 
analysis (analysis of covariance) was performed to test for differences in the 
myo-inositol, zinc and glucose concentrations in amniotic fluid between 
pregnancies complicated by spina bifida and controls. Thus, adequate tests with 
appropriate estimates can be obtained simultaneously at a gestational age of 15 
and 38 weeks. Multiple linear regression analysis was performed for each 
determinant separately with the determinant as the dependent variable. The 
group was the independent class variable with two levels (1 = spina bifida, 0 = 
control) and gestational time (weeks) was the independent regression variable. 
Although the interaction between gestational age and group was included in the 
model, it was not significant for either determinant. P-values equal to or less 
than 0.05 were considered significant. All analyses were performed using the 
SAS System for Windows version 6.12. 
 
 
Results 
 
Amniocentesis was performed at a significantly more advanced gestational age 
in the spina bifida group compared with the control group, respectively mean 28 
(weeks) ± 6.8 (S.D.) vs. 20 (weeks) ± 9.1 (S.D.), Mann-Whitney U-test: P<0.05. 
By indication women in the control group were older than those in the spina 
bifida group, respectively mean 37 (years) ± 3.5 (S.D.) vs. 28 (years) ± 4.5 
(S.D.), Mann-Whitney U-test: P<0.05.  
In the spina bifida group, the myo-inositol, glucose and zinc concentrations 
gradually decreased during pregnancy, respectively, r=-0.75, -0.55 and -0.45, 
P<0.05 (Figures 1-3).  
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Figure 1. Amniotic fluid myo-inositol concentrations (µmol/L) versus gestational age (weeks) in the spina bifida 
and control group. The (−) character represents the estimated mean myo-inositol concentration with standard 
error in the control group at a gestational age of 15 and 38 weeks, respectively. 
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Figure 2. Amniotic fluid glucose concentrations (µmol/L) versus gestational age (weeks) in the spina bifida and 
control group. The (−) character represents the estimated mean glucose concentration with standard error in 
the control group at a gestational age of 15 and 38 weeks, respectively. 
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Figure 3. Amniotic fluid zinc concentrations (µmol/L) versus gestational age (weeks) in the spina bifida and 
control group; nine missing values. The (−) character represents the estimated mean zinc concentration with 
standard error in the control group at a gestational age of 15 weeks. 
 
At a gestational age of 15 weeks, the estimated mean amniotic fluid 
concentrations of glucose and zinc were significantly different in the spina 
bifida group compared to controls (P≤0.5), whereas the estimated mean 
concentrations of myo-inositol were comparable (Table I). By contrast, at a 
gestational age of 38 weeks no significant differences were observed in the 
estimated means of myo-inositol, glucose and zinc between the spina bifida and 
control group. 
 
Table I. Amniotic fluid concentrations at 15 and 38 weeks of pregnancy 
 Gestational age: 15 weeks  Gestational age: 38 weeks 
 Spina bifida group Control group  Spina bifida group Control group 
Myo-inositol    121 ± 8.0  111 ± 4.0  49.2 ± 6.5   43.6 ± 7.3 
Glucose 2138 ± 229 2670 ± 88.1*  947 ± 186    1177 ± 161* 
Zinc   2.62 ± 0.29   1.47 ± 0.11*  0.96 ± 0.24 ND 
The data are given as estimated mean (µmol/L) and standard error based  
on multiple linear regression analysis with N=76 for myo-inositol and  
glucose and N=66 for zinc. ND: not determined. * P ≤ 0.05  
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Discussion 
 
This study is the first to determine myo-inositol concentrations in amniotic fluid 
of spina bifida fetuses. The data show that at a gestational age of 15 weeks, in 
contrast to the myo-inositol concentrations, the estimated mean concentrations 
of glucose and zinc in amniotic fluid of women carrying a fetus with spina bifida 
are significantly different compared with controls. Therefore, these findings 
partially support the hypothesis that the transfer or metabolisms of glucose and 
zinc are deranged in spina bifida fetuses and/or their mothers.  
Amniotic fluid myo-inositol concentrations in controls at a gestational age of 15 
weeks were 77% higher than previously reported, which is likely to be due to 
the use of different laboratory methods (18). It cannot be clarified whether the 
mean myo-inositol concentration determined in term amniotic fluids was only 
34% of that reported by Hallman et al (19).  
The mean glucose concentration in amniotic fluid of controls was comparable to 
that reported by Weiss et al. in 1,600 amniotic fluids of healthy controls at a 
similar gestational age (20). This is in contrast to the mean glucose 
concentration in the spina bifida group that was only 80% compared to the 
glucose concentration at a gestational age of 29 weeks (20). The significantly 
lower amniotic fluid glucose concentration at a gestational age of 15 weeks 
seems to support the hypothesis that the absence of hypothalamic hormones in 
anencephalic fetuses results in a loss of glucose homeostasis and dysfunction of 
placental transport (21). This has been suggested by other authors, who 
demonstrated a respectively 50% lower concentration of glucose in amniotic 
fluids of fetuses with anencephaly and 57% lower concentration in amniotic 
fluids of fetuses with neural tube defects at a mean gestational age of 28.7 
weeks (21,20).  
At a gestational age of 15 weeks, the estimated mean amniotic fluid zinc 
concentration in the spina bifida group was significantly higher than in controls. 
The estimated zinc concentrations were comparable to previously reported 
values (17,22,23). Although the amniotic fluid zinc concentrations in spina bifida 
fetuses decreased with advancing gestational age, we were not able to verify 
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whether this was applicable for controls as well. In literature, zinc 
concentrations do not seem to change throughout normal pregnancy (17,22). 
Therefore, we carefully suggest that the two-fold higher zinc concentration in 
the spina bifida group may be due to a derangement in zinc transfer, metabolism 
or by the increased use of zinc for protein synthesis and cell multiplication by 
the developing fetus. 
This study shows significantly lower and higher amniotic fluid concentrations of 
glucose and zinc, respectively, at a gestational age of 15 weeks in pregnancies 
with a spina bifida fetus compared with controls. Whether these different levels 
between the groups are a primary cause or a secondary consequence of spina 
bifida remains to be answered. Since compounds in amniotic fluid are only a 
very crude marker for the actual fetal condition, studies that focus on the 
transfer and metabolism of myo-inositol, glucose and zinc on tissue or even 
cellular level should be performed to clarify their role in the pathogenesis of 
spina bifida.  
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OBJECTIVE: To quantify proton containing metabolites by in vitro 1H-NMR 
spectroscopy of amniotic fluids from fetuses with spina bifida and controls.  
STUDY DESIGN: Fourteen amniotic fluids from spina bifida fetuses and eighteen 
controls were obtained. Concentrations of carbohydrates, organic acids and amino acids 
were determined. Multiple linear regression analysis was used to evaluate the data. 
RESULTS: At 15 and 39 weeks amenorrhea the estimated median amniotic fluid 
concentrations of succinic acid and glutamine were significantly higher in the spina 
bifida group compared to controls, 37% and 64%, respectively. Whereas creatine and 
creatinine were significantly lower, 27% and 36%, respectively. Amenorrhea influenced 
the concentrations of most compounds with the exception of lactic acid.  
CONCLUSION: 1H-NMR spectroscopy shows significantly higher succinic acid and 
glutamine concentrations in amniotic fluids derived from spina bifida fetuses compared 
with controls. A derangement in amino acid metabolism is suggested.  
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Introduction 
 
First reports on the application of 1H-NMR spectroscopy to human body fluids 
appeared in the early 1980s. The feasibility of determining many small proton-
containing metabolites simultaneously renders 1H-NMR spectroscopy a 
powerful tool and has proven itself in the elucidation of metabolic disorders 
under which dimethylglycine dehydrogenase deficiency (1). Numerous body 
fluids, amniotic fluid included, have already been analyzed (2). However, data 
on amniotic fluids derived from spina bifida fetuses and normal fetuses is still 
limited (3). 
Spina bifida, classified as a neural-tube defect, is prenatally diagnosed by 
ultrasonography and amniocentesis for the determination of alpha-foetoprotein 
and choline-esterase in amniotic fluid. Amniocentesis is an invasive technique 
and still carries a risk, albeit small. In vivo 1H-NMR spectroscopy is a non-
invasive technique and may be useful in future prenatal screening of congenital 
birth defects such as spina bifida. 
Evidence of the involvement of the carbohydrate metabolism in the patho-
genesis of spina bifida originates from studies that report increased risks for 
spina bifida offspring in maternal diabetes mellitus (4). Although the underlying 
mechanism is largely unknown, the maternal glucose concentration is suggested 
to be the teratogenic agent. The glycosylation of hemoglobin (HbA1c) is used 
as a sensitive predictor of pregnancy outcome in maternal diabetes. In 1997, 
Greene and Copp showed that the administration of the carbohydrate myo-
inositol reduced the birth prevalence of neural tube defects in the folate-
resistant curly tail mouse (5). It has been postulated that the high glucose 
concentration in diabetic patients interferes with the cellular uptake of myo-
inositol resulting in a tissue specific myo-inositol shortage (4). Myo-inositol is 
involved in the inositol-tri-phosphate protein kinase C signaling pathway and 
DNA transcription processes. Our hypothesis therefore is that a myo-inositol 
shortage of the embryonic neural tissues results in disturbances of the 
migration and differentiation of neural crest cells, through which the closure of 
the neural tube may be deranged leading to spina bifida. 
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Amino acids play an important role as precursor for hormones, biological 
pigments and can act as neurotransmitters. During fetal development the 
availability of amino acids is of great importance to ensure cellular and tissue 
growth. In a previous study, the methionine derivative homocysteine was 
present in a significantly higher concentration in amniotic fluid from fetuses 
with a neural tube defect compared to controls (6). This finding indicates that 
neural tube defects could partially be explained by a maternal or fetal 
derangement in the metabolism of homocysteine. Of interest is that in the early 
eighties Weston postulated that the embryonic melanocyte population along the 
neural crest influences the closure of the neural tube (7). Since melanin 
production is tyrosine dependent, a deranged tyrosine metabolism may interfere 
with the normal function of the embryonic melanocytes, resulting in abnormal 
closure of the neural tube (7). 
In this study, we used 1H-NMR spectroscopy to determine the carbohydrate, 
organic acid and amino acid composition of amniotic fluids derived from spina 
bifida fetuses and controls. The results may give more insight in the 
pathogenesis of spina bifida. 
 
 
Subjects and Methods 
 
Patients and controls 
Amniotic fluid samples were collected from thirty-two women who underwent 
amniocentesis at the outpatient clinic of the department of Obstetrics and 
Gynecology of the University Medical Center Nijmegen in the Netherlands 
between January 1991 to January 2000. Fourteen women carried a fetus with 
spina bifida. Spina bifida was diagnosed after ultrasonography and determination 
of α-foetoprotein and later confirmed by pregnancy outcome. The control group 
consisted of eighteen women. For advanced maternal age (≥ 36 years) 
amniocentesis was conducted in twelve women. Amniotic fluids of six women 
were collected at the moment of Cesarean section. Amniotic fluid samples were 
obtained by collecting material after routine transabdominal amniocentesis or by 
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informed consent before the Cesarean section was carried out. All data were 
anonymized before analyses.  
 
Sample handling  
The amniotic fluid samples were centrifuged for ten minutes at 3,000xg in a 
Hettich Rotanta/AP centrifuge and stored at -20°C until assayed. Samples 
contaminated with blood were excluded for analysis.  
 
1H NMR determination 
Samples were prepared as previously described (8). For deproteinization 2 mL 
of the sample was centrifuged over a 10 kDa filter for ½ hours at 3,000xg 
(Centrisart no. 13239, membrane type omega, molecular mass cut-off 10 kDa; 
Sartorius AG, Goettingen, Germany). To avoid contamination with glycerol, the 
filters were washed twice with 2.5 mL of distilled water before use. 
Subsequently, to 700 µL of the ultrafiltrate 20 µL of a mixture of 8.7 mg 
trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP) dissolved in 2.5 mL D2O 
was added. The pH was then carefully adjusted to 2.5 ± 0.10 with concentrated 
HCl and diluted NaOH. Finally, 700 µL of the prepared sample was transferred 
in a diameter of 5 mm NMR tube and single pulse 1H-NMR spectra (500 MHz) 
were obtained on a Bruker AMX-500 (Bruker Analytische Messtechnik, 
Karlsruhe, Germany) spectrometer at 298K. A 60° radio frequency pulse (6 µs) 
and a 10 s relaxation delay were used (repetition time 12.3 s). For each 
spectrum, 128 scans were recorded and 32K data points were sampled. The 
sweep width was 6667 Hz. The residual H2O resonance was presaturated during 
the relaxation delay. The NMR spectra were evaluated using the one-
dimensional WINNMR software (version 960901) by Bruker Analytische 
Messtechnik. The free induction decays (FIDs) were zero filled to 65K data 
points, which provided sufficient data points for each resonance. The acquired 
spectra were Fourier transformed and the chemical shift calibrated with respect 
to the chemical shift position of the TSP resonance. Phase and baseline were 
corrected manually and resonances were assigned using a database of pure 
compound spectra obtained at pH 2.5 and based on previous published data 
(9,10). The concentrations of metabolites were calculated by comparing the fit 
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integral of the metabolite to the fit integral of TSP, corrected for the number of 
protons corresponding to the resonances, Table 1. Glucose quantification was 
based on the 5.22 ppm doublet resonance caused by the αC1 proton. The 
glucose equilibrium of α and β forms is pH-dependent and based on earlier 
experience the ratio of 39:61 was used (11).  
 
Statistical analyses 
Multiple linear regression analysis was used to test for differences in the 
determinants in amniotic fluid between the pregnancies complicated by spina 
bifida and normal pregnancies. The descriptive statistics of the concentrations 
of the compounds from amniotic fluid indicated that the variance is dependent 
on amenorrhea. Therefore, the data were logarithmic transformed prior to the 
analysis in order to obtain homoscedasticity. Consequently, multiple linear 
regression analysis was performed for each determinant separately with the 
logarithmic transformed concentration of the determinant as the dependent 
variable. The independent class variable was group with two levels (1 = spina 
bifida and 0 = control) and gestational time (weeks) was the independent 
regression variable. At the first stage of the analysis the interaction between 
gestational age and group was included in the model. However, this term was 
never significant for either determinant even at a level of 0.10 and was 
therefore removed from the final model. Consequently, the ultimate model used 
was: 
Ln(concentration) = α + β1*(group) + β2*(amenorrhea) 
 
where α is the mean Ln(concentration) in the control group at an amenorrhea of 
15 weeks (i.e., intercept), β1 is the mean increase/decrease in Ln(concentration) 
in the spina bifida group compared to the control group (i.e., regression 
coefficient of group) and β2 is the mean increase/decrease in Ln(concentration) 
per week increase in amenorrhea (i.e., regression coefficient of amenorrhea). 
Thus, adequate tests can be performed simultaneously while obtaining 
appropriate estimates. The estimated medians with 95% confidence intervals 
(CI) are presented after back-transformation of the estimated means (with the 
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95% CI) from the linear regression analysis. The SAS System for Windows 
Version 6.12 was used to fit the regression models. 
 
 
Results 
 
Because of a technical problem with the automatic shimming procedure and 
sample volume limitations, four spectra (three spina bifida and one control) 
could not be properly quantified and were therefore excluded from further 
analysis. In Figure 1 a 500 MHz 1H-NMR spectrum of a representative control 
amniotic fluid is shown.  
 
Figure 1. 1H-NMR spectrum of an amniotic fluid sample from a control fetus, with full spectrum view (1A) and 
enhanced view of the 0.8-2.0 ppm region (1B). 
 
By indication control women were older than those of the spina bifida group at 
the moment of amniocentesis (mean ± SD: 35.6 ± 3.8 years and 29.6 ± 5.1 
years, respectively, Mann-Whitney U-test, p≤0.01). Amniocentesis was 
performed at a higher amenorrhea in the spina bifida group than in controls 
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(mean ± SD: 28.8 ± 7.0 weeks and 24.7 ± 12.2 weeks, respectively, Mann-
Whitney U-test, p≤0.05). 
Table 1. 1H-NMR spectroscopy chemical shifts from amniotic fluid samples (n=28) (H2O; 500 
MHz; pH 2.50).  
Metabolite N (%) Chemical shift and multiplicity [proton(s)] Body fluid (3,8,11,12) 
TSP (IS)   0.00 [Si-(CH3)3]  
2-Hydroxy isovaleric acid 6 21 0.89 d[CH3]; 0.98 d[CH3]; 2.06 m[CH3];  
4.13 d[CH] 
C,P,O 
Isoleucine 28 100 0.94 t[CH3]; 1.02 d[CH3]; 1.28 m[CH2];  
2.00 m[CH]; 3.80 d[CH] 
C,P,O,A 
Leucine 28 100 0.95 t[CH3]; 0.97 d[CH3] C,P,O,A 
Valine 28 100 1.00 d[CH3]; 1.04 d[CH3]; 2.29 m[CH];  
3.72 d[CH] 
C,P,O,A 
2-Oxo 
isovaleric acid 
27 96 1.13 d[(CH3)2]; 3.02 m[CH] C,P,O 
3-Hydroxy butyric acid 27 96 1.23 d[CH3]; 2.53 AB [CH3]; 4.23 m[CH] C,P,O 
Threonine 28 100 1.33 d[CH3]; 3.70 d[CH]; 4.29 m[CH] C,P,O,H 
Lactic acid 28 100 1.41 d[CH3]; 4.36 q[CH] C,P,O,A 
Alanine 28 100 1.51 d[CH3]; 3.87 d[CH3] C,P,O,A 
Lysine 28 100 1.47 m[CH2]; 1.72 m[CH2]; 1.92 m[CH2];  
3.01 t[CH2]; 3.77 t[CH] 
C,P,O 
Acetic acid 27 96 2.08 s[CH3] O,A 
Methionine 17 63 2.13 s[CH3]; 2.18 m[CH2]; 2.67 t[CH3];  
3.99 t[CH] 
C,P,O 
Glutamine 28 100 2.16 m[CH2]; 2.47 m[CH2]; 3.91 t[CH] C,P,O,A 
Pyruvic acid 28 100 2.37 s[CH3] C,P,O 
Succinic acid 28 100 2.67 s[CH2-CH2] C,P,O,A 
Citric acid 28 100 2.91 AB [CH2-C-CH2] C,P,O,A 
N,N-Dimethylglycine  14 50 2.93 s[N-(CH3)2]; 3.80 s[CH2] P,O 
Creatine 28 100 3.05 s[N-CH3]; 4.06 s[N-CH2] C,P,O 
Creatinine 28 100 3.13 s[N-CH3]; 4.29 s[N-CH2] C,P,O,A 
 Choline 27 96 3.19 s[N-(CH3)3]; 3.50 m[N-CH2];  
4.05 m[CH2-OH] 
C,P,O 
Carnitine  27 96 3.23 s C,P,O 
Betaine 28 100 3.27 s[N-(CH3)3]; 3.94 s[CH2] C,P,O 
Myo-inositol 17 61 3.26 t[CH:C-5]; 3.52 dd[CH:C-1/CH:C-3];  
3.61 t[CH:C-4/CH:C-6]; 4.05 t[CH:C-2] 
C,O 
Glucose 28 100 3.23 dd[CH:βC2]; 3.3-3.9(various);  
4.64 d[CH:βC1]; 5.22 d[CH:αC1] 
C,P,O,A 
Tyrosine 28 100 3.15 m[CH2]; 4.07 m[CH];  
6.89 d[aromatic protons];  
7.19 d[aromatic protons] 
C,P,O 
Phenylalanine 27 96 3.15 m[CH2]; 3.29 m[CH2]; 4.13 m[CH];  
7.30-7.44 m[aromatic protons] 
C,P,O 
Formic acid 21 75 8.25 s C,P,O 
Histidine 28 100 3.35 m[CH2]; 4.09 t[CH2]; 8.68 d[ring proton];  
7.41 s[ring proton] 
C,P,O 
N = number of amniotic fluid samples out of 28 in which the metabolite was detected; 
% = frequency of amniotic fluids in which the metabolite was detected;  
(IS) Internal standard; s= singlet; d= doublet; dd= double doublet; t= triplet; q= quartet; m= 
multiplet; AB = AB-system; C/P/O/A = detected in cerebrospinal fluid (C), plasma (P), ovarian 
cyst fluid (O) and human amniotic fluid (A) samples.  
Table I lists twenty-eight compounds detected by spectroscopy. The underlined 
compounds have been quantified at the underlined chemical shift and the 
concentrations were compared between the spina bifida and control group. 
Amenorrhea affected both log-transformed and raw data. Because of unknown 
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amenorrhea one additional amniotic fluid sample in the spina bifida group was 
omitted from the regression analyses. The backward-transformed data are 
presented in Table II. Figures 2-4 show the glucose, glutamine and succinic 
acid concentrations.  
 
Table II. Estimated median (95% confidence interval) of carbohydrate, organic acid and amino acid concentrations 
by amenorrhea and pregnancy outcome.  
 Amenorrhea 
15 weeks 
Amenorrhea 
39 weeks 
P 
Group       Trend 
R2 
 Spina bifida Control  Spina bifida  Control     
Carbohydrates        
Glucosea 3.3 
(2.4 – 4.6) 
3.6 
(2.8 – 4.6) 
1.0 
(0.7 – 1.4) 
1.1 
(0.8 – 1.5) 
NS ≤.05 0.64 
Myo-inositol 370 
(270 – 508) 
396 
(299 – 523) 
128 
(93.4 – 177) 
137 
(107 – 177) 
NS ≤.05 0.70 
Organic acids        
Lactic acida 19.0 
(13.3 – 27.2) 
16.0 
(12.2 – 20.9) 
15.5 
(11.1 – 21.6) 
13.0 
(9.3 – 18.1) 
NS NS 0.06 
Succinic acid 25.0 
(16.9 – 37.0) 
15.3 
(11.4 – 20.6) 
60.0 
(41.6 – 86.5) 
36.6 
(25.4 – 52.8) 
≤.05 ≤.05 0.52 
Citric acid 697 
(499 – 973) 
630 
(490 – 811) 
467 
(342 – 637) 
422 
(309 – 576) 
NS ≤.10 0.16 
Amino acids        
Isoleucine 61.6 
(44.1 – 85.8) 
70.2  
(54.6 – 90.3) 
9.1 
(6.7 – 12.4) 
10.4 
(7.6 – 14.2) 
NS ≤.05 0.82 
Valine 284 
(230 – 352) 
324 
(275 – 380) 
43.5 
(35.6 – 53.0) 
49.5 
(40.5 – 60.4) 
NS ≤.05 0.91 
Threonine 242 
(105 – 560) 
342 
(181 – 644) 
70.5 
(32.3 – 154) 
99.4 
(45.5 – 217) 
NS ≤.05 0.26 
Alanine 684 
(584 – 801) 
644 
(571 – 725) 
169 
(146 – 196) 
159 
(137 – 184) 
NS ≤.05 0.91 
Lysine 561 
(432 – 727) 
596 
(490 – 726) 
172 
(135 – 219) 
183 
(144 – 233) 
NS ≤.05 0.74 
Glutamine 644 
(494 – 839) 
469 
(384 – 574) 
351 
(274 – 449) 
256 
(200 – 327) 
≤.05 ≤.05 0.45 
Tyrosine 113 
(92.7 – 139) 
111 
(95.1 – 129) 
34.9 
(28.9 – 42.1) 
34.1 
(28.3 – 41.1) 
NS ≤.05 0.82 
Histidine 178 
(144 – 219) 
178 
(152 – 209) 
69.8 
(57.3 – 84.9) 
70.0 
(57.5 – 85.2) 
NS ≤.05 0.72 
Others        
Betaine 60.9 
(49.1 – 75.6) 
66.0 
(56.1 – 77.7) 
108 
(88.2 – 132) 
117 
(95.6 – 143) 
NS ≤.05 0.47 
Creatine 73.2 
(54.3 – 98.7) 
99.8 
(79.6 – 125.2) 
38.3 
(29.0 – 50.6) 
52.2 
(39.5 – 69.0) 
≤.10 ≤.05 0.48 
Creatinine 66.6 
(46.5 – 95.4) 
106 
(81.1 – 140) 
200 
(143 – 279) 
319 
(228 – 446) 
≤.05 ≤.05 0.57 
Concentrations given in µmol/L or ammol/L ; P-value of statistical significant differences between pregnancies 
with spina bifida (N=10) and healthy control (N=17) fetuses (group) and for decrease/increase by amenorrhea 
(trend), linear regression analysis; R2: R-square of the multiple linear regression model, representing the 
percentage explained variance.  
  181
The estimated median amniotic fluid concentrations of succinic acid and 
glutamine were significantly higher in the spina bifida group compared with the 
control group, respectively 37% and 64%. The estimated median amniotic fluid 
concentrations of creatine and creatinine were significantly lower in the spina 
bifida group than in controls, respectively 27% and 36%. All compounds were 
significantly associated with amenorrhea, except for lactic acid. 
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Figure 2. The individual glucose concentrations by amenorrhea and regression line for the spina bifida (N=10) 
and control group (N=17). : spina bifida; : control;  estimated median; z  observed median 
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Figure 3. The glutamine concentration by amenorrhea and regression line for the spina bifida group (N=10) and 
control group (N=17). : spina bifida; : control;  estimated median; z observed median 
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Figure 4. The succinic acid concentration by amenorrhea and regression line for the spina bifida group (N=10) 
and control group (N=17). : spina bifida; : control;  estimated median; z observed median 
 
The goodness-of-fit (R2) for all models ranged from acceptable to good (0.45 
– 0.91) with the exception of poor fit for lactic acid, citric acid and threonine, 
0.06, 0.16 and 0.26, respectively. 
 
 
Discussion 
 
This study is the first to show quantitative 1H-NMR data of metabolites in 
amniotic fluid samples of fetuses with spina bifida and controls. Previous work 
only included qualitative data, i.e. peak height ratio's between the metabolite of 
interest and citrate only indicate how these metabolites are present in amniotic 
fluid relative to citrate (3). In this study, however, we quantified the observed 
metabolites by calculating the area under the curve (AUC) of each metabolite of 
interest and comparing this to the AUC of a known standard (TSP). This 
ensures that actual concentrations can be estimated which may be of usage in 
clinical diagnostics. 
The estimated median glucose and myo-inositol concentrations in amniotic fluid 
were not significantly different between the groups. This is in contrast to the 
study by Weiss et al. who reported that at 29 weeks, amenorrhea amniotic fluid 
glucose concentrations in spina bifida affected fetuses were 56% lower 
compared to controls (13). 
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The estimated median amniotic fluid succinic acid and glutamine concentrations 
were significantly higher in the spina bifida group compared to controls. The 
higher concentration of succinic acid may hint towards a disturbance in the 
citric acid cycle or in the oxidative phosphorylation. Glutamine resonates as two 
multiplets in the proton NMR spectrum. Its triplet resonance cannot be observed 
as it co-resonates with glucose. Glutamine quantification in this study was 
accomplished via the multiplet resonances. It may well be that CH2-groups from 
other compounds interfere with proper quantification. The finding of 
significantly elevated glutamine in spina bifida samples requires confirmation 
with an independent technique in future studies, e.g. amino acid analysis using 
ion-exchanging chromatography. This data support the hypothesis that a 
derangement in amino acid metabolism could be involved in the pathogenesis of 
spina bifida.  
Both succinic acid and glutamine are present in cerebrospinal fluid. A remote 
hypothesis is that a different pattern of metabolites present in amniotic fluid 
may arise from leakage of cerebrospinal fluid through the skin defect present in 
spina bifida into the amniotic fluid. In adults, the cerebrospinal fluid 
concentration of succinic acid is less than 5 µmol/L and is barely detectable by 
1H-NMR (8). By contrast, depending on amenorrhea the amniotic fluid 
concentration is 3 to 5 fold higher and 7 to 30 fold higher at 15 and 39 weeks, 
respectively. Glutamine gives a well-defined 1H-NMR resonance and is present 
in concentrations ranging from 480 to 640 µmol/L in adult cerebrospinal fluid 
(14). This is comparable to the amniotic fluid concentrations at 15 weeks. 
However, at 38 weeks amniotic fluid contains only half the concentration of 
cerebrospinal fluid. The question whether cerebrospinal fluid in adults is 
comparable to fetal cerebrospinal fluid remains. It seems unlikely though that 
the significantly higher succinate can be explained by leakage from the 
cerebrospinal fluid into the amniotic fluid through the local skin defect. 
Glutamine is intracellularly used in the biosynthesis of proteins, peptides and 
aminosugars, purines and pyrimidines and the production of γ-glutamylcysteine 
(15). In adults, glutamine is metabolized by the kidney into glutamate and 
ammonia (NH3/NH4+) where ammonia is excreted in the urine and glutamate 
used intracellularly or excreted into the blood. An explanation could be that the 
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fetal kidney is immature at that stage and is therefore not able to metabolize 
glutamine. This is supported by the observation that the glutamine 
concentration in amniotic fluid decreases with advancing gestational age. We 
hypothesize that the renal function in fetus with spina bifida is even more 
impaired resulting in higher amniotic fluid glutamine concentrations. This is 
strengthened by the observation that young children with spina bifida have 
lower urinary concentrations of creatine and creatinine as compared to controls 
(16,17). Another explanation for these lower concentrations could be a 
diminished muscle mass as a result of the paralysis induced by the spina bifida 
or due to impaired glomerular filtration, a condition often seen in children 
suffering from spina bifida (16). Since amniotic fluid is mainly fetal urine, it is 
conceivable that impaired glomerular filtration is already present in the 
antenatal period and reflected by altered concentrations in the amniotic fluids of 
these fetuses. 
While case-mothers were significantly older compared with controls, it seems 
very unlikely that this has affected the results. Firstly, as discussed in the 
above, amniotic fluid mainly is a fetal product. Although poor maternal 
nutritional status may be reflected by altered metabolite concentrations in the 
amniotic fluid, this does not seem very likely in the Dutch population. Secondly, 
the mean age difference was approximately 6 years. Therefore, differences in 
life-style that may alter amniotic fluid metabolite concentrations appear highly 
improbable. Additional regression analysis with maternal age added as a co-
variable, did not show maternal age as a significant co-variable. 
Although the number of amniotic fluid samples investigated is small, multiple 
regression analysis seems a suitable technique to tackle hypotheses regarding 
concentrations of compounds in amniotic fluid given the R2-values ranging from 
acceptable to good. In most cases the models explained more than 50% of the 
total variance indicating that both amenorrhea and group membership explained 
most of the variance. Furthermore, the models emphasize to always consider 
amenorrhea in these studies. 
In conclusion, our results give some evidence that would justify extending this 
study in order to gain more insight in the pathogenesis of spina bifida. 
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C H A P T E R   12 
General discussion and Future perspective 
 
 
The main focus of this thesis was to investigate the role of myo-inositol and 
zinc in the etiology of nonsyndromic spina bifida by studying blood and amniotic 
fluid concentrations and some related genetic factors in children with spina 
bifida and their parents. We also considered preconceptional health and lifestyle 
determined by maternal nutrient and folic acid intakes, maternal B-vitamin 
status and parental illnesses, medication, smoking and alcohol use in association 
with spina bifida risk. It revealed that myo-inositol and folate concentrations 
were indeed lower in children with spina bifida between 1 and 3 years of age 
compared to the controls. Adjustment for age attenuated these differences. The 
myo-inositol finding is supported by our previous results in which myo-inositol 
levels in brain tissue of fetuses with spina bifida and hydrocephalus were also 
significantly lower than in controls (1). Mothers with spina bifida offspring 
demonstrated significantly lower myo-inositol, zinc and vitamin B12 
concentrations and higher glucose concentrations. The identification of these 
risk factors is in line with the determination of a lower concentration of glucose 
and a higher concentration of zinc in amniotic fluid of pregnancies complicated 
by spina bifida than in controls. Of particular interest is that the preconceptional 
nutritional intake of Dutch women in reproductive age seems to be 
compromised in food groups containing iron and folate. Low preconceptional 
nutrient intakes as plant proteins, iron, magnesium and niacin were associated 
with a two- to fivefold increased risk of spina bifida offspring. The fact that we 
also identified maternal and paternal health related and lifestyle factors such as 
maternal illnesses, the use of medication, a health promoting diet and the 
planning of pregnancy, support the importance of research in this field and the 
consecutively implementation of the findings in preconceptional care to 
contribute to the primary prevention of spina bifida in the future. However, 
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before we make inferences of our findings for future research and 
preconceptional health care, some methodological issues will be discussed. 
 
 
Methodological issues 
 
Comparability of information 
The study moment of approximately 24 months after the preconceptional period 
of the index-pregnancy in the case-control triad study was based on our 
assumption that the preconceptional status of the mother is comparable to that 
of 2 years later, with regard to the biochemical and hormonal status, and 
nutritional intake. This assumption is substantiated by the data derived from our 
longitudinal study in which we determined maternal myo-inositol, glucose and 
zinc concentrations before and during pregnancy (chapter 9). Recently, in the 
Netherlands De Weerd et al. (2) showed in a similar longitudinal study that the 
determined preconceptional vitamin concentrations are comparable during 
pregnancy to those described by us in chapter 5. Finally, Leck et al. also 
demonstrated that folate status determined by red blood cell folate in early 
pregnancy is well correlated with that of one year after pregnancy (3). The 
comparison of the periconceptional biochemical myo-inositol data (chapter 9) 
with those obtained 24 months after the preconceptional period and in healthy 
non-pregnant women are herewith in line also (chapters 2 and 8). With regard 
to nutrient intake we assumed that every individual has a rather constant 
'habitual' food intake, which only temporarily varies due to episodes of dieting, 
illnesses, pregnancy and breastfeeding. When these effect modifiers are taken 
into account, we assume that the preconceptional nutrient intake data covering 
the month before the study moment are comparable to those 24 months later. 
Devine et al. (2000) demonstrated that dietary habits even at the beginning of 
pregnancy are comparable to those one-year after pregnancy (4). The issue of 
recall bias due to the retrospective design of our case-control studies has to be 
considered as well. Parents who experienced a pregnancy with an adverse 
outcome may have a better recall of harmful periconceptional health and 
lifestyle factors than control parents. The studies presented in chapters 2 
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through 7 all share the case-control design. Especially the study described in 
chapter 7 would be the most susceptible to recall bias. Although recall bias 
cannot be excluded, literature suggests that in case-control this kind of bias is 
not a major concern (5). Moreover, biochemical parameters determined 24 
months after the referred periconceptional period will not be affected by recall 
bias. The nutrient intake data obtained referred to the intake of the precluding 
year to the date of interview, which makes recall bias as a strong confounding 
factor not very likely (chapter 5).  
The myo-inositol and glucose concentrations were slightly lower compared to 
that of others who used the same techniques, i.e. trimethylsilylation of 
carbohydrates followed by gaschromatography (6,7). Deproteinization of the  
sample may have resulted in losses of myo-inositol and glucose leading to 
lower concentrations. It seems however unlikely that these losses occurred 
differentially. Fasting blood samples were drawn to improve the homogeneity of 
the samples. The samples of cases and controls were randomly distributed over 
the batches to prevent differential changes in concentrations. By taking these 
measures, we believe that the internal validity of this data is very high through 
which valid conclusions can be drawn from the comparison of the data between 
the case and control group.  
Both zinc and folate were determined in red blood cells to estimate the long-
term status of these nutrients, thus reflecting the tissue status (8,9). Both 
nutrients are incorporated in red blood cells during erythropoiesis and therefore  
are more stable determinants than plasma or serum concentrations, that are 
used to reflect the situation around the moment of blood sampling (8,10). The 
turnover of red blood cells is 120 days and the red blood cell zinc and folate 
concentrations thus cover the period of 2 to 4 months before sampling. We did 
not choose for zinc in toenails or hair suggested in literature to reflect the zinc 
status over months, because the methodology remains controversial.  
The determinations of folate, total homocysteine, pyridoxal-5'-phosphate 
(vitamin B6) and cobalamin (vitamin B12) were performed using standard 
techniques. The control data were comparable to those determined in our 
previous studies (11-14) and comparable to that of others (14,15). 
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Accuracy and power 
Before the start of this study, a power calculation was performed. We 
calculated that nutritional and biochemical information of 80 case and 80 control 
triads (child, mother, father) would be needed to obtain reliable answers to the 
research questions. For genetic analyses we calculated that the sample sizes 
needed to be doubled. This was based on the neural tube defect studies in 
which a 8% difference of the MTHFR 677TT genotype and an approximately 
20% difference in frequency of maternal hyperhomocysteinemia was 
determined. We recruited 132 nonsyndromic spina bifida and 236 control triads, 
from whom in 76 spina bifida and 111 control mothers and their infants the 
biochemical status was determined. Therefore there was sufficient power to 
detect relevant biochemical effects. So far, we were not yet in the opportunity 
to investigate gene-environment interactions in the case-control studies. 
However, it is very likely that the power to detect relevant polymorphisms with 
a low frequency is too limited as illustrated in the case-triad-only designs 
described in the chapters 3 and 4.  
 
Comparability of populations 
The medical ethical committees of the hospitals of several participating spina 
bifida teams did not give their permission for recruiting the control group via 
the case parents. Therefore, approximately 50% of the controls were enrolled 
via posters and leaflets at public nurseries and health care centers in Nijmegen 
and surroundings. The educational level of this latter group appeared to be 
higher compared to the case group, while the educational level of the controls 
recruited by the case-parents was similar to that of the cases. Because 
education is related to health and lifestyle factors such as illnesses, medication, 
the use of alcohol and tobacco, and nutrition, and is associated with spina bifida 
risk, we accounted for the probability of confounding by differences in 
educational level. For this reason we adjusted the associations between spina 
bifida risk and the biochemical and nutrient intake data for education (chapters 
2, 5 and 6). Fortunately, the difference in education did not distort the 
associations but was considered to be an independent risk factor for spina 
bifida (chapter 7).  
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Ascertainment of nonsyndromic spina bifida 
In the general population spina bifida 'occulta' has a reported prevalence of up 
to 23% (17-19). Although it is debated whether this type of spina bifida shares 
the same etiology with spina bifida 'aperta', it is assumed that it is a common 
anomaly without clinical symptoms in early life (17). Misclassification may have 
occurred in the control group resulting in an underestimation of the risk 
estimates. If spina bifida occulta however has a different etiology than spina 
bifida aperta the effect on the risk estimates depends on the determinant and 
may result in bias towards the null but also away from the null. To overcome 
this problem X-rays of the vertebral arcs should be performed in particularly in  
controls. 
 
 
Inferences of the main results 
 
Most evidence is available on folic acid supplementation to prevent spina bifida 
(20,21). As a result from 1993 onwards, the Dutch Health Council recommends 
women who are planning pregnancy to take a folic acid supplement at least one 
month prior to conception through at least two months after conception. Given 
the fact that spina bifida is a complex disease it is not surprising that an 
adequate maternal folate status does not provide a 100% protection against 
spina bifida offspring. The observation that maternal diabetes increases the risk 
of spina bifida offspring raised the awareness for the involvement of a deranged 
carbohydrate metabolism in the pathogenesis of spina bifida (22-25). To date, 
most experimental and observational studies have been focused on associations 
between hyperglycemia, hyperinsulinemia and spina bifida (23-25). Therefore, 
of great interest were the investigations on myo-inositol supplementation in the 
prevention of neural tube defects in the curly tail mice and diabetic Sprague-
Dawley rats (23,24). Except for a recent case-report by Cavalli and Copp (26), 
our study is the first performed in humans in which myo-inositol has been 
associated with spina bifida risk. We speculate that a tissue shortage of myo-
inositol in early embryogenesis may affect intracellular signaling processes 
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involved in neural tube closure. The related genetic factors may be directly or 
indirectly controlled by myo-inositol and glucose. Of particular interest was 
that a relatively normal glucose concentration with a cutoff point of 4.5 mmol/L 
was associated with an increased spina bifida risk. Although this glucose 
concentration is much lower than in diabetes, a suggested underlying 
mechanism for diabetes-induced spina bifida is the competitively inhibition of 
cellular myo-inositol uptake by elevated glucose concentrations (27-29). The 
comparison of the myo-inositol and glucose concentrations in amniotic fluid of 
spina bifida children with controls revealed lower glucose concentrations in the 
spina bifida group, whereas myo-inositol concentrations were comparable 
(chapter 10). Whether these different levels reflect a primary cause or a 
secondary consequence of the spina bifida remains to be answered. An 
explanation for the higher maternal serum glucose concentrations may be the 
higher dietary intake of mono- and disaccharides in mothers of children with 
spina bifida compared to the control. These higher intakes may result in 
prolonged periods of transiently increased blood glucose concentrations, 
thereby lowering cellular uptake of myo-inositol. Of interest in this regard is 
that in diabetic rats the teratogenic effects can be amplified by mild zinc 
deficiency (30). Zinc deficiency by itself is an independent risk factor for spina 
bifida as can be concluded from experimental studies and observational studies 
in Turkey and in women with a rare recessive autosomal disease called 
Acrodermatitis Enteropathica (31-36). From this background we studied the 
1069C>T polymorphism in the SLC39A4 gene (36-38) in which no significant 
interaction between the SLC39A4 polymorphism and red blood cell zinc 
concentrations in the spina bifida children and mothers was observed (chapter 
3). This may be due to the power problem. 
In line with other information (12,15) we found that low maternal cobalamin 
levels are an independent risk factor for spina bifida offspring (chapter 6). In 
contrast to previous findings, folate, total homocysteine and pyridoxal-5'-
phosphate concentrations were comparable in mothers and children of both 
groups (39-41). Dietary intakes of cobalamin and pyridoxine were comparable 
between spina bifida and control mothers, suggesting impaired intestinal uptake 
and transfer of cobalamin due to polymorphisms in transcobalamins. The 
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dietary intakes of folate and iron were below the Dutch recommended daily 
intakes in more than 95% of the spina bifida and control mothers. In addition, 
only 33% of the spina bifida mothers and 42% of the control mothers reported 
the use of periconceptional folic acid supplements as advised. These 
observations should have implications for preconceptional health care. 
 
 
Future research 
 
The data presented in this thesis justify additional research into the role of 
myo-inositol, glucose and zinc into the etiology of spina bifida. Randomized 
controlled trials are not feasible because of the low occurrence and recurrence 
rates of spina bifida, and the demonstrated preventive effect of periconceptional 
folic acid supplementation. A prospective cohort study to determine blood myo-
inositol, glucose and zinc concentrations in the periconceptional period is for 
the same reasons not feasible. We calculated that for the inclusion of 200 spina 
bifida affected pregnancies approximately 200,000 pregnancies without 
additional selection criteria have to be included. Therefore, a better approach 
may be to perform case-control studies like the ones presented in this thesis, in 
a high-risk population. Such a high-risk group could for example include 
diabetic women who are at increased risk of spina bifida offspring.  In order to 
improve the homogeneity of the study groups the exclusion of carriers of the 
MTHFR 677C>T polymorphism could be considered. This will partially exclude 
the folate-sensitive spina bifida cases and increase the contribution of spina 
bifida cases due to disturbances in carbohydrate metabolism. Moreover, it is 
feasible to study diabetic women in the Netherlands since they are very well 
organized in Diabetic societies and therefore relatively easy to approach.   
In addition to human studies, investigations on the underlying molecular genetic 
metabolisms related to myo-inositol and zinc in the curly tail mouse may 
provide clues as to which genes and/or enzymes are involved in spina bifida. 
This may lead to new insights into the etiology and prevention of spina bifida by 
myo-inositol and/or zinc. 
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Implications for current health care 
 
This thesis shows that low myo-inositol and low zinc status and a mild 
hyperglycemia are factors involved in spina bifida pathogenesis. Previous 
observations support these associations (23,24,26). With the current knowledge 
however, it is in our opinion too early to advise all women who are planning 
pregnancy to use a myo-inositol and zinc supplement in addition to folic acid 
supplement to prevent spina bifida offspring (26). Nevertheless, women at risk 
for a low myo-inositol status, zinc deficiency or derangement in carbohydrate 
metabolism, such as diabetic women, should be preconceptionally screened and 
if necessary adequately treated to optimize their preconceptional status. Of 
particular interest is the significantly higher intake of some carbohydrates in 
spina bifida mothers suggesting the recommendation to prevent the high intake 
of sugar and sweets. The finding that food folate and iron intakes were below 
the Dutch recommended daily intakes raises the question whether the 
nutritional pattern of women in reproductive age is adequate. This is supported 
by our findings that low intakes of nutrients as niacin, magnesium, fibres and 
plant protein are associated with spina bifida offspring. We showed that health 
and lifestyle factors are important players in the etiology of spina bifida 
(chapter 5 and 7). The overall nutritional pattern of spina bifida mothers showed 
slightly lower dietary intakes of all nutrients as well as intakes of food groups 
such as vegetables and fruits, compared to controls. Moreover, women on a 
macrobiotic, vegetarian or veganistic diet and couples that are planning 
pregnancy have a decreased spina bifida risk in offspring. This is possibly 
explained by the increased awareness of the importance of a healthy lifestyle to 
prevent reproductive disorders in these couples. 
In this light, fortification of foodstuffs has been suggested in particular for iron 
and folate. Food fortification with folate has been shown to effectively increase 
the average folate levels in the American population (42). While food 
fortification may have beneficial effects, e.g. prevention of spina bifida (20,21), 
there are also many reservations. For instance, little is known about prolonged 
exposure to for instance folic acid. Additionally, is there really a need for 
fortification and is it ethical to expose a large group healthy individuals who will 
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not directly benefit from fortification programs for the benefit of few? Until this 
question can be substantiated by studies showing that prolonged exposure to 
synthetic supplements does not harm involuntary exposed individuals or by 
studies that show that the potential adverse effects of fortification outweigh the 
possible gain, it is the author's opinion that fortification should not be 
implemented for the Dutch population as a whole. However, voluntary 
fortification of products fortified with folic acid may be considered for specific 
target populations such as women who are planning pregnancy. 
 
 
Conclusions 
 
The data presented in this thesis emphasize the importance of the nutritional 
status, in particular that of myo-inositol, glucose and zinc, largely determined 
by nutritional intake, and health and lifestyle factors in the etiology of spina 
bifida. Most of these factors are amendable and therefore the screening of 
these factors should be implemented in the preconceptional care of women who 
are at risk for spina bifida offspring and in those who are exposed to these risk 
factors and as such belong to a high-risk group for spina bifida offspring. If 
adjuvant myo-inositol and/or zinc supplementation is preconceptionally 
administered, careful documentation and observation of beneficial and side 
effects on the mother and fetus is required. Moreover, this study hopes to 
stimulate health authorities to address the importance of nutritional intake by 
women in reproductive ages, in particular that of vegetables and fruits, and to 
stimulate their awareness of folic acid supplementation. This would sub-
stantially contribute to the prevention of spina bifida and other congenital 
malformations in the short term and probably other diseases in the long term.  
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Summary 
 
 
Spina bifida is classified as a neural tube defect, which is a congenital birth 
defect of the spinal column and is often accompanied by impaired bladder and 
intestinal function and paralyses of the legs. The birth-prevalence of spina 
bifida in the Netherlands is estimated to be 5-7 per 10,000 births. Although 
surgical treatment of the skin defect drastically improves the survival and life 
expectancy of these children, it is still not possible to repair the neurological 
functions. Spina bifida belongs to the category of multifactorial diseases, in 
which genetic and environmental factors are involved in the pathogenesis. 
Sofar, genetic factors cannot be modified. Therefore, we have to focus on the 
identification of risk factors that can be amended. Maternal nutritional and life 
style factors play a role in the development of spina bifida and periconceptional 
folic acid supplementation partially prevents these severe birth defects. The 
focus of this thesis is to investigate the role of other nutrients, especially  myo-
inositol and zinc, related genetic factors and lifestyle factors in the 
pathogenesis of spina bifida in man.   
The introduction of this thesis presents some background on neural tube 
defects in general and their embryology. A state-of-the art on the etiology of 
spina bifida focusing on the role of myo-inositol and zinc in particular, 
demonstrates our present knowledge. The objectives of this thesis are 
investigated in a nation-wide case-control triad study supplemented with 
several sub investigations. In the case-control triad study, myo-inositol, zinc, 
and related genetic factors, maternal nutrition and parental life-style are 
investigated in the etiology of spina bifida. The kinetics of myo-inositol and the 
concentrations of myo-inositol, glucose and zinc preconceptionally, during and 
after pregnancy and amniotic fluid as the resultant of fetal and maternal 
metabolism are studied as well. 
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Part I 
Part I consists of six chapters in which the results of our case-control triad 
study carried out in collaboration with nine spina bifida centers in the 
Netherlands are described. In total, 132 families with a child suffering from a 
nonsyndromic spina bifida were recruited in collaboration with the Spina Bifida 
Teams. To compare these families with controls, we enrolled 236 control 
families via acquaintances of the case-families and via posters and leaflets at 
nurseries and public health centers in Nijmegen and surroundings. Control 
children were healthy children without a structural birth defect. All individuals 
included were of Dutch Caucasian origin. The moment of the investigation was 
standardized at the age of approximately 15 months of spina bifida and control 
children. The investigation comprised the collection of data by questionnaires 
and bloodsampling for biochemical and genetic determinants. 
In chapter 2 the myo-inositol, glucose and zinc status in 63 mothers and in 70 
children with spina bifida and in 102 control mothers and in 85 children was 
determined to investigate the association between these determinants and spina 
bifida risk. The maternal myo-inositol concentrations tended to be 5% lower in 
mothers of spina bifida children. Interestingly, a maternal myo-inositol 
concentration of less than 13.2 µmol/L increased the risk of spina bifida 
offspring 2.6-fold. The maternal glucose and zinc concentrations were 7% 
higher and 5% lower, respectively, in the mothers of spina bifida children 
compared with the control-mothers. A 4.6-fold and 2.9-fold increased risk of 
spina bifida offspring was calculated for maternal glucose concentrations ≥ 4.5 
mmol/L and for zinc concentrations of <190 µmol/L. This suggests that the 
maternal myo-inositol, glucose and zinc status is associated with the risk for 
spina bifida in the offspring. Although the myo-inositol concentrations tended to 
be lower in children with spina bifida, after age-adjustment myo-inositol, 
glucose and zinc concentrations appeared to be comparable in spina bifida and 
control children.  
In chapter 3 we evaluated the blood concentrations of myo-inositol, glucose and 
zinc together with the polymorphisms in the myo-inositol transporter KST1 
gene, myo-inositol synthase ISYNA1 gene and zinc transporter SLC39A4 gene 
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in a case-triad only design of the parents and their child with spina bifida. No 
association between KST1, ISYNA1 and SLC39A4 and spina bifida was 
detected. However, a lower maternal myo-inositol concentration was observed 
in mothers with a KST1 CC-genotype compared with mothers with a KST1 TT-
genotype. Maternal glucose concentrations were comparable for the three 
KST1 genotypes as were the myo-inositol and glucose concentrations for the 
three ISYNA1 genotypes and the zinc concentrations for the three SLC39A4 
genotypes. Of interest was the interaction demonstrated between a maternal 
glucose <4.5 mmol/L and ISYNA1 1029A>G polymorphism on spina bifida risk. 
While the results are suggestive for a role of KST1 and ISYNA1 in the etiology 
of spina bifida, albeit minor, these findings should be confirmed in larger 
studies.  
In chapter 4 the mutation analysis of the ZIC1, ZIC2 and ZIC3 genes in spina 
bifida triads, has been described. In ZIC1 a deletion of one codon that encodes 
an alanine residue located in the amino terminal alanine stretch of the protein 
was identified that was present in only one patient, but not in a large set of 
controls. This finding suggests a minor role of this variant in the etiology of 
spina bifida in humans. No association was found between a frequent 
polymorphism in the ZIC2 gene (1059C>T, H353H) in parents and their child 
with spina bifida after statistical analysis by using the Transmission 
Disequilibrium Test. Of interest was one silent polymorphism (858G>A,V286V) 
of unknown significance that was identified in ZIC3. Neither mutations nor 
polymorphisms were found in the coding region or flanking sequences of ZIC1. 
This study indicates that ZIC1, ZIC2 and ZIC3 are no major risk factors for 
spina bifida in humans.  
In chapter 5 we describe the evaluation of the maternal dietary nutrient intake 
data collected 24 months after the periconceptional period of the index-
pregnancy as a proxy of the periconceptional nutrient intake in association with 
the risk for spina bifida. While most nutrient intakes were comparable to the 
Dutch Food Consumption Survey data, the intakes of fat, cholesterol, iron and 
folate were below the Dutch Recommended Daily Allowances (1998). These 
findings strengthen the importance of a maternal diet rich in vegetables and 
fruits and emphasized that periconceptional folic acid supplement use is 
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necessary since the average Dutch diet does not provide enough folate. 
Furthermore, we demonstrated that the dietary intake of iron, magnesium, 
niacin, fibres, plant proteins and polysaccharides was significantly lower in 
mothers of spina bifida offspring compared to the control-mothers. The lowest 
intakes were associated with a 2 to 5-fold increased risk for spina bifida 
offspring. This was observed independent of the periconceptional use of folic 
acid supplements. In contrast, a 'high' dietary intake of mono- and 
disaccharides 3-fold increased spina bifida risk, while the intake of 
polysaccharides was associated with a reduction in spina bifida risk. The 
importance of an optimal carbohydrate status during embryogenesis is 
supported by this data and the previous finding that a mildly increased maternal 
glucose concentration is associated with an elevated risk for spina bifida 
offspring,  
In the following chapter 6, we evaluated the blood concentrations of the B 
vitamins folate, vitamin B12 and pyridoxine, and homocysteine determined 24 
months after the periconceptional period of the index-pregnancy in a subset of 
the case-control triad study. This comprised 45 mothers and their children with 
spina bifida and 83 control-mothers with their healthy children. Of significance 
was the finding that a serum vitamin B12 concentration ≤185 pmol/L increased 
the risk of spina bifida offspring 3.5-fold. Vitamin B12 is a cofactor of 
methionine synthase, an enzyme important in folate-related homocysteine 
metabolism. A mild maternal hyperhomocysteinemia is a risk factor for spina 
bifida offspring. A folate shortage as well as a lack of vitamin B12 lead to a mild 
hyperhomocysteinemia. Therefore, this finding supports the role of vitamin B12 
in the pathogenesis of spina bifida.  
In the last chapter of Part I the impact of periconceptional health and lifestyle 
factors on the risk of spina bifida offspring are evaluated. Data of 128 parents 
of spina bifida offspring and of 233 parents of healthy children were obtained by 
questionnaires filled out at approximately 24 months after the periconceptional 
period of the index-pregnancy. The data comprised information on 
periconceptional health aspects as illnesses, pregnancy planning, use of folic 
acid and a health improving diet. The lifestyle factors included were smoking 
and alcohol use. A logistic model identified risk factors for spina bifida as the 
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periconceptional maternal use of medication, illnesses and preconceptional oral 
contraceptive use. Also, a parental familial history of congenital malformations 
more than 4-fold increased spina bifida risk. The maternal periconceptional use 
of a health improving diet reduced spina bifida risk, while those couples who 
had planned pregnancy showed a 60 percent lower risk for spina bifida 
offspring. Of interest was the observation that periconceptional folic acid use 
reduced all odds ratios except the family risk for congenital malformations, 
emphasizing the importance of folate-nonresponsive spina bifida. These data 
are of importance because some new amendable health and life-style factors 
are identified that can be treated after preconceptional counseling in order to 
further contribute to the primary prevention of spina bifida in future.  
 
Part II 
In chapter 8, we describe the results of a myo-inositol loading test, which we 
designed to investigate the kinetics of myo-inositol in healthy women of 
reproductive age. Five healthy non-obese women of reproductive ages were 
recruited. After ingestion of 100 mg/kg body weight of myo-inositol, venous 
blood and urine samples were collected. Random intercept models were fitted to 
evaluate the serum myo-, epi- and scyllo-inositol and glucose, and plasma 
insulin concentrations. The myo-inositol and scyllo-inositol concentrations both 
reached maximum values at 180 minutes post loading, while the plasma insulin 
and serum glucose concentrations decreased slightly during the experiment. 
Also, urinary myo-inositol concentrations were increased 180 and 270 minutes 
post loading, while urinary glucose concentrations were unchanged. It was 
concluded that myo-inositol quickly enters the bloodstream after oral ingestion 
and that a small amount of myo-inositol is converted to scyllo-inositol.  
In chapter 9, a longitudinal study is presented, in which myo-inositol 
concentrations have been evaluated in the same women from the 
preconceptional period, during the pregnancy and after the pregnancy. For this 
study we included 37 women of couples who were planning pregnancy. Fasting 
venous blood samples of 18 nulliparae and 19 multiparae were determined for 
serum inositol and glucose and red blood cell zinc concentrations 
preconceptionally, at 6, 10, 20, 30 and 37 weeks amenorrhea, and 6 weeks post 
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partum. The preconceptional serum myo-inositol, and glucose and red blood 
cell zinc concentrations were comparable to the concentrations at 6 weeks 
amenorrhea. Moreover, these concentrations appeared to be comparable to 
those determined 15 months after the index-pregnancy (chapter 2). This finding 
supports our assumption that the preconceptional 'nutritional' state is 
comparable to the 'nutritional' state 24 months after the preconceptional period 
of the index-pregnancy. 
In the chapters 10 and 11 the concentrations of myo-inositol, glucose and zinc 
are determined in amniotic fluids from pregnancies with a spina bifida and in 
amniotic fluids from healthy control fetuses.  
In the case-control study described in chapter 10, we collected amniotic fluids 
of 27 pregnancies complicated by spina bifida and 49 controls. By indication, 
the samples were taken at different gestational ages, which was adjusted for by 
using multiple linear regression analysis. In the spina bifida group, amniotic fluid 
myo-inositol, glucose and zinc concentrations gradually declined throughout 
pregnancy. At a gestational age of 15 weeks, the glucose and zinc 
concentrations in the spina bifida group were, respectively, lower and higher 
compared with the control group, while the mean myo-inositol concentrations 
were comparable. At a gestational age of 38 weeks, all three biochemical 
parameters were equal. From the results may be concluded that a derangement 
in zinc and glucose transfer or metabolism is associated with spina bifida. 
Nevertheless, since compounds in amniotic fluid are only a very crude marker 
of the actual fetal condition, studies that focus on the metabolism of these 
compounds on tissue or even cellular level should be performed to clarify their 
role in the pathogenesis and future prevention of spina bifida.  
In chapter 11 the non-invasive 1H-NMR technique was used to quantify proton 
containing metabolites of amniotic fluids from fetuses with spina bifida and 
controls. We obtained 14 amniotic fluids from spina bifida fetuses and 18 
controls and the concentrations of carbohydrates, organic acids and amino acids 
were determined by the 1H-NMR spectroscopy. At 15 and 39 weeks 
amenorrhea the amniotic fluid concentrations of succinic acid and glutamine 
were significantly higher in the spina bifida group compared to controls, 
whereas creatine and creatinine were significantly lower. Amenorrhea 
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significantly influenced the concentrations of most compounds with the 
exception of lactic acid. Nevertheless, the results are suggestive for a 
derangement in the amino acid metabolism which may be of importance in the 
pathogenesis of spina bifida. 
In chapter 12, we discuss our findings together with the literature and consider 
methodological issues as comparability of information, accuracy and power, 
comparability of populations and ascertainment of nonsyndromic spina bifida. 
Research on gene-environment interactions, in particular gene-nutrient 
interactions, in association with congenital malformations is rather new. 
Therefore, the case-control triad approach and the standardized investigation 
by questionnaires and biochemical determinants 24 months after the 
preconceptional period of the index-pregnancy as described in this thesis is 
promising for future research and the achievement of primary prevention of 
other multifactorial birth defects.  
From the results we conclude that it is too early to launch supplementation 
programs with myo-inositol and zinc in addition to folic acid. However, women 
at risk for a low myo-inositol status, zinc deficiency or deranged carbohydrate 
metabolism, in particular diabetic women, should be preconceptionally screened 
and treated to optimize the preconceptional status of these nutrients. If, 
however, adjuvant myo-inositol and/or zinc supplementation is 
preconceptionally administered, we emphasize that careful monitoring and 
documentation is essential to evaluate this treatment on efficacy and safety 
aspects in both the mother and fetus. Because food folate and iron intakes were 
below the Dutch Recommended Daily Allowances, the questions arise whether 
our foods contain enough amounts of these nutrients and whether our life styles 
and habits with regard to food intake are adequate to meet the needs, in 
particularly in women in childbearing age. The anwers to these questions should 
not be solved by food fortification programmes. We hope however, that our 
findings will stimulate open discussions between health authorities, nutritional 
industries, clinicians, scienticst and media with the ultimate goal to improve the 
health and nutritional status of women in reproductive ages who are planning 
pregnancy. A significant contribution can only then be given to the prevention 
of spina bifida and possibly other birth defects in future.
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Samenvatting 
 
 
Spina bifida, een neurale buisdefect, is een aangeboren afwijking van de 
wervelkolom en wordt vaak vergezeld door incontinentie, darmstoornissen en 
(uitgebreide) paralyse van de onderste extremiteiten. De geboorte prevalentie 
van spina bifida wordt in Nederland geschat op ongeveer 5-7 per 10.000 
geboorten en is daarmee één van de meest frequent voorkomende congenitale 
afwijkingen. Ondanks het feit dat chirurgische behandeling van het huiddefect 
de levenskansen en verwachting van kinderen met spina bifida drastisch heeft 
verhoogd, is het nog niet mogelijk de neurologische schade te herstellen. Spina 
bifida behoort tot de groep van multifactoriële ziekten in welke zowel 
genetische als omgevingsfactoren betrokken zijn. Omdat er tot dus ver niets 
kan worden gedaan aan de genetische factoren, focussen wij ons op de 
identificatie van risico factoren waar wel iets aan kan worden gedaan. 
Maternale voedings- en lifestyle factoren spelen een rol in het ontstaan van 
spina bifida en periconceptionele foliumzuur suppletie geeft een partitiële 
bescherming tegen deze congenitale afwijkingen. De focus van dit proefschrift 
is het onderzoeken van de rol van andere nutriënten, met name myo-inositol en 
zink, gerelateerde genetische factoren en lifestyle factoren in de pathogenese 
van spina bifida in de mens. 
In de introductie van dit proefschrift werd een algemene achtergrond voor 
neurale buis defecten in het algemeen en de embryologie gegeven. Daarnaast 
wordt in hoofdstuk 1 de huidige wetenschappelijk stand van zaken omtrent 
spina bifida en de rol van myo-inositol en zink geschetst. De doelstellingen van 
dit proefschrift werden onderzocht in een nationale case-control triad studie 
(Part I) aangevuld met substudies die worden beschreven in Part II. In de case-
control triad studie werd de rol van myo-inositol, zink en gerelateerde 
genetische factoren, maternale voeding en lifestyle van de ouders in de 
etiologie van spina bifida onderzocht. In Part II wordt de kinetiek van myo-
inositol, en het concentratieverloop van myo-inositol, glucose en zink 
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preconceptioneel, tijdens de zwangerschap en post partum  als een resultante 
van het foetale en maternale metabolisme beschreven. 
 
Part I 
Part I bestaat uit zes hoofdstukken waarin de resultaten van een in Nederland 
uitgevoerd case-control triad studie die is uitgevoerd in samenwerking met de 
negen spina bifida centra in Nederland, zijn beschreven. In totaal zijn 132 
families met een kind met niet syndromatische spina bifida gerekruteerd via de 
Nederlandse Spina Bifida Teams en 236 controle families die zijn geworven via 
de spina bifida families of via posters en foldertjes bij kinderdagverblijven in 
Nijmegen en omgeving. De controle kinderen mochten geen congenitale 
afwijkingen hebben. Alle deelnemers waren van Nederlands Caucasische 
afkomst. De timing van het onderzoek was gestandaardiseerd op een leeftijd 
van ongeveer 15 maanden van de spina bidida en controle kinderen. In het 
onderzoek werd data verzameld door middel van vragenlijsten en bloed afnamen 
ter bepaling van biochemische en genetische determinanten. 
In hoofdstuk 2 werd de myo-inositol, glucose en zink status in relatie tot het 
risico op spina bifdia onderzocht in 63 moeders en 70 kinderen met spina bifida 
en 102 controle moeders en 85 kinderen op ongeveer 24 maanden na de 
conceptie. De maternale myo-inositol concentraties lagen ongeveer 5% lager in 
case-moeders. Een interessante bevinding was dat een maternale myo-inositol 
concentratie van minder dan 13.2 µmol/L het risico op spina bifida met een 
factor 2.6 verhoogd. De maternale glucose en zink concentraties lagen 
respectievelijk 7% hoger en 5% lager vergeleken met controle moeders. 
Maternale glucose en zink concentraties van respectievelijk ≥4.5 mmol/L en 
<190 µmol/L verhoogden het risico op spina bifida in het nageslacht met een 
factor 4.6 en 2.9 respectievelijk. Dit suggereert dat de maternale myo-inositol, 
glucose en zink status geassocieerd is met het risico op spina bifidia in het 
nageslacht. In kinderen met en zonder spina bifida werd geen verschil tussen de 
myo-inositol, glucose en zink concentraties gevonden. Ondanks het feit dat de 
myo-inositol concentraties in kinderen met spina bifida aanvankelijk lager 
waren dan in controle kinderen, bleek dat na correctie voor leeftijd de 
concentraties gelijk waren in beide groepen. 
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In hoofdstuk 3 worden de resultaten van een onderzoek beschreven naar de rol 
van de biochemische parameters myo-inositol, glucose en zink in combinatie 
met polymorfismen in de myo-inositol transporter KST1, myo-inositol synthase 
ISYNA1, en de zink transporter SLC39A4 in een 'case-triad only' design met de 
ouders en hun kind met spina bifida. Er werd geen associatie tussen KST1, 
ISYNA1 en SLC39A4 en spina bifida gevonden. Desalniettemin werd in moeders 
met het KST1 CC-genotype een lagere myo-inositol concentratie gevonden dan 
in moeders met het KST1 TT-genotype. De maternale glucose concentraties 
waren vergelijkbaar voor de drie KST1 genotypen net als de myo-inositol en 
glucose concentraties voor de drie ISYNA1 genotypen en de zink concentraties 
voor de drie SLC39A4 genotypen. Interessant was de interactie die werd 
aangetoond tussen een maternale glucose concentratie van <4.5 mmol/L, het 
ISYNA1 1029A>G polymorfisme en het risico op nageslacht met spina bifida. 
Hoewel de resultaten lijken te wijzen op een (kleine) rol van KST1 en ISYNA1 
in de etiologie van spina bifida, moeten deze bevindingen worden bevestigd in 
grotere studies. 
In hoofdstuk 4 worden de resultaten van een mutatie analyse in spina bifida 
triads beschreven voor de ZIC1, ZIC2 en ZIC3 genen. In ZIC1 werd in één 
patiënt een deletie gevonden van een codon welke codeert voor een alanine 
residu. Deze deletie werd niet teruggevonden in een grote groep controles. 
Deze bevinding lijkt te duiden op een mogelijke rol, zij het een kleine, van deze 
genetische variant in de etiologie van NBD in de mens. Met behulp van de 
Transmission Disequilibrium Test werd geen verband gevonden tussen spina 
bifida en een frequent polymorfisme in het ZIC2 gen (1059C>T, H353H) in 
ouders met een kind met spina bifida. Opmerkelijk was een 'stil' polymorfisme 
(858G>A,V286V) in het ZIC3 gen, waarvan de significantie nog nader moet 
worden onderzocht. Er zijn geen mutaties of polymorfismen gevonden in het 
coderende en aanliggende gebied van ZIC1. De resultaten van deze studie 
suggereren dat ZIC1, ZIC2 en ZIC3 geen grote risicofactoren zijn in de etiologie 
van NBD in de mens. 
In hoofdstuk 5 beschrijven we de resultaten van een studie naar de maternale 
voedingsinname in relatie tot het risico op spina bifida in het nageslacht. De 
data werden verzameld 24 maanden na de periconceptionele periode van de 
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index zwangerschap als proxy voor de periconceptionele voedingsinname. 
Hoewel de meeste voedingsinnamen vergelijkbaar waren met de gegevens uit 
de Nederlandse Voedsel Consumptie Peiling, lagen de innamen van vet, 
cholesterol, ijzer en folaat onder de Nederlandse Dagelijks Aanbevolen 
Hoeveelheden (1998). Deze bevindingen onderbouwen het belang van een 
maternaal dieet dat rijk is aan groenten en fruit. Daarnaast benadrukt dit het feit 
dat periconceptionele foliumzuursuppletie noodzakelijk is omdat het gemiddelde 
Nederlandse dieet onvoldoende folaat bevat. Verder toonden we aan dat de 
inname van ijzer, magnesium, niacine, voedingsvezels, plantaardige eiwitten en 
polysacchariden significant lager was in moeders met kinderen met spina bifida 
in vergelijking tot controle moeders. De laagste innamen waren geassocieerd 
met een 2- tot 5 maal verhoogd risico op spina bifida in het nageslacht. Deze 
bevinding was onafhankelijk van het gebruik van periconceptionele 
foliumzuursupplementen. In tegenstelling hiermee was de observatie dat een 
hoge inname van mono- en disacchariden het risico op spina bifida met een 
factor 3 verhoogd, terwijl de inname van polysacchariden juist geassocieerd 
was met een risico daling. Dit en de eerdere bevinding dat een licht verhoogde 
glucose spiegel samenhangt met een verhoogd risico of spina bifida, 
onderstreept het belang van een optimale koolhydraat status tijdens de 
embryogenese.  
In het zesde hoofdstuk, bestudeerden wij in een subset van de case-control 
triad studie in bloed de concentraties van de B-vitaminen foliumzuur, vitamine 
B12, pyridoxine, en homocysteine. De bloedsamples werden verzameld van 45 
moeder en hun kinderen met spina bifida en 83 controle moeders met gezonden 
kinderen op 24 maanden na de periconceptionele periode van de 
indexzwangerschap. Van belang was de bevinding dat een serum vitamine B12 
concentratie van ≤185 pmol/L het risico op spina bifida in het nageslacht met 
een factor 3.5 verhoogd. Vitamine B12 is een cofactor voor methionine synthase, 
een enzym dat een belangrijke rol speelt in het foliumzuur gerelateerde 
homocysteine metabolisme. Een milde maternale hyperhomocysteinemie is een 
risicofactor voor nageslacht met spina bifida. Een tekort aan foliumzuur alsook 
een gebrek aan vitamine B12 leidt tot een milde hyperhomocysteinemie. In dit 
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licht bevestigd onze bevinding de rol van vitamine B12 in de pathogenese van 
spina bifida. 
In het laatste hoofdstuk van Part I werd de impact van periconceptionele 
lifestyle factoren op het risico op spina bifida in het nageslacht. Vragenlijstdata 
van 128 ouders van kinderen met een spina bifida en 233 ouders met gezonde 
kinderen werd verkregen 24 maanden na de periconceptionele periode van de 
indexzwangerschap. De data hebben betrekking op periconceptionele 
gezondheidsaspecten zoals ziekten, planning van de zwangerschap, gebruik van 
foliumzuur en een 'gezond' dieet. De lifestyle factoren waren onder andere 
roken en gebruik van alcohol. Een logistisch regressie model identificeerde 
maternaal gebruik van medicatie en orale anticonceptiva en ziekten als risico 
factoren voor spina bifida in het nageslacht. Daarnaast bleek dat een met 
congenitale afwijkingen belaste familie anamnese het risico op spina bifida met 
een factor 4 verhoogd. Maternaal gebruik van een 'gezond' dieet reduceerde het 
risico op spina bifida. Ook bleek dat paren die de zwangerschap hadden gepland 
een 60% reductie hebben op het krijgen van een kind met spina bifida. 
Interessant was de bevinding dat het periconceptionele gebruik van foliumzuur 
de meeste odds ratios reduceerde behalve wanneer er sprake is van een 
belaste familie anamnese. Dit benadrukt het belang van onderzoek naar 
'foliumzuurresistente' spina bifida. De gegevens uit deze studie zijn van groot 
belang omdat enkele nieuwe voorkombare gezondheids- en lifestyle factoren 
zijn geïdentificeerd welke behandeld kunnen worden met preconceptionele 
counseling. Op deze manier kan in de toekomst een bijdrage worden geleverd 
aan de primaire preventie van spina bifida. 
 
Part II 
In hoofdstuk 8 beschrijven we de resultaten van een myo-inositol loading test 
welke was opgezet om de kinetiek van myo-inositol in gezonde vrouwen in de 
reproductieve leeftijd te bestuderen. Vijf gezonde niet obese vrouwen in de 
reproductieve leeftijd werden gerekruteerd voor dit onderzoek. Na de inname 
van 100 mg/kg lichaamsgewicht van myo-inositol, werd veneus bloed en urine 
monsters verzameld. Random intercept modellen werden gefit om de 
concentraties van serum myo-, epi-, en scyllo-inositol en plasma insuline te 
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beschrijven. Zowel de myo-inositol als de scyllo-inositol concentraties 
bereikten 180 minuten post-loading maximum serum concentraties, terwijl de 
concentraties van plasma insuline en serum glucose geleidelijk afnamen 
gedurende het experiment. Daarnaast nam de concentratie van myo-inositol in 
urine toe, terwijl de urine glucose concentraties onveranderd bleven. We 
concludeerden dat na orale inname myo-inositol snel door het lichaam wordt 
opgenomen en dat een klein deel van het myo-inositol wordt omgevormd tot 
scyllo-inositol. 
In hoofdstuk 9 wordt een longitudinale studie gepresenteerd waarin myo-
inositol concentraties voor de conceptie, tijdens de zwangerschap en post 
partum werden bestudeerd in een groep vrouwen. Zevenendertig vrouwen van 
paren die een zwangerschap planden werden geïncludeerd. De serum inositol en 
glucose en rode bloed cel zink concentraties werden bepaald in het nuchtere 
veneuze bloed van 18 nulliparae en 19 multiparae voor de conceptie, op 6, 10, 
20, 30 en 37 weken amenorroe en 6 weken post partum. De preconceptionele 
concentraties van serum myo-inositol en glucose en zink in rode bloed cellen 
waren vergelijkbaar met de concentraties op 6 weken amenorroe. Daarbij 
bleken de concentraties zoals die in hoofdstuk 2 werden gevonden vergelijkbaar 
met die op 6 weken amenorroe. Deze bevinding ondersteunt onze 
vooronderstelling dat de preconceptionele voedingsstatus vergelijkbaar is met 
de voedingsstatus 24 maanden na de preconceptionele periode van de 
indexzwangerschap. 
In de hoofdstukken 10 en 11 werden de concentraties van myo-inositol, glucose 
en zink bepaald in amnionvloeistof van foetussen met en zonder spina bifida. 
Voor de case-controle studie in hoofdstuk 10, verzamelden we 
amnionvloeistoffen van 27 spina bifida zwangerschappen en 49 controles. Als 
gevolg van indicatie stelling waren de monsters verzameld op een verschillende 
zwangerschapsduur. Voor dit verschil werd gecorrigeerd in multipele regressie 
analyse. In de spina bifida groep nam de concentratie van myo-inositol, glucose 
en zink in amnionvloeistof gestaag af gedurende de zwangerschap. Bij een 
zwangerschapsduur van 15 weken, was de glucose lager en de zink 
concentratie hoger in de spina bifida groep dan in de controle groep. De 
gemiddelde myo-inositol concentraties waren echter vergelijkbaar. Bij een 
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zwangerschapsduur van 38 weken waren er geen verschillen tussen de 3 
biochemische parameters. Uit de resultaten kan worden afgeleid dat een 
afwijking in zink en glucose transfer of metabolisme met spina bifida is 
geassocieerd. Desalniettemin, amnionvloeistof is een slechts een ruwe marker 
voor de conditie van de foetus en studies die focussen op het metabolisme van 
deze stoffen op weefsel- of zelfs cellulair niveau moeten worden uitgevoerd om 
de rol van deze stoffen in de pathogenese en toekomstige preventie van spina 
bifida nader te onderzoeken. 
In hoofdstuk 11 gebruikten we de niet-invasieve 1H-NMR techniek om proton 
houdende metabolieten in amnionvloeistoffen van foetussen met en zonder spina 
bifida te kwantificeren. In veertien amnionvloeistoffen van spina bifida 
foetussen en 18 controles werden de concentraties van koolwaterstoffen, 
organische zuren en aminozuren bepaald door middel van 1H-NMR 
spectroscopie. Bij een amenorroe van 15 en 39 weken lagen de concentraties 
van succinine zuur en glutamine significant hoger in de spina bifida groep in 
vergelijking tot de controle groep. De creatine en creatinine concentraties 
waren daarentegen lager in de spina bifida groep. Amenorroe heeft een 
significante invloed op bijna alle metaboliet concentraties in amnionvloeistof 
met uitzondering van lactaat. Desalniettemin wijzen de resultaten in de richting 
dat een afwijking in het aminozuur metabolisme een rol kan spelen in de 
pathogenese van spina bifida. 
In hoofdstuk 12 bediscussiëren we onze bevindingen in het licht van de 
literatuur en nemen methodologische zaken zoals vergelijkbaarheid van 
informatie, betrouwbaarheid en power, vergelijkbaarheid van de populaties en 
rekruteren van kinderen met nonsyndromale spina bifida in beschouwing. 
Onderzoek naar gen-omgeving interacties, gen-voeding interacties in het 
bijzonder, in relatie tot aangeboren afwijkingen is betrekkelijk nieuw. De case-
controle triad aanpak en gestandaardiseerd onderzoek door middel van 
vragenlijsten en bepaling van biochemische determinanten 24 maanden na de 
preconceptionele periode van de indexzwangerschap, lijkt zeer geschikt te zijn 
voor toekomstig onderzoek om de doelstelling van primaire preventie van spina 
bifida en andere multifactoriële congenitale afwijking te verwezenlijken.  
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Uit de resultaten leiden we af dat het nog te vroeg is om myo-inositol en zink 
suppletie programma's additioneel aan foliumzuur te starten. Echter, vrouwen 
die een verhoogde kans hebben voor een lage myo-inositol status, zink 
deficiëntie of een afwijking in het koolwaterstof metabolisme, zoals vrouwen 
met diabetes mellitus, zouden preconceptioneel gescreend kunnen worden en 
worden behandeld om de preconceptionele status van deze nutriënten te 
optimaliseren. Wanneer preconceptioneel myo-inositol en/of zink suppletie 
wordt toegepast, willen wij benadrukken dat goede monitoring en documentatie 
plaatsvindt om het effect en veiligheid voor zowel moeder als foetus van deze 
behandeling te waarborgen. Omdat de voedingsinname van folaat en ijzer lager 
ligt dan de Dagelijks Aanbevolen Hoeveelheden, rijst de vraag of ons voedsel 
genoeg van deze nutriënten bevat en of onze levensstijl met betrekking tot deze 
voedingsinnamen wel adequaat is, in het bijzonder voor vrouwen in de 
reproductieve leeftijd. De antwoorden op deze vragen zouden niet moeten 
worden beantwoord door middel van voedselverrijkingsprogramma's. Eerder 
hopen wij dat onze bevindingen de discussie tussen de autoriteiten op gebied 
van gezondheidszorg, voedingsmiddelen industrie, clinici, wetenschappers en de 
media zal bevorderen om op deze manier het doel te bereiken van een zo 
optimaal mogelijke gezondheid en voedingsstatus voor vrouwen die een 
zwangerschap plannen. Alleen dan kan een significante bijdrage worden 
geleverd aan de toekomstige preventie van spina bifida en mogelijk ook andere 
congenitale afwijkingen. 
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